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ABSTRACT 
Cervical cancer is the most common cause of cancer-related death in black South 
African women. Human papillomavirus (HPV) has been found to be a necessary 
causative agent of cervical cancer and has been reported to be associated with 84% of 
cervical intraepithelial neoplasia (CIN). HPV type 16 (HPV-16) is the most prevalent 
HPV type associated CIN and cervical cancer with -56% of women with cervical 
disease being infected with HPV 16. Yet studies have shown that 47-85% of CIN 
regressed, suggesting that perhaps an effective immune response could result in HPV 
clearance and lesion regression. Since HPV infection does not disseminate and there 
is no systemic phase of infection, it is hypothesized that local cervical immune 
responses are important in lesion regression and clearance of HPV infection. There 
are, however, very few studies of mucosal immune responses to HPV infection. The 
aim of this study was to determine the type of mucosal immune response elicited by 
the CD4 and CD8 T cell subsets to HPV infection at the cervix of women diagnosed 
with varying grades of CIN and to compare these to systemic responses. One hundred 
women with varying grades of histologically confirmed CIN attending the Groote 
Schuur Hospital Colposcopy Outpatient Clinic were enrolled into the study. Cervical 
T cells were isolated from the endocervixltransfonnation zone of these women using a 
Digene cytobrush. Of these 100 women, only 33 were found to have suitable cervical 
cytobrush specimens for analysis of mucosal T cell responses based on CD3+ T cell 
numbers and absence of red blood cell contamination. 
Peripheral and cervical T cells were stimulated with the major capsid protein 
Ll of HPV-16 which self assembles into virus like particles (VLP) and the major 
xiii 
HPV -16 oncogenic protein E7 and the subsequent production of intracellular 
cytokines (ICC) was detected through flow cytometry. 
Women with CIN 1 consistently had the strongest CD4 IFN-y (but not 
necessarily CDS T cell) responses at the cervix to HPV-16 antigens compared to 
women with no cervical neoplasia or those with more severe disease (CIN 213). This 
was observed particularly if one focused on women with active HPV-16 infection but 
also if one looked at the group as a whole (irrespective of the type of HPV causing 
infection). There was a significant trend towards decreasing Th2 responses (IL-13 
production) with increasing disease severity, in cervical CD4 and CDS T cells to both 
HPV antigens (Ll and E7) if one looked at the group as a whole. Conversely, this 
trend was reversed with increasing Th2 responses with increasing disease severity in 
the women with active HPV-16 infection. When PBMC responses from women with 
HPV-16 DNA at the cervix were compared with those that were infected with other 
HPV types, the HPV-16 DNA+ women generally produced a Thl dominant response 
(more IFN-y and less IL-13) which changed to a Th2 dominant response with 
increasing disease severity (particularly for E7 antigen). In contrast, the HPV-16 
negative women (infected with other HPV types) showed a complete reversal of this 
profile with increasing IFN-y responses and decreasing IL-13 responses with 
increasing disease grade. The only cervical immune response that correlated with 
disease grade in this study was that both CD4 and CDS T cell IL-13 production 
decreased with increasing disease severity but this was observed in both women 
infected with HPV -16 and those infected with other HPV types. Although evidence 
ofHPV-16 specificity is lacking, the results do imply that Th2 dominant responses are 
associated with a "healthier" disease state and IL-13 responses (possibly driving a 
protective antibody-mediated response) diminish with increasing disease grade. The 
xiv 
magnitude of Thl responses elicited by cervical T cells was generally lower than 
those produced by T cells from peripheral blood. This study shows that the cytobrush 
method of obtaining cervical lymphocytes combined with intracellular cytokine 
analysis and flow cytometry is a non-invasive and potentially useful approach to 
studying immune responses in the genital tract and also suggests various 
modifications to improve the low numbers of suitable cervical specimens for study. 
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CHAPTER ONE: 
LITERATURE REVIEW 
1.1 The Prevalence of Cervical Cancer in the Female Population 
Cancer of the cervix is a worldwide problem. It is estimated that in 2002 a 
total of 493,243 women were diagnosed with cervical cancer (Ferlay et al., 2002). 
International cancer registries have estimated that it is the second most prevalent 
cancer disease among women (after breast cancer), making up 16.8% of the total 
number of cancer cases reported (International Association of Cancer Registries, 
2002). Here in South Africa, the statistics are just as alarming. The Cancer 
Association of South Africa announced in 2002 that cervical cancer has now become 
the leading cause of cancer related deaths in black Mrican women (CANSA, 2002). 
This means that South African women are now at higher risk of suffering from 
cervical cancer than they are of breast cancer. It was also pointed out that of all the 
women between the ages of 15 and 29 yr who were diagnosed with cancer, 13.4% 
were suffering with cervical cancer, making it the most common cancer in that age 
group. Therefore this is an area of growing concern, especially for South Mricans, 
and there is much research being undertaken to understand the disease itself and 
various other factors, which may either predispose women to, or protect them from, 
cancer progression. 
1.2 Progression from CIN to Cancer of the Cervix 
Many clinics in South Africa offer screening to detect early onset of cervical 
cell abnormalities. The initial screening is usually performed by papanicolaou (pap) 
1 
smear, which involves smearing a scraping of the cervical cells onto a glass slide for 
analysis of cellular abnormality under a microscope (World Health Organisation, 
1988). This is referred to as a cytological diagnosis. If unusually high cellular 
abnormality is detected, the patient is referred for colposcopic or histological 
diagnosis, since these are both more accurate than pap smears. A colposcopy 
diagnosis involves washing the cervix with acetic acid and thereafter using a 
colposcoscope to visualize any white (HPV infected) lesions (WHO, 1988). A 
histological diagnosis makes use of the microscope to analyse the patients degree of 
cellular abnormality, but a biopsy specimen (2-4mm of cervical epithelium) is taken 
and therefore allows determination under the microscrope of the degree to which the 
epithelium is dysplastic (WHO, 1988). The lesions are graded under the microscrope 
according to the extent of the abnormal cells; if 1/3 of the epithelium is cytologically 
abnormal, the lesion will be graded as a cervical intraepithelial neoplasia grade 1 
(CIN 1) (NCI Workshop, 1988; Shah and Howley, 1996). As the lesions get 
progressively worse (and therefore more of the cervical epithelium is classed as 
abnormal cell growth) the lesions will be graded CIN 2 and CIN 3, depending on the 
severity of the lesion. 
A woman diagnosed with CIN is either immediately treated to prevent 
progression to cervical cancer or depending on the severity of the lesion, asked to 
return for a follow up visit at a later stage in order to check the lesion progression. 
This is due to the fact that not all cervical lesions will progress to cervical cancer. In 
fact studies have shown that 47-58% of grade 2 and 3, and up to 85% of grade 1 
cervical lesions regress naturally (Chan et al., 2003; Iatrakis et al., 2004). Therefore 
although a woman is diagnosed with CIN this does not mean that the lesion will 
necessarily become cancerous. 
2 
This raises the question then, what other factors playa role in the progression 
or regression of CIN? Articles published in the interest of increasing public 
awareness regarding cervical cancer have cited the following as risk factors for 
progressive worsening of the cervical lesion: sexually transmitted diseases (including 
Human Papillomavirus [HPV] , Human Immunodeficency Virus [HN] , Chlamydia 
and various Herpesviruses), high sexual activity with multiple partners, high parity, 
long term use of hormonal contraceptives, socioeconomic and ethnic differences 
(cervical cancer incidence is higher in less developed countries - although this is 
probably due to the improved and more accessible screening facilities in well 
developed countries which allow for earlier detection and treatment of cervical 
lesions), smoking and an inherited genetic predisposition to cancer (Ho et al., 1998; 
Well-Connected, 2002; Bosch and de Sanjose, 2(03). 
1.3 The Biological Structure of the Cervix 
Apart from the above-mentioned factors, the cervix itself is predisposed to 
abnormal cytological growth in the way that it is biologically structured. The cervix 
is the meeting point of the columnar endocervical cells from the uterus and the 
squamous ectocervical cells of the upper vaginal tract (Figure 1.1 and 1.2) (Crompton, 
1976; Cartier, 1984). The area where these two very different cell types have to meet 
in the cervix is labelled the 'Transformation Zone' (TZ), and this is where most of the 
cervical lesions occur (Shah and Howley, 1996). At the TZ there is a high rate of cell 
turnover and this is conducive to cellular proliferation and tumour formation. 
3 
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The greatesl risk faclor for progression 10 c~rvical cancer is Human 
Papillomavirus (HPV) infeelion. It has bce-n reponed Ilml al leasl 94% of o;eryical 
c:meers and grealer than 84% of CIN were associaled ",ilh HPV D~A (K!ly el aI .. 
2003; Chan el a1 .. 2(03). HPV infection has now been r«ognized as a necessary 
causative agent in progressiOll 10 cervical cancer (Walboomers eI al. 1999; Bosch et 
aI . 2002:a: Bosch and San~, 2(03). 
During a 3 yr longitud iM.l smdy of unh'Crsity students. 43% of the pnn icipants 
acquired new I-IPV infections and of ttr new infections clearance occum:d within the 
first 12 monlhs in 70% of the women (Ho et at.. 1998). Although studies have ~hown 
thai 70-80% of HPV infections can be cleared (Ho et al.. 1998; Evandcr et aI., 1995) 
other smdies have soown that a small percentage (7%) do persist for as long as 5 years 
(Mo lano et al.. 2(03). The persistence of an HPV infection is the moS! important risk 
factor for CIN progression (Molano el aI., 2003). Another imponant ris~ factor is the 
type (,f HPV infecti ng the: cervix since not aU HPVs have the same oncog.:nie 
potential (Sehlechl el aI., 20(3). Higll·ri~k I-/PV infeclions resuh in lower rates of 
CIN regression than infections wllh low-risk HPV Iypes. The most prominenl and 
persislent HPV 1)'pI:. associmed wilh CIN and ~...,rvicaJ cancer. has been soown to be 
HPV 16 as shown in Figure J.3 (Bosch et al" 1995: Kay N 31" 2003: Mo l:mo el aI .• 
2003). CIN regression unalyses indicate Ihut withoul HPV infcrtion patients suffering 
fW lIl CIN had a four fold higher regression rate than palienls in whom lhe lesion was 
as-ocialed wilh HPV infct:tion (etlan el al.. 20(3). 
When viewed witl! (he knowledge Ihm these siudies also reponed a mortalily 
rale of approxim . Ild}l 50% for all cervical cancer inciclcnces, lhe significance of these 
, 
sl:ali)li~ :md Ihe I.il"ge of imp~CI HPV infeO:lion on llie f~m:lJ~ populnlioo ~'!U1 be 
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Eigyrs: I \ Pre,"l<~ rlIICS of , '.noul HI'\' l)-poes ~ In C~ o(!he C",""OJ< Of ""1Oa1 
l"'rIqIllhtlial !Ie<lI!b.!las (.,....so l aIIfJ )) , •• $Iud) of Soulh "(ncaa ... ........". (Tdcto I'toon K.oy ot al... 
2OO~) 
1.5 III' \' : Pr .. perlles and Charatlcorisllcs 
Human P~plIlOI1l;I\'INS i, a small DOn-cn"dopcd double stranded DNA ,-iNs 
of ll00tJl 8000bp (HOYoley el ai, 1996), II b ~kagcd in IIf1 iroo-:m.:dr .... J capsid 
composed of I~'O protem!\. 8O'l: LI gene prodoct (nlaJOr <;;apsid protein):and 20% 1..2 
gene prodOCI (mmOl" <;;apsid prou:ln). HPV has a double stranded drcular genome. 
Only one "!rand ~rves a~ till: coding template (figure 1.4) and 1111 the open read ing 
frurrot's (ORFs) Ilt1: located 011 Ih:1I one strand (Uowley Cl Ill .• 1996). llIc IIPV 
genome coo~is .... of a Jong oonlrol reginn (l.CR). Whl<;;h contllJIlS the ori gin of 
repticauoo and 1:OII5Uluti \e enhancer elernent~. ThcllC elel1l~nl~ are respollSl,'e 10 both 
oo--t and , ',railranseription promotion foClors. thereby ensuring Illal the "ira! genome 
is tr.LRSl:uoo once it n.1S successfully iufecled lhe cell (Cripe et 011.. 1987). Thc rei$! or 
lhe genollK" consists of 8 trunslDtionalty xlhe ORF .. : 6 encode 'e~rl y' gcne~ Ilfld the 
Oilier t\\·o encode the ·true· genes (LI alld 12), TllellC genes are designated °latc' due 
10 the nature of their transcription. which only occurs at the vcry end of the Ylral 
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tifecycle. Tran>cnPliOll of Ihl"'Oe gene-. b delayed. bee:!U:>4" Ilk') are capsid proIel,"" 
and lherefore onty need 10 be ~ynlhcsi~ed .. hen I'ira] Iqltil:alion is comptete (i.e . 
.. hen large quantilies o f \ira] DNA ha\e occumui3lni) and tM I'irat p~cny are ready 
for packaging and Q.iling the: cell to CQllllnue infection ofnaghbouring cells. 
A boer summary of lhe: functions o f all lhe: gene:. encoded in the HPV genome are 
descnbed III Table l.t below MO»I sludies dcmon~trJunJl: immunoJl:cnicity to HPV 
infection hale focU$Cd tither 0/1 the major cap~id protein l.l or the: oncogcnic protein~ 
E6 and E7, 
We 1 I ()c<criCli"n of '''''"OO I" th; Hl'Y 8fOOQlE tD![ Ibs", 'yuLin'"' 
" 
i"",allon >Jl .' .... ,1 DNA rcr1inl"''' 
• 
alilD![ ~Ie,",," • ,r.>! paructCl iDoorl>.v .. aI .• 19'11) 
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tl,," ! :\ G .... omic ""'I' or Human l'ap'!ilHtlll"iM (HPV ) It) j..Jicao< lI'o: locallOOl 0( lh1: ,,,a! ,<lid On 
m. ~ool", ~,",<l<U (Ta~~n f'l"Mll Mu"¥,. 2004). 
1.5. 1 1.1 
'The IIPV LI gcuc encodoes tilt major capsid prolein. a 55 1..0.\ pl"Olem .... tilth m 
comhlMtlon ..... llh the L2 selIC fonll5 the ·coat· around the ,·ira] DNA 10 make an 
,nfeelLOus I'ir:al pankle (Fane, 1975). 1bc HPV U coal protem is the most common 
wlUgen from HPV used for testing antibody and irnnwnc ccll re"ponslVcntsS to ttPV. 
since i! is lilt. Jirst antigen thal the host comes into contaet ..... ith during HPV lnfeclion 
and It is also !he IDOS! tonSCr.'ed HPV gt:ne (de Villiers et 31 .. 200-\ ). Yet production 
of L t pl'Olelns occurs ooly laIc in !he 'or'" life eydc, due 10 the dependence of I'irnl 
uunscripuon on the differen! Slagcs of tile ker:ltinocytcs ..... h,Ch it infects. It IS only lit 
tbe IllIbt tcnninally differentiated cpithehullayers that the LI protein is produced in 
abundanl qUJntni~ in o~r to rfICil it ~tc pacltaglng of all the replicated I'irul DNA, 
and 10 aUO\\ HPV 10 funher infect the neighbouring epithelial ceJb (SL:ll\ley et al.. 
lOOt). 
For re-earch purposes it IS pos~ib~ to expre"s the HPV Ll virus like panicles 
(VLP) in fe(:Ombmllnt 5)"tem, follOlllng IIhieh the LJ panicles as.>emble 
, 
automatically into conformationally correct VLPs (Zhang et al., 2000). Therefore 
HPV Ll VLPs can be successfully used to induce HPV specific antigen responses in 
host immune cells, allowing assessment of host immune function to HPV infection. 
I.S.2 E6 and E7 
The oncogenic early genes, E6 and E7, are transcribed into proteins which 
bestow on HPV the ability to cause abnormal cell proliferation by facilitating 
immortalisation of the infected cell (Munger et al., 2004). The E6 protein complexes 
to a host cell protein called p53. The function of p53 is to halt cell cycling if DNA 
damage has occurred, and thereby facilitate the repair of the DNA (Brenna and 
Syrjanen, 2003). When E6 binds to p53 it prevents it from performing its vitally 
important function. The E7 gene product binds the retinoblastoma tumour suppressor 
protein (pRB), a nuclear protein that regulates gene expression (Brenner and Syrjanen, 
2003). In its dephosphorylated state, pRB is a negative regulator of cell growth by 
inhibiting a cellular transcription factor (E2F-l). E7 preferentially binds the 
dephosphorylated pRB and therefore allows the cell to continue cycling (Howley et 
al.,1996). 
In non-productive HPV infections (Le. infections which are not progressing 
through the epithelial layers, but rather causing abnormal cellular growth of the basal 
keratinocytes) a large quantity of the early E7 protein accumulates in the basal 
infected cells as they undergo repeated cell cycling (Middleton et al., 2003). 
Therefore in late stage eIN and early cervical cancers, E7 proteins are abundant in the 
basal epithelial layer and these proteins could then induce priming of the immune 
system in order to elicit a response to the HPV infection. 
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1.5.3 Diversity of HPV Genotypes 
HPV belongs to the Papillomaviridae family of which 118 different 
papillomavirus (PV) types have thus far been sequenced and grouped according to the 
relatedness of their genome sequences (de Villiers et al., 2004). HPV types are host 
species and tissue specific. They are primarily grouped as either mucosal or 
cutaneous depending on the location of their preferred site of infection; mucosal HPV 
types infect the genital and oro-pharynx area whereas the cutaneous HPV types infect 
the skin (Frazer, 2004). 
It is the mucosal HPV types which cause infections at the cervical mucosal 
epithelium, but not all of those HPV types are associated with cervical cancer. The 
mucosal HPV types have been classified as either high risk (HPV type 16, 18,26,31, 
33,35,39,45,51. 52, 55, 56,58,59,68,82,83 and 73) or low risk (HPV type 6, II, 
40,42, 53, 54, 57, 66 and 84) (Gravitt et al., 1998). The high-risk types are so called 
since they are more likely to cause cellular transformation and progression to 
cancerous lesions (zur Hausen, 2(02). 
There are some functional differences between the high-risk HPV types and 
the low-risk types. Firstly the E6 protein transcribed off the low risk DNA can not 
bind the p53 protein and secondly, the E7 proteins from low risk types bind the pRB 
with ten fold less affinity compared with the high risk types (Wemess et al., 1990; 
Gage et al., 1990). Another difference between the HPV types is that low-risk viral 
DNA remains extra-chromosomal, whereas the high-risk HPV genomes become 
integrated into the host cell's chromosome, which allows the increased and persistent 
expression of the HPV viral genes, thereby leading to HPV persistence and lesion 
progression (Tjiong, 2(01). 
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Studies have shown that the HPV antigens were entirely type specific and 
elicited only responses from patients who were previously infected with that HPV 
type, especially in serum antibody responses (de Gruil et al., 1996, 1998; Gill et al, 
1998). This strict type specificity in immune responses to HPV is not absolute since 
there is some evidence for cross-reactivity of both serum antibodies and T cell 
responses to HPV types other than the HPV type with which the patient was infected 
(Hopfl et al., 2000; Kadish et al., 2(02). This could imply that immunity to one HPV 
type is cross-protective against infection by other HPV types, or it could suggest that 
those patients who had responses to an HPV type that they were not currently infected 
with, might have had a previous infection with that specific HPV type. 
1.5.4 HPV: Infection Mechanism and Viral Lifestyle 
Papillomaviruses are host species and tissue specific (Stanley, 2(01). 
Therefore HPV only infects humans and the site of infection (skin or mucosal 
epithelial cells) depends on the specific HPV type causing infection. Initial infection 
by HPV is at the basal epithelial cells (Shah et al., 1996). Epithelial cells 
continuously undergo differentiation until they become terminally differentiated (at 
the outermost surface of the epithelium) after which they are shed. HPV utilizes the 
continuous cell division of keratinocytes (subtype of epithelial cells) in order to 
vegetatively increase the original viral copy number at infection (of 10 copies) to 50 
copies per cell (Figure 1.5). HPV is fully dependant on the differentiation stages of 
the keratinocyte and only in the late stages of differentiation can the virus initiate 
expression of 'late' genes and exponentially increase the copies of viral DNA in the 
cell (Oriel, 1971). 
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This dependence on the differentiation stages of the epithelial keratinocytes 
has prevented the culturing of HPV in the lab, since it is difficult to make a tissue 
culture in which the cells gradually become more differentiated. Therefore it is not 
possible to collect HPV antigens through culturing, it is necessary to express the 
genes of interest recombinantly, as HPV genes expressed in other vectors. 
Eventually, the dead keratinocyte laden with viral particles is sloughed off the 
epithelium and the infectious viral particles are released and able to infect a new host, 
or to infect neighbouring cells (Tindle, 2(02). Infection with HPV is a long process -
approximately 3 weeks from time of infection to virus particle release, since this is the 
time it takes for a keratinocyte to fully differentiate (Stanley, 2(01). 
Due to the nature of HPV infection which was described above, it has several 
advantages over the immune system. Firstly, HPV causes only a localized infection at 
the outermost periphery of the host where immune cells are less abundant (Tindle, 
2002; Frazer, 2003; Stanley 2(03). This selective location, combined with the ability 
of HPV to prevent apoptosis of infected cells thereby preventing inflammation of the 
infected area, protects HPV antigens from coming into contact with cells of the 
immune system (Stanley, 2001; Tindle, 2(02). Secondly, at the early stages of 
infection, only low levels of viral transcription occur and it is only once the infected 
cell is almost fully differentiated that the virus initiates high viral gene expression 
(Stanley et al., 2(01). Finally, studies have shown that viral proteins may modulate 
the immune response, by interfering with cytokine production or through modulation 
of antigen presentation, in order to disrupt any immune response that might have been 
initiated (Frazer et al., 1999; Arany et al., 2002; Woodworth, 2(02). It is almost as 
though HPV was designed to avoid immune surveillance. 
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d,f(c"r<nli.ufd kralin"'")1e IS laden "ilh IIPV v,ral p.vude; re:>tly 10 ",uP<> lilt dc:><J ",II and onr, ,, 
nCl< b"",,,1 .",I""1>3.l ",,11. ,"thn from Stanley" 200 I)" 
All IlJis illformatiOIl raises Ihe qlll'Slioll: .. "hal j~" Ihe jllvo/'"emmf 0/ fhe host's 
imlll/lIlt sJ..,em ill prt'>"elllioJl Or t:iearollce 0/ II/'V ill/eelioll aud regrt!JSirlll of erN 
det"elopmrllf? TIll" foNoK-rug scctiolls .. "m go illto IIIOrt! detail at to Ihe expen"",ellfs 
Iltal /10'"" bl"t'II performed 10 dclumfllc the correlaus of protcrtiol/ ill 111'1' illfeetioll 
olld how I"e"~e resl/lts IIl!>"e improved ollr kllo.<"/"dge 0/ IIPV il/feeliOIl olld lesio" 
regressioll or progressirm. 
1.6 Immune Responses to HPV Infection 
Due to the nature of HPV, infection usually remains localized to the original 
site of entry of the HPV virion into the basal epithelium (Frazer, 2003; Stanley 2(03). 
This is especially so since the various HPV types are highly tissue specific (infecting 
either skin or mucosal epithelium). Unlike some other viruses, which can be found 
systemically throughout the body after the initial replication stages have occurred (e.g. 
HIV), it is unlikely for HPV infection to disseminate and cause a lesion at another 
site. 
One would expect that any immune responses that are elicited by HPV 
infection at the cervix would only be found locally in the immune cells situated in the 
mucosal epithelial strata of the cervix. It follows then that one would not expect a 
strong immune response to the HPV infection in the systemic T cells which patrol the 
body, circuiting in the blood. Yet many studies have shown that there are significant 
responses to HPV antigens in the PBMC isolated from the blood of patients suffering 
with HPV infections. 
1.6.1 Antibodies: the mediators of Humoral Immunity 
In most viral infections, neutralizing antibodies are the first line of defense to 
protect the host from the pathogen. Antibodies have been shown to play a very 
important role in the immunity of the cervix and are an effective protective 
mechanism in the host's defense against Papillomavirus (PV) infection (reviewed by 
Stanley, 1997; Kutteh, 1999; Quayle, 2(02). 
Studies of antibody responses in humans to HPV show clearly that systemic 
HPV16 specific IgG responses to HPV 16 VLP are associated with HPV16 
persistance and late stage CIN lesions whereas systemic IgA HPV16 VLP specific 
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antibodies seem to be associated to viral clearance (Luxton et al., 1997; Marais et aI., 
1997; Bontkes et al, 1999; de Gruil et al., 1997, 1999a). Local HPV16 specific 
antibodies at the cervix were not correlated with viral clearance (Bontkes et al., 1997). 
These studies showed that patients with HPV 16 specific IgG reactivity to HPV VLP 
Ll in their serum had an increased risk of cervical cancer or late stage eIN 3. 
There is also clear evidence that serum HPV specific IgA antibodies to the 
HPV16 E7 antigen are significantly associated with HPV clearance at the cervix, 
whereas the HPV specific IgG antibodies to E7 antigen seem to be more 
representative of previous immune response activity to HPV (de Gruil et al., 1996a, 
1996b). 
From these results, it is now apparent that using antibodies as a marker for 
cleared or persistent viral infection depends on which HPV antigen the HPV specific 
antibodies are reactive against. Antibodies to VLP seem to indicate a persistant HPV 
infection whereas antibodies to E7 might be the result of an effective immune 
response (which responded to the virus when it was in the early stages producing E7 
in the basal keratinocytes) and therefore perhaps indicates viral clearance. 
1.6.2 Cell Mediated Immunity at the Female Reproductive Tract 
The host defense system for the female reproductive tract has evolved to be 
highly advanced, involving sophisticated interaction between many different parts of 
the immune system. This need has arisen due to the complicated immune 
requirements placed on the reproductive tract. It must facilitate the entry of 'foreign' 
sperm cells and allow the attachment and unhindered growth of a foetus. Yet any 
pathogens which could potentially cause infections must be prevented from accessing 
the completely sterile uterus and fallopian tubes (Quayle, 2(02). The lower genital 
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tract, comprising the vagina and ectocervical areas, is particularly interesting in that it 
is able to facilitate the growth of commensal bacteria which in tum prevent the 
survival of any pathogenic microbes (Hillier, 1999). 
1.6.2.1 Antigen Presentation at the Cervix and the CeUs Facilitating the Process 
At the cervix there are many different cells, some structural (squamous and 
columnar epithelial cells and keratinocytes) and some for protection. The cells which 
serve to protect the cervical epithelium include the CD4 and CD8 T cells, antigen 
presenting cells (APC), B cells and natural killer (NK) cells (AI-Saleh et al., 1998; 
Bell et al., 1995; Jacobs et al., 2003; Johansson et al., 1999). 
In the mucosal epithelium there are two main types of cells that can present 
foreign antigen to the T cells in order to initiate an immune response; these are 
langerhans cells and keratinocytes. The langerhans cells (LC) are a subset of 
immature dendritic cells (DC). Dendritic cells are professional antigen presenting 
cells (APC) that patrol the mucosal epithelium throughout the body, and after 
encountering foreign antigen, can initiate a primary immune response by presenting 
the antigen to T cells. In comparison with the exocervix, the epithelium of the 
transformation zone (TZ) has decreased numbers of LC and these have been shown to 
generally have impaired function, which implies that the TZ is highly vulnerable to 
pathogen challenge (Giannini et al., 2(02). 
Prior experiments on DC activation using HPV VLP showed that DC successfully 
bind and take up the VLP, following which induce a Thl immune response at the site 
of the infection (Lenz et al., 2001; Rudolf et al., 2(01). But the DC subset at the 
cervix, LC were shown to have significantly reduced functional abilities in 
comparison to other DC (Fausch et al., 2(02). Since LC are the primary APC at the 
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cervix, these results indicate that there is a serious deficit in the immunity of the 
cervix in relation to HPV infection. 
Keratinocytes (or epithelial cells) are the primary target of HPV infection, 
therefore it is highly beneficial that these cells are able themselves to present foreign 
antigens to the T helper cells through the use of the major histocompatibility complex 
n (MHC m complexes. Unfortunately, in order to fully induce activation of the T 
cells, when presenting antigen the connection needs to be strengthened and the 
activation signals enhanced through the involvement of co-stimulatory molecules 
(Abbas et al., 1994). Since keratinocytes are not professional antigen presenting cells, 
they are unlikely to have costimulatory molecules on their surface. Keratinocytes 
presenting HPV antigens have been shown to induce anergy (a state of antigen 
tolerance) in T cells and allow lesion progression (Nickoloff and Turka, 1994; 
Nickoloff et al., 1995). Yet after induction of B7 costimulatory molecule expression, 
the keratinocytes were able to present effectively to the T cells resulting in an immune 
response and lesion regression. 
The fact that LC and keratinocytes are the most abundant cells presenting 
HPV antigens at the cervix and both show varying inability to successfully activate T 
cells to induce immune responses, suggests that there may be even lower numbers of 
antigen specific T cells to elicit immune responses to pathogens at the cervix than 
elsewhere in the epithelium. Fortunately there are other cells involved in HPV 
clearance and lesion regression, for example the natural killer (NK) cells and the 
macrophages. These cells have both been shown to cause apoptosis of the infected 
keratinocytes, upregulate adhesion molecules and MHC class I expression and also to 
secrete IFN-y and TNF-a to initiate a THI immune response (Woodworth, 2002). 
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1.6.2.2 T cell Responses to HPV Infection 
Probably the most important host immune cells involved in viral clearance, 
found both locally (at the cervix) and peripherally (in the blood) are CD4 T Helper 
cells and the CD8 Cytotoxic T Lymphocytes (CTL). The importance of both CD4 
and CD8 T cell infiltration into areas of HPV infection has been thoroughly 
investigated. Studies which have looked at HPV associated warts, and analysed the 
lymphoctes which infiltrated those warts in healthy but HPV infected women, have 
begun to define the type of immune responses and/or cytokine profiles that are 
associated with the clearance of an HPV infection (Coleman et al., 1994; Nicholls et 
al., 2001; Stanley, 2(01). Spontaneously-resolving genital warts were compared with 
those that did not regress, and it was found that the non-regressing warts did not show 
any immune infiltration while the regressing warts showed an infiltration of CD4 T 
cells (and CD8 T cells) into both the stroma and epithelium of the lesion (Nicholls et 
al., 2(01). A Thl dominant response was found in these regressing warts with 
detectable levels of pro-inflammatory cytokines (IFN-y, TNF-a and IL-12). These 
wart infiltrating lymphocytes were activated memory cells, which supports previous 
evidence that the CTL responses from patients who could clear their HPV infections, 
lasted for up to 20 months (Nakagawa et al., 2(02). These studies suggest that 
effective immune responses result in immunological memory and long term immune 
protection. 
In response to an attack of the immune system (e.g. invasion of the host by a 
pathogen) the T cells that recognize the pathogen's foreign antigens will induce 
cytokine production and/or kill the infected target cell. CD4 T cells produce 
cytokines that activate local immune cells and recruit other types of immune cells 
(e.g. phagocytes) to the local area of infection in order to eliminate the pathogen 
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(Abbas, 1994). Similarly to the CD4 T cell, CDS T cells are capable of producing 
cytokines, but the CDS cells also have the ability to directly kill cells that they 
recognize are infected (Barry and Bleackley, 2002). 
1.6.2.3 Cytotoxic T cell responses to HPV antigens 
The actual cytolytic functions mediated by CTLs involve either a granule 
dependant or a ligand to ligand induced cellular death. The granule dependent death 
is more complicated, involving the recruitment of pre-formed cytotoxic granules to 
the cell surface membrane location of the activated T cell receptor and then the 
exocytosis of the contents of the granule into the immunological synapse between the 
CTL and the infected cell (Peters et al., 1991). The granules contain compounds that 
are toxic and cause damage to the contents of a cell, including perforin and granzyme 
B. Perforin polymerizes and polyperforin complexes create holes in the cell surface 
membrane which act as ion channels (Abbas, 1994). These holes allow the infiltration 
of the cell by granzyme B which specifically cleaves a family of caspase protein 
which subsequently cause damage to the DNA (Barry and Bleackley, 2002). The 
resultant permeabilisation of the cell membrane and entry of toxic compounds into the 
cell, induces apoptosis of the infected cell and subsequent death of the pathogen. 
The method used for testing the HPV specific cytolytic functional ability of T 
cells is the chromium release assay (Nakagawa et al., 1997). This assay requires 1-3 
week stimulation and culturing of the patient's T cells. Simultaneously antigen 
presenting target cells have to be prepared, which express HPV gene products (e.g. 
VLP Ll, E6 or E7) and are labeled with radioactive chromium. Upon completion of 
the culturing period, the target cells are added to the cultured effector cells and the 
cellular mixture is left to incubate. The amount of chromium which is released during 
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antigen specific CTL activity is measured as a reflection of the ability of the CD8 T 
cells to elicit cytotoxic functions against HPV antigens (Nimako et al., 1997). 
Although the cytolytic activity is a function of CD8 T cells, the responses detected 
through chromium release assays are unable to clearly differentiate CD8 and CD4 T 
cell involvement (Nakagawa et al., 1999). 
HPV16 specific cytotoxic T lymphoctye responses were found to be 
significantly higher in disease free women than in those women suffering from CIN 
(Nakagawa et al., 1996, 1997). Furthennore, in a longitudinal study of 8 HPV16 + 
women who became HPV negative, CTL responses could be detected in all women up 
to 20 months after clearance of their HPV infection. In some cases a second detection 
of HPV infection occurred during follow up but this was cleared within 4 months. It 
was suggested that this might be evidence of immunological memory against HPV 
infection (Nakagawa et al., 2(02). 
1.6.2.4 Proliferation of T cells to HPV antigens 
Proliferation assays determine whether cells are responding to the antigen by 
stimulating the cells in a culture medium to which radioactive thymidine is added for 
the last part of the stimulation period. As the cells proliferate in response to antigen, 
they incorporate radioactive thymidine into their daughter cell's DNA strands (Luxton 
et al., 2(03). The relative amount of proliferation is determined by the amount of 
radioactivity incorporated into the final proliferated cell population. Another method 
of measuring T cell proliferation is by measurement of IL-2 production by T cells 
following antigenic stimulation (de Gruil et al., 1998). 
Proliferation studies have reported conflicting results. In some studies of 
patients suffering with CIN, proliferation of PBMC to HPV16 E7 antigens was 
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significantly associated to HPV clearance and HPV associated lesion regression 
(Kadish et al., 2002; Hopfl et al., 2(03). 
Other studies have shown that percentages of responding PBMC were higher 
in patients with persistent disease than in those patients in whom disease was cleared 
or fluctuating (Luxton et al., 2(03). It was also reported that 75% of women who 
acquired disease also seemed to acquire a response to the E7 antigen and that 
increased magnitude and breadth of proliferation responses by PBMC to HPV 16 E7 
antigen is associated to increased lesion progression at the cervix (de Gruil et al., 
1998; Luxton et al., 1996, 2(03). It has also been suggested that CIN 1 patients 
elicited the highest responses to HPV E5 antigen, compared with both patients with 
more severe disease or less dysplasia at the cervix (Gill et al., 1995). 
This phenomenon of proliferation responses to HPV E7 antigen in patients 
who are diseased but seem unable to clear their disease might indicate that those 
patient's T cells are proliferating following stimulation by the HPV E7 antigen, but 
they are not actually eliciting an effective response to clear the virus and induce lesion 
regression. Another reason for the increased responses to E7 in patients who are 
suffering with late stage CIN could be due to the fact that in a non-productive HPV 
infection, the type that leads to abnormal cell proliferation and CIN development, it is 
the E6 and E7 proteins that are abundantly expressed. Therefore, in HPV -associated 
CIN there are probably much higher levels of E7 antigen to prime the T cells whereas 
in HPV infections without CIN, where the virus is progressing with the keratinocyte 
to a fully differentiated level, there are very low levels of the early E7 gene product 
and the predominantly expressed antigen is rather the late gene Ll capsid protein 
(Middleton et al, 2(03). 
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1.6.2.5 Cervical Cancer Patients Have Impaired Immune Responses 
Immune cells isolated from the blood of patients with cervical cancer have 
been shown to exhibit impaired functional abilities in comparison with PBMC from 
healthy women or patients with CIN (Clerici et al., 1997; Luxton et al., 1996; Hopfl et 
al., 2000). These studies showed that both the non antigen specific responses to 
PMNionomycin and the HPV specific responses of PBMC were reduced in cervical 
cancer patients. 
Perhaps the lack of T cell responses to HPV specific antigen is due to the state 
of disease in a cervical cancer patient. Cervical cancer is usually the end result of a 
long-lasting chronic HPV infection. At that stage only low levels of the HPV antigen 
are expressed, which could result in T cell anergy, immune tolerance and therefore a 
lack in the ability to kill infected cells, allowing the tumour cells to proliferate 
unchecked. 
1.6.2.6 CD4 Responses in HPV Immunity: the Thl versus Th2 Paradigm 
T helper cells are CD3+ (T cells), which also display the CD4 co-receptor on 
their surface. Following stimulation by specific antigen, the T cells secrete soluble 
cytokine molecules to signal to and induce activation of other immune cells. The T 
helper cells are divided into three groups; T helper 1 (Th1), T helper 2 (Th2) and 
Naive T cells (ThO), each defined by the cytokines they produce. Th1 cells produce 
primarily inflammatory cytokines (IFN-y and interleukin-12 [ll.,-12]) and Th2 cells 
produce higher levels of ll.,-4 and ll.,-5 cytokines (to induce an anti-inflammatory 
response) (Cousins et al., 2(02). It must be noted that both inflammatory and immune 
inhibitory cytokines can be produced simultaneously by a T cell, therefore the T cell 
is assigned as Th1 or Th2 depending on which cytokine is predominant. ThO cells are 
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called 'naIve' since they haven't yet been exposed to antigen and produce both types 
of cytokines (Thl and Th2) in equal amounts due to their undifferentiated state 
(Openshaw et al., 1995). Therefore a population of T cells is defined to be type 1 if 
IFN-y is being produced in the absence (or relative absence) of IL-4. 
Studies have shown that a Thl cytokine response to HPV infection is 
preferential for clearance of the pathogen and regression of lesions (Al-Saleh et al., 
1998; Luxton et al., 1997). Women displaying predominantly Thl inflammatory 
cytokines at the cervical mucosa have been shown to be more likely to clear their 
HPV infections than women with Th2 or ThO profiles (Luxton et al., 1997; Scott et 
al., 1999). 
Following stimulation with HPV E7 antigen, only CD4 T cells were found to 
produce IL-2 and not CD8 T cells (de Gruil et al., 1998). Although it was 
demonstrated that these cells did produce IL-2 following stimulation of PBMC, no IL-
2 was detected in cervical biopsies of the patients (de Gruil et al., 1999). Therefore, 
although the assays and cells used to detect IL-2 differed, it is tempting to speculate 
that PBMC in these women were capable of producing this cytokine, but cells at the 
site of pathology were not. 
1.6.2.7 Impact of HIV Infection on Progression of HPV associated CIN 
Probably the ideal cohort of women in which to study the role of CD4 T cells 
in HPV lesion progression, would be one in which their CD4 cells are suppressed, for 
example a cohort of HIV+ women. Currently this is an area of great interest and 
much research, since HN infection has been shown to be associated to increased 
infection with high-risk HPV types. This is particularly true in those high risk women 
with CD4 counts < 500 cellslmm2, where rapid progression to late stage CIN and 
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cervical cancer is clearly noted (Hawes et al, 2003; Schuman et al., 2003; Lee et al, 
1999). In HN +HPY + women, the time from HPY infection to subsequent CIN and 
cervical cancer detection is significantly shorter, in comparison with HPY infected but 
otherwise healthy women (Schuman et al, 2(03). This indicates that perhaps the lack 
of immunocompetent CD4 T cells in HIV+ women allows for rapid progression of the 
HPY associated lesion and one would therefore deduce that CD4 T cells are integral 
to the cell mediated immunity (CMI) against HPY infection and lesion progression. 
But the study by Schuman et al. (2003) revealed that this conclusion might not be 
correct, by analyzing HIV+HPY+ patients receiving highly active anti-retroviral 
therapy (HAART) in whom the number of CD4 cells should have increased to > 500 
cells/mm2 and observed that there was no associated decrease in risk of CIN 
development or progression as the T cell numbers increased. Perhaps this is due in 
part to functional impainnent of the CD4 T cells that survived the infection of the 
immune system by HIV (McCune, 2(01). The above-mentioned studies suggest that 
CD4 T cells play an important role, but are not exclusively involved in HPY 
immunity. 
1.6.2.8 Cytokines Play an Integral Role in the Progress of HPV Infection 
The cytokine microenvironment is a crucial factor when initiating an immune 
response. At the cervix, it is maintained through the constant release of cytokines 
from both keratinocytes and the local immune cells (Malejczyk et al, 1997). Most 
studies have suggested a role for Th 1 cytokines in HPY clearance and a role for Th2 
cytokines in CIN development (Scott et al, 1999; de Gruil, 1999). 
The cytokine profile of tissues from sections of cervical biopsies of normal or 
diseased women showed that IL-12 (inflammatory) and IL-tO (anti-inflammatory) 
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cytokine levels were increased in the eIN biopsies as compared to the normal 
exocervix tissue (Giannini et al., 1998). Yet interestingly the IL-12 levels peaked in 
low-grade biopsies and began to decrease again in high-grade eIN, which could 
suggest (since this is an inflammatory cytokine) that in the early eIN 1 lesions, the 
immune system is attempting to initiate a response to kill the infected tumour cells, 
but as the eIN progressively worsens the immune system can somehow no longer 
fight the onslaught and therefore allows (or can no longer prevent) the switch to a Th2 
environment. Of importance, they also observed in the study that the region of the 
cervix where most eIN occur, the transformation zone, was on average associated 
with higher levels of the immuno-suppressive cytokine, IL-IO (Giannini et al., 1998; 
Jacobs et al., 2(03). 
These studies suggest how a skewing of the cytokines towards a Th2 profile 
does result in a more immunosuppressive and antigen-tolerant cervix and therefore 
could make the cervical cells more susceptible to infection by pathogens including 
HPV and less able to prevent persistence of the infection, which could in turn lead to 
lesion formation and cervical cell dysplasia. 
In a longitudinal study to analyse the effects of the cytokines on HPV status, 
100% of the women who cleared their HPV infection had a Th1 response at the visit 
preceding clearance (Scott et al., 1999). None of these women's samples showed any 
presence of IL-4 (the immunosuppressive cytokine). This situation was not apparent 
in the HPV negative patients, in which equal percentages of IL-4 and IFN-y mRNA 
were detected in the samples. This suggests that the Th2 cytokines might be 
employed by the immune system once the virus is cleared to then modulate and 
decrease the inflammatory response in order to prevent excess damage to the 
surrounding tissues. 
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Cytokines can have more specific roles in HPV immunity than the broad 
skewing of the host's immune response between inflammatory and suppressive. 
Studies have shown that IFN-y actually reduces HPV gene expression, especially 
expression of E7 RNA, simultaneously preventing the immortalisation of 
keratinocytes by interfering with production of the E7 protein. Yet, in defense, HPV 
E6 and E7 proteins are able to inhibit and decrease the IFN-y signaling (Woodworth, 
2(02). 1NF-a is also able to perform an anti-viral function; by repressing HPVl6 
early gene transcription and therefore expression where IFN-y can not (Kyo et al., 
1994). 
The anti-inflammatory IL-IO works against the host, increasing HPV16 E7 
mRNA levels significantly (by upregulating the transcription rate) thereby enhancing 
the progression of the CIN (Arany et al, 2002). This is an area for concern since the 
levels of IL-I0 at the cervix were found to increase, with increasing severity of the 
cervical lesion (Giannini et al, 1998). But the cytokine balance between pro- and anti-
inflammatory is a complicated one. In contrast to the many studies that have labelled 
IL-IO as an anti-inflammatory cytokine, a possible role has been observed for IL-l 0 in 
promoting inflammatory responses (Santin et al., 2000). PBMC were incubated with 
a combination of IL-IO and IL-2 (a growth cytokine and inducer of T cell 
proliferation) before stimulation. Results were compared with those elicited by 
PBMC incubated with just IL-2 or IL-IO alone. The results showed both a significant 
increase in the proliferation ability of the T cells and a significant CTL response when 
the cells were exposed to specific antigen in the presence of both cytokines in 
combination. Interestingly, the cells that had been incubated with both IL-2 and IL-IO 
were also expressing significantly higher levels of IFN-y. 
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1.6.2.9 Conclusion of T cell Mediated Immunity to HPV Infection 
From previous studies it is evident that a Thl inflammatory type of cell 
mediated response at the cervix of HPV infected individuals is a necessary factor in 
the clearance of the HPV infection and regression of cervical lesion. Yet, there is 
much confusion surrounding the optimal T cell proliferation response needed to 
induce lesion regression and HPV clearance. Most published work to date used either 
the ability of T cells to proliferate in response to HPV antigens (proliferation assay) or 
the ability of cytotoxic T cells to lyse HPV antigen expressing target cells (Chromium 
release cytotoxicity assay). The major difficulty with both of these approaches is that 
it is not possible to determine from the results which T cell subsets are eliciting the 
strong antigen specific responses, and thereby inducing the disease regression. 
Therefore it could be that the different studies are finding conflicting results since 
they are detecting responses from different T cell subsets. Therefore, more techniques 
for analysing T cell responses need to be developed in order to (i) determine the 
intracellular cytokine (ICC) responses of the individual T cell subsets (CD4 vs CDS) 
and (ii) to compare the ability of the T cells to elicit cytotoxic activity as well as ICC 
production, in response to the HPV 16 specific antigens. 
Most importantly, many published reports of CMI responses during HPV 
infection have focused on responses in the peripheral blood of infected or diseased 
women. It is well recognized that HPV types that infect the genital mucosa (such as 
HPV-16) do not cause systemic infection but viral replication is localized, highly 
tissue specific (only infecting basal keratinocytes) and tightly controlled. The value 
of studies of systemic T cell responses to such a localized infection is questionable 
without a representative comparison from T cells isolated from the site of pathology, 
the genital mucosa. 
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1.7 Objectives of Project 
Studies which have used chromium release based cytotoxicity assays have 
been able to indicate a strong role for CD8 cytotoxic T cells in HPV immunity. 
Proliferation studies and IL-2 assays also suggest an important role for the T helper 
cells in clearing HPV infections and associated lesions. Yet none of these studies 
were able to specifically distinguish between the T cell populations and determine 
which T cell subset is more involved in inducing a response to the HPV antigens. 
Therefore this study proposes to use the technique of flow cytometry, which 
allows individual analysis of the cytokine profiles and cytotoxic ability of each cell in 
a sample, thereby allowing accurate and sensitive analysis of the immune responses 
from T cells and facilitating distinct separation of which responses were elicited by 
the CD4 or CD8 cells. 
Because cervical immunity to genital HPV infections is rarely studied and 
investigations of this nature add significant value to our collective knowledge of HPV 
correlates of protection, the major focus of this dissertation was to study cervical T 
cell responses in women with active HPV infections and HPV -associated cervical 
disease. This was done using a cervical cytobrush to non-invasively obtain a sample 
of the cells present at the cervical transfonnation zone for investigation into cervical T 
cell responses to HPV. In order to relate these findings back to published reports, all 
studies on cervical T cell responses to HPV were compared with T cells responses in 
peripheral blood. 
Since HPV-16 is the major high-risk type associated with CIN and cervical 
cancer in South Africa (Kay et al., 2(03), this study focused exclusively on responses 
to this oncogenic type. Because the major capsid protein Ll and the major oncogenic 
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protein E7 have demonstrated some degree of immunodominance in published 
reports, these 2 gene products were selected for this study. 
1.7.1 Development of Techniques for Investigating Cervical T cell Responses 
Because only a single HPV study (Scott et al., 1999) and a very small number 
of HIV studies (Musey et al., 1997; 2003; Kaul et al., 200 1) have used this approach 
to investigate T cell responses from the cervix, the first objective was to develop 
approaches and technology to obtain and functionally assess cervical cytobrush-
derived T cell responses (Chapter 2). This involved detennining the viability of the 
cellular sample following collection by cytobrush method. The reliability of various 
counting methods were compared, to detennine which would provide a quick and 
accurate estimate of the approximate number of T cells per cervical samples. Flow 
cytometry was also used to develop an accurate method to quantify the actual 
peripheral blood cell contamination of cervical samples. Finally a statistical model 
was used to establish the validity of the cervical cellular sample and whether the T 
cell populations were sufficiently large to be used in the subsequent ICC assay. 
1.7.2 Determination of cervical versus peripheral blood T cell intracellular 
cytokine responses to HPV16 specific antigens 
This project used flow cytometry (as described by Passmore et al., 2(02) to 
analyse the Thl or Th2 responses from cervical and PBMC T cells isolated from 
women with CIN and genital HPV infections (Chapter 3). The T cells were 
stimulated with HPV16 specific VLP Ll and E7 in order to induce T cell activation 
and allow the detection of HPV antigen specific responses. Because immune 
responses at the genital mucosa are likely to be influenced by a whole variety of host 
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and pathogen determined factors, the intracellular cytokine T cell responses detected 
in this study were interpreted in light of these confounding variables. The major 
factors that were compared in this study are: (i) Impact of HPV type actively infecting 
the cervical tissues (as determined by Roche Reverse Line Blot); (ii) influence of 
HPV viral load (as determined by relative light units from Digene Hybrid Capture II); 
(iii) impact of previous HPV-16 infection (as determined by seropositivity in patients 
to HPV-16 VLPs); and (iv) effect of cervical inflammation on T cell responses and 
disease severity (as determined using BD Cytometric Bead Array analysis of cervIcal 
washes by flow cytometry). 
1.7.3 Determination of the cytotoxic ability of HPV specific T cells 
Finally, this project aimed to develop a flow cytometry-based cytotoxicity 
assay in order to accurately determine the level cytolytic T cell activity in a cervical T 
cell population in response to HPV 16 specific stimulation (Chapter 4). A previous 
study had reported the use of the molecule CD107a (LAMP 1) to act as a marker of 
degranulation (Betts et al., 2(03). Initially various markers of degranulation (e.g. 
Perf orin, CD107a) were compared and the CD107a based assay was favoured since it 
yielded optimal results. PBMC T cells isolated from twenty three women with 
varying grades of cervical disease and HPV-16 infection status were then investigated 
for CD107a expression (indicative of cytotoxicity) following stimulation with HPV-
16 L1 and E7. 
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CHAPTER Two: DEVELOPMENT OF TECHNIQUES FOR PROCESSING 
CERVICAL CELL SAMPLES 
2.1 Introduction 
It is known that HPV -16 is the most prevalent HPV type associated with CIN and 
progression to cervical cancer in Western Cape (Kay et al., 2(03). HPV preferentially 
infects cells of the transformation zone of the cervix because this is the zone most rapidly 
dividing (Crompton, 1976). Therefore, several techniques have been developed to evaluate 
cells or immune responses directly from the cervix. The most common include cervical 
biopsy, cervical lavage, weck cel and cervical cytobrush (NCI Workshop, 1989; Snowhite 
et al., 2002; Musey et al., 1997; 2(03). This chapter focused on cervical cytobrush 
sampling to evaluate mucosal HPV-16-specific T cell responses direct ex vivo. 
It was necessary to determine the most efficient method for collecting T cells from 
the cervical epithelium and transformation zone of patients with cervical disease (CIN), so 
that these cells would be both competent for use in direct ex vivo functional studies and 
sufficient in number for the results to be statistically meaningful. Phenotypic 
characterization by immunohistochemical staining of immune cells at the cervical 
epithelium have mostly been studied through biopsies of cervical tissues, which were 
obtained following standard hysterectomy in both healthy and diseased individuals (Bell et 
al., 1995; AI-Saleh et al., 1998). The major advantage of this approach is that it yields very 
high numbers of cells for study, but an obvious disadvantage of this approach is that study 
participants are restricted to those undergoing hysterectomy. This can be avoided by using 
small tissue biopsy sections (Jacobs et al., 2(03), which requires the removal of only a 2-
4mm3 area of the cervical epithelium in order to obtain sufficient cells for further analysis. 
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The least invasive method for collecting cervical cell samples which makes use of a 
cone-shaped brush inserted into the cervical os and rotated 360°C in order to dislodge and 
obtain cells from the cervical epithelium, was described by Musey et al. (1997). This 
cytobrush method has been successfully utilised in other studies. although further 
development and refinement of the subsequent processing of the cervical samples is still 
required (Koelle et al., 2000; Passmore et al., 2002; Milner, 2(03). 
Factors of importance when collecting cells for subsequent analysis include (i) 
viability of cellular sample, (ii) the number of mucosal T cells available for analysis and 
(iii) establishing a reliable screen and cut-off level for T cell number in a sample in order 
for the subsequent functional assays to be statistically meaningful. The first aim of this 
study was to develop the cytobrush method of cervical sample collection through 
optimisation of basic techniques and determination of reliable checks to ensure that 
samples were sufficient in T cell number and were not contaminated with peripheral blood 
cells. 
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ng a Digene Cervical cytobrush sampler 
~d according to the method described by Musey 
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lnal speculum examination, a Digene Cervical 
)s and gently rotated 360°. The brush was then 
Ibe containing 3ml transport media (10% human 
g/ml streptomycin and 2.5 J.1g/ml amphotericin B 
lting microbial organisms). Patients who were 
reported discharge (and therefore other potential 
mpact on the immune microenvironment) were 
e stored on ice and transported to the laboratory 
m cytobrush specimens 
)rush samples were incubated for 15 min in a 37°C 
samples collected where significantly contaminated 
lponent of the samples had to be broken down using 
lY trapped T cells. This was done by the addition of 
lOJ.1l1ml DTT (500rilM Dlthiomrenol; Sigma-Aldreich, Germany) and the cells were 
incubated for a further 15 min. Thereafter, the cervical cytobrush was vigorously rotated 
against the sides of the tube in order to dislodge all of the cervical cells and a pipette was 
utilised to flush the media through the cytobrush bristles to ensure all cells were 
resuspended in the medium. The cytobrush was then discarded and the transport media 
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containing cervical cytobrush-derived cells was then transferred to a conical bottom 15ml 
centrifuge tube and centrifuged for 10 min at 200 x g in order to pellet the cells. The 
supernatant was removed (and stored at -20°C for evaluation of cytokine content), the cells 
were washed once in 10ml PBS and then finally resuspended in Iml PBS from which two 
50111 aliquots of sample were removed to 2 BD Falcon FACS tubes for the CD3 Screen and 
determination of RBC contamination (section 2.2.3 and 2.2.4.3 below). The remaining 
sample containing cervical cells was stored on ice to await further processing. 
2.2.3 CD3+ Screen to accurately determine the quantity of T cells in specimens 
The technique of flow cytometry enables the study of intracellular cytokines (ICC), 
allowing sensitive and individual analysis of the cellular phenotype and cytokine contents 
of each cell in a sample population. Briefly, monoclonal antibodies to markers of interest 
(e.g. receptors: CD3, CDS or cytokines: IFNy, n..-13) are supplied pre-conjugated to 
fluorochromes. These fluorochromes emit light of specific wavelengths when they become 
activated through laser beam excitation. The monoclonal antibodies are used to 'stain' the 
cells in order to determine whether the cells are carrying the markers of interest. Thereafter 
the samples are analysed on a flow cytometer to allow detection of the antibodies. Flow 
cytometers are able to channel individual cells through a stream of fluid in the flow cell, 
which is intersected perpendicularly at one point with a laser beam. As cells pass through 
that point, the laser beam activates any fluorochromes bound to the cellular surface or the 
intracellular constituents, and the emitted light is captured by various photo-detectors, 
which then translate to the computer the relative quantity of each marker on each cell. 
Flow cytometery can be used on many different cellular samples to detect many 
different cellular characteristics or events. In this development part of the study, flow 
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cytometry was used to determine more accurately the numbers of CD3+ cells in the 
cervical samples. This was necessary since cervical cytobrush specimens generally yield 
very low levels of CD3+ T cells for analysis (-104 cellslbrush; Prakash et al., 200 1; 
Passmore et al., 2002), and the responses I was interested in characterizing were likely to 
be present at an extremely low frequency (Waldrop et al., 1997). Therefore a minimum 
level of statistical power and hence cell number had to be determined to allow for 
statistically meaningful results. 
In order to determine the absolute number of T cells present in the cervical sample, 
cells were stained with a monoclonal directed against CD3. CD3+ T cells in the cervical 
samples were then evaluated using a Becton Dickinson FACS Caliber Flow cytometer. 
Briefly, from the Iml sample of cervical cells, an aliquot of 50Jll was removed for CD3+ 
screening. The cells were incubated in the dark on ice for 15 min in the presence of anti-
CD3-APC conjugated antibody (BD Biosciences). The sample was washed with 2ml PBS 
(PCS) for 5 min at 200x g to remove unconjugated antibody and the cells were finally fixed 
in 400Jll BD CellFix solution (BD Biosciences). The CD3+ screen samples were acquired 
on a BD FACS Caliber Flow Cytometer within 24 hours of staining and analyzed using BD 
Cell Quest software. 
2.2.4 Determination of Red Blood Cell (RBC) contamination of cervical specimens 
When using the cervical cytobrush, the disturbance of the epithelium through the 
brushing can sometimes result in bleeding and hence potential contamination of cervical 
immune cells from those derived from peripheral blood. Prevention of this potential 
contamination is another important consideration in cervical specimen collection. This is 
especially important when cervical T cell responses to HPV are to be compared with the 
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responses elicited by the peripheral blood T cells, as is the case in this study. The results 
are not reliable if there is blood contamination of the cervical sample. 
Previous studies (Museyet al., 1997; 2003) have excluded cervical samples on the 
basis of RBC contamination by visually assessing contamination. This study evaluated the 
usefulness and sensitivity of this visual assessment method compared to an objective 
quantification method based on glycophorin A (CD235) staining) (Data not shown). 
CD235 or glycophorin A is expressed on RBC but not on peripheral blood mononuclear 
cells (BD Pharmingen Technical Catalogue, 2004; Chasis and Mohands, 1992) so may 
serve as a useful marker for RBC contamination. 
2.2.4.1 Sensitivity of CD235 staining for use on cervical specimens 
Once the cervical T cell sample had been processed (as described in section 2.2.2), a 
50J..lI aliquot of the cellular sample (which had been resuspended in Iml PBS) was 
transferred to a BD FACS Falcon tube and incubated for 15 min at 4°C in the presence of 
anti-CD235a-CChr antibody. The sample was washed once with 2ml PBS for IOmin at 
200 x g and fixed with 400J..lI BD CellFix (BD Biosciences). Percentage contamination of 
cervical samples with CD235a expressing cells was determined using a BD FACS Caliber 
Flow Cytometer and the BD CellQuest software. 
2.2.5 Trypan Counting method using haemcytometer 
The number of T cells in a cervical sample was also quantified using Trypan Blue 
staining and counting on a Nubaur haemcytometer. Once cervical cytobrush specimens 
had been processed to release T cells from cervical mucous, a 10J.!l aliquot of the sample 
containing cervical cells was stained with 0.4% Trypan Blue stain (Sigma; equal volume of 
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cells to Trypan stain). The stained cells were placed onto a haemcytometer slide and 
viewed under a light microscope (lOOx magnification). The dead or apoptotic cells are 
permeable to the trypan stain (Shapiro, 1988), therefore these cells will become pigmented 
with a dark blue colour which clearly distinguishes them from the translucent viable cells 
(which can not be permeated by the stain). 
2.2.6 7 AAD Staining to measure cell viablllty of cervical cells by FACS analysis 
Due to the DNA-binding nature of 7-Amino Actinomycin D (7AAD) , which 
intercalates between the guanine and cytosine bases in the DNA of dying cells, this stain is 
a simple and accurate method for determining the percentage of non-viable cells in a 
sample (Philpott et al., 1996). The stain is taken up readily by dead cells, faintly by 
apoptotic cells and is not taken up by healthy living cells (since their membranes are not 
permeable to the stain), 7 AAD is capable of emitting a fluorescence which can be detected 
through the use of a flow cytometer, therefore on a flow plot of forward scatter (FSC) 
versus 7 AAD fluorescence, the cells are depicted as three distinct populations. The dead 
population is that which has the highest fluorescence intensity and the healthy living cells 
are the 7 AAD negative population, therefore the percentages of viable cells can easily be 
determined (Figure 2.2). 
7AAD (Sigma) stocks were dissolved in acetone at 5mglml and stored at -20°C. 
Working stocks were made up in PBS with 7 AAD at a concentration of 200J.1g1ml. This 
test was performed on 50J.11 of the processed cervical cellular sample which had been 
stained with monoclonal antibodies to the CD3 marker (anti-CD3-APC). Cells were 
washed with 2ml of PBS and then resuspended in 4OOJ.11 of PBS. A volume of 4OJ.11 7 AAD 
stain was added to the 4OOJ.Il cellular sample and this was incubated for 20min at 4°C 
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followed by inunediate analysis using the BD FACS Caliber Flow Cytometer. Samples 
have to be analysed within 20min of staining in order to obtain maximum fluorescence 
readings before the stain begins to fade (Philpott et al., 1996). Unstained cellular sample 
was used as a negative control. 
Dead (7AAD Dript) 
7AAD(FL3)1 
1----+---: 
Apoptoti.c but Live (7AAD Dim) 
Live (7AAD Neptive) 
Forward Scatter 
Figure 2.1 Diagram of Facs plot of forward scatter (FSC) vs 7 AAD stain showing the three positions of the 
distinct populations relative to their viability. The uppennost population with brightest 7AAD fluorescence 
are where the dead cells are expected to sit, below that the apoptotic cells which take up stain but not as 
readily as dead cells, and finally in the 7 AAD negative area, the healthy and viable cellular population. 
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2.3 Results 
2.3.1 Viability of cervical cell sample after collection using cytobrush method 
Unlike peripheral blood samples, where the isolated PBMC is made up primarily of T 
cells, cervical cytobrush samples have a much more varied cellular composition (with the 
majority of cells being epithelial in origin) where the frequency of T cells in the sample is 
always low and varies drastically between donors. Since the diverse range of cells found in 
a cervical sample constitutes the environment in which the T cells will be stimulated ex 
vivo, it was necessary to check the viability of all cells in the cervical samples, since dead 
cells emit toxins, which at high concentrations could inhibit the function of the T cells. 
To determine the viability of the cervical samples. the cells were stained with 7 AAD. 
As shown in Figure 2.2a. the results show that 95% of the CD3+ were viable and excluded 
7 AAD stain, while 2% of the CD3 population was dead and a further 3% were apoptotic. 
Similarly. if 7 AAD staining was assessed on an ungated plot (Figure 2.2b; representing all 
cells present in the cervical sample including epithelial cells). then 70% were alive, 11 % 
were apoptotic and 19% were dead. This confirms that the cells collected through the 
cytobrush technique were viable after processing and supports previously published 
literature (Prakash et al., 2001). 
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taCh , .. Ion .. po ...... ptf't'm1lJ," oiloW an .. T <rlll (A)0 ... 1"..&0(8,_." cidIcr Ii"", "f"Vd"' .... 
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1.3.2 Quantll)' or c n J+ f~ 1I1 obillinnl IIwng eyl llbnsil ' f'I' lon iq uf 
203.2.1 NeliabillEy of Various COllnling Meillods 
One of !he main COrK;ems .. hen colll:(:lillg "",lis u5ing ,"" C)1obrush melbod is Ik 
variability in Ihe quamity Qf CO};. cells m;ovC'!lIblc: from diffcrrm pnienl !ifK'Cimcns. 
Prl.'Vioo$ studies havr shown lila! IhC' quantilY ofCD3+ T cells may range from l.!ilK 10' 
to I.B l( 10' cells (Pamoon:: CI at, 2(02). lbel'l.'f~ il is absolutely roecei'SaI) 10 
dctcnninc ",hellier then: al'l.' suffICient nllmbers ofT cell s pt'Cscnl in the CCT\'icaJ c)1obrush 
specimens for funher analy5is bt:fon: illilialill¥!he ~imuhuion processcs.. 
The u!>lIlIl method of dctennining approximale T l)mphoc)1c lIumbers ill 11M: cenular 
$!lI!Ipk;$ through 11M: uype.n coo~illJ! method wilh II. haemcyromclcr sliik, lbe number or 
T cells pn::SCIII in oeNical SMlples ... as go:tM:r.ll1y so low Ihal the) could IlOl be accurately 
QlU1I(ed 011 !he haemc:ytomeu:r slide. Based on Trypan $lainini and mBllual CQunlinll usi", 
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!I tllltJllOC}10r'nCter chamber slJde. mononuclear edl numb.: 1"'1 ranl,>cd fmm S lI. 1O~C"~1I9m1 
104.74 .11; IcfC"cll<Jml lD allthc patients investigated. Who:n one compared the ctr\ Ical ~11 
conrentrnhons detmnincd by Trypan stalntng with a~lllte CDl+ coonts on the flow 
C}10f0elet" (Figure 2.]). tile rC'suh~ 00fTl'.l3tCd \'ery poorly mdIC3ting th!!T Trypan counts 
could DOl be reliably LI§C'(] as an C'sTim31e of lympooq1e numbers [Of" cervical samples. 
Funhermore, the abullll:tocC' of epuheliaJ cells present in the cer.,.ical samples (a 5ubsTanhal 
propoftion of\O"hich were the.- same!iJU as mononuclear cell~) and the ract that Trypan does 
IlO( dj~Tioguish noclC'ar morph%gy, often made IlCcurnte differentiation of the 
mooonudcar C"ells in ttle population c)(trerlleiy diffiC"ul!. 
It '''as the n dcc-idlld thai a CD3+ "senen", u~ing now C")lometriC" detectlOO of tbe 
Iluotochromc Illhelled CD3+ T cells would be II C"(IIl,idcrably more :l('C"Uf3te reprtSC'OIauon 
of the number ofT cells in ttJr c-en'jcal sample. The numbers ofT cells in C"Cnical samples 
r::1Dg<:d from <100 TO 14'KlO C03+ T C"C'lIs per patient sample (-I50-foJd diffe!"ellC"e). The 
mean WIlS 5822 (: 1207; SD) cells ana.Iysed per patient sample. The datJ i5 represenled in 
grarl1iC" fonn (Figure 2.4). " 'hich shows thai although there W!lS mllC"h YlIfi:lbility beLween 
the T cell numbers colle("(ed from different donors. the C03+ SC"TeCn T cells e~en t s counted 
on the flow e)1omcter wen: indiCJti ... c of Itle octual number of C0 3+ T ceJl~ in the total 
sample. Therefore. theM' I'l'~ults show that although the C D3+ ~reen might not be accuraTe 
uough \() be' used as _ quantiutive aSSi'ssme.ot, it could pro'e to be a userul quaillalhc test 
LO check the quanTity orT lymphocytes in samples where the number 0( C"C'lIs might be LOO 
low to be detected by other techniques. 
For lh~ purpo~s of Ihi ~ <;Iudy, a "'toff was SCI at >.500 CD3+ C\'enls io the CD3+ 
M"!'Ccn which tran~lIe~ IntO an aC1ual CD3+ COUI'II of ..Kl15 cell< per p:uic/lt sample. m 
order 10 elimin;ue samples which had T cel l populations that would be TOO low to yield 
S1atiSllC'3lly meaningfu l results. 
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2.J.2.2 \' a lidit) of cen 1e,,1 cellula r Slullple SilO! ror fu rt ht' r u~ in .5t at~t iC".1I a Jl:lIl~('~ 
The anaIy.is of cellular responses 10 lIOn anugeo <pecific stimuli .uch as 
PMAiiOllOUlytin or PHA (which non-specilically dim 3 response from most T cells) is 
n:lalI\"C~ly e:by to analyse on the flo", c)1omecer, siocc the number:-. of stimubled 
responding T cclls is usually I~ and much higher than the bac!;groUIld value~ from the: 
unstimulated population. In CODlp;:lnson. umllysi! of a T cell populattoJn'S respomes 
follOWing exposure 10 a specific ::mligen (such as virus like panicles (VLPj. proleins or 
IIldi\'tdual pc'pides) is 001 as simple. ~iroce the percent:tge of T cell ~ which will m:ognio;c 
and rcspond 10 tbat specifIC antigen are usually relauvely low. This Iypc of dOla captunng 
is rtrerred to as Rare Event Analysis, which impJie ... that m;l)limal IlUUllx'rs of T cells need 
to be analy-;ed in order to irocrea,e the sign ificallce of the low ftc-quency posiuve responses 
above the background lel'ch (Waldrop et al.. 1997 , Roederer el al.. 2(04). 
The repercu."ion, from r.lf(" e~ell! anal),,;., ()!I a study such :b thb one. where the 
number, of cells pcr ,ample i, ill mo,! cases ICr)' limited. can rt:_ull In In~UmCtcnt 
numbe~ of cdb being :tCquired and therdon' le:rd to data of que,tionable signifICance 
11M:refore 11 is nC'CCli.l.."U)' 10 determine the minimum num~r of cells .... ltich need 10 be 
a"quitl'd in onter 10 give an 3I;curate or significant rq'lresc:nl.:ttiOO of the: low frequency 
anltgcn,sp«ific T eeJJ resJl'Ofl'>Cli el1pected from lhe ce ..... ic.al region. I hiwe u~ a 
srn:lIlhhect based stat lsucal modd (kindly ~'ided by Dr Holden Maect~r, IkcIQn 
Dit kenson, pel'>Ollnel eommunJcalioo) to calculate the mimmum number of e,en\., needed 
10 have ;;latl5l1eal confidence in the w....' frequenty HPV-spo'"Clfic Il'spon~ anticipated in 
the: )t oo), comparoo to baekgroond (unstimulated) lel·t ls of re>tpon;,e 
f'Or tbis ~ludy Tallie 2.1 below w.ss eakulated to Indicate the minimum even\) 
IlCCC.'!k\1)' for acceptance of the vanous differeoce. between predicted ~rcentagc s of 
unstimulated and le.t samples lIS st ot i~ticnlly significant From the hightightoo blocks it is 
possible 10 see thai !he previously mnllioncd CO). SC~ QII off of >500 cells (",hich 
cormlllCS 10 1 liMI amoont of "PP"W'imalcly 1000 T Q:11s pa 'ilimulation coodilion 
as signiflcam vlllucs. UnfontIfWIleiy. whooi is Iiso evident fram Table: 2.1 is that the 
djffc~c bc1"'~n bad;groorKI un~imulatc:d valuo:s and amillnl-$po:ciflC ~ses need to 
he quite high (on avmge - 0.9·1.3%) to have slali~1ical C(lnfldencc in tho: data and this is 
~usc orthc 10 ... ' nllmbers of cells ~veJllble by cytobrush. Tho: obvious implications of 
this .... ould be th. many poIentiBlIy ~al but low..,.. f~qllCncy pusiti .·+: events would have to 
be i~ in I study StICh IS this. 
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2.4 Condll~ion 
11Ie initial development of techniques for processing c;;rvical c)'tooru.,h ~a1l\pk~ 
proved to be lughly bellCficiaito tbe purposes of thi s study. By exploring new methods to 
dctcnnillC with greater 3CCuracy the numt>er of CD3+ cells in tbe sample and also the 
""RBC contamination of Ihe samples. I was benee ahle to make ~i~ion~ ~garding which 
cellular samples would be of no use in the subsequent intracellular C)1okine (ICC) a.'~y 
lind ~hould therefore be d l'oCardcd. 
In studies wliel1.l tile T ce lls are being isolated in order to undergo t:f 1'/1'0 stimulation 
with various virus specific ant igens and the frequency of positi-e e~'enIS to those $pecl lic 
antigens 15 10 .... •• the number of e~ents evaluated by flo w e)'tonlCtty need to be as 1argt Illi 
pos~ible so that the strength o f numbers might lend signifICance to the few positive e\'ents 
Doove the b~kground unstimulated population. The mosl important criteria foc lhis study 
wa.~ a CD3+ event number >~ in the CD3+ SCrNn. This correlated 10 an apprn~lnl:ltc 
qU.1ntity of 4000 T cells in the toW een.ical sample and 1000 T cells per stimulation 
condition (unstimulmcd. PMA. VLP-16 and E1). AC'COI"ding 10 a statistical model tltis 
number of cells would be suffiCient to suppon differe~s betl'ccn the IInt lgen specific 
\llrnuJ:lIion and a background or O.Sj% 10 L1'JJ dependm~ on the level or response in the 
unSlImulated sample The hIgher the b~lgrwnd the greater the antigen speci fic responses 
need to be, in order to be considered signtlicant. FolJOI' ing 1hc5e results. the CD3+ SClUn 
II'IClhod and FACS is ~col1lmcnded as an accuftlle T cell cotJDling tool. 
A technique utiltsed by many studies in onkr 10 maxlrni..c tilt: ct llular ~mnples 
potential IS ill l·j.'O culturing of the cells foc 1·3 weeu in the pre..encc or stimulauxy 
f:lCtO\'S. This method alms 10 induce proli feration or responding T cells. thcteby ampltfying 
Ihc lrdetecluble responses to specific IlDti1,'CM. This i, a nece$s,'Lty step in studies where the 
., 
T cell response to antigen is measured by a proliferation or cytolysis assay, since both of 
these techniques have low detection rates. In comparison, flow cytometry is much more 
sensitive in its detection of many different markers simultaneously, at a high rate, with high 
sensitivity, accuracy and reproducibility. An in vitro culturing step was not included in the 
processing of the cervical samples for this study since the major aim was to attempt to 
investigate HPV -specific cervical responses directly ex vivo. A major concern of in vitro 
expansion is that both phenotypic and functional properties of the T cell populations may 
change and some T cell subsets may expand preferentially over others (Moscicki et al., 
1995). In addition, because the female genital tract is not a sterile environment and many 
pathogenic and commensal organisms co-exist at the site, long-term culture sterility is 
another concern. However, it would be very interesting and useful for future studies which 
also have to rely on the cytobrush collection method to obtain cervical cell samples to 
include a comparison of direct ex vivo with an in vitro culturing stage. This could 
potentially improve both the numbers of responding T cells and the number of women that 
could be studied. 
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CHAPTER THREE: 
CERVICAL T CELL RESPONSES TO HPV ·16 Ll AND E7 IN WOMEN WITH 
HPV ·ASSOCIATED CERVICAL DISEASE 
3.1 Introduction 
The inununology surrounding HPV infection is an area of research which has recently 
gained much interest and subsequent insight. The reason for this interest is due to the 
well-established fact that certain high-risk HPV infections are strongly associated 
with the development of cervical cancer (Walboomers et al., 1999; Bosch et al., 2002; 
Bosch and Sanjose, 2003). Cervical cancer is a fatal disease and it is currently the 
primary cause of cancer related deaths in black South African women (CANSA, 
2003). 
The interesting fact is that not all women who become infected with a high 
risk HPV progress to cervical cancer. Seventy to ninety percent have been shown to 
clear their HPV infection within 12 to 30 months (Evander et al., 1995; Ho et al., 
1998). Those who have more persistent infections are at increased risk of 
developing cervical disease (Molano et al., 2003; Schlecht et al., 2003). Therefore 
knowledge regarding the profiles of the inunune responses which correlate with HPV 
associated disease progression and those that are rather associated with HPV 
clearance and lesion regression are of vital interest to research groups which are 
attempting to generate effective HPV vaccines. 
Previous insight into the inunune responses which are elicited by the many 
different inunune cells following exposure to the HPV infection has revealed 
conflicting evidence in terms of the type of T cell responses that are associated with 
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protection or disease progression. Investigation into wart infiltrating lymphocytes 
(Coleman et al., 1994; Nicholls et al., 2001; Stanley, 2001) from healthy but HPV 
infected women have begun to define the type of immune responses and/or cytokine 
profiles that are associated with the clearance of an HPV infection in this modeL 
When spontaneously-resolving genital warts were compared with those that did not 
regress, the non-regressing warts did not show any immune infiltration (Nicholls et 
al., 2001) while the regressing warts showed an infiltration of CD4 T cells (and CDS 
T cells) into both the stroma and epithelium of the lesion. These wart infiltrating 
lymphocytes were activated memory cells. A Thl dominant response was found in 
these regressing warts with detectable levels of pro-inflammatory cytokines (IFN-y, 
TNF-a and IL-12). From studies of systemic T cell responses to HPV, most studies 
used either proliferation assays to measure T cell clonal expansion in response to HPV 
specific antigens or Chromium-release assays to measure cytotoxic T lymphocyte 
(CTL) responses (Luxton et al., 1996; Nakagawa et al., 1996). Although both of these 
methods allow determination of the quantity of HPV specific responses in a patient's 
T cell population, neither allows the analysis of the actual T cell subtype (CD4 or 
CDS) eliciting the response. This is important because CD4 T helper cells perform 
different functions to the CDS CTLs therefore if only one T cell subtype was 
responding to the antigen this could result in a less efficient immune response to HPV 
infection. Importantly, most of the published data on T cell responses to HPV have 
used cells derived from peripheral blood and not the site of pathology, the cervix. 
Because HPV causes localized infection and is not cytopathic, it does not disseminate 
or have a systemic phase of infection (Tindle, 2002; Frazer, 2004), therefore it is 
obviously best to focus studies on T cells derived from the cervix. For this reason, the 
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present study will be focusing on a comparison between T cells derived from the 
cervix and peripheral blood of women with CIN and/or HPV -infection at the cervix. 
Although there is evidence showing an association between Thl responses and 
HPV lesion regression, the viral antigens targeted by the immune response are poorly 
defined. Studies in mice have shown that the strongest cell mediated immune (CMI) 
responses are against E6 and E7 (McLean et al., 1993; Chambers et al., 1994). In 
clinical studies using PBMC from healthy women and patients with cervical disease, 
T cell responses were predominantly against Ll (Shepherd and Luxton, 1999). 
Studies on wart-infiltrating lymphocytes, showed that 75% of HPV-specific T cell 
responses were against Ll (Hong et al., 1997). Therefore. I have chosen to focus this 
study on both Ll and E7 HPV-16 antigens. 
The aim of this study was to compare the HPV-16 Ll and E7-responsive 
immune cells derived from cervix to those from peripheral blood; by determining 
their phenotype (CD4 versus CD8) and their ability to produce cytokine responses to 
HPV specific stimulus. Of particular interest for the purpose of this study is the ratio 
of Thl (IFNy): Th2 (IL-13) cytokines produced in response to the HPV antigens. In 
this chapter, the technique of flow cytometry was used, which allows the automated 
and fast, individual analysis of each cell in a stimulated population. Using these 
techniques, it was possible to characterise (i) the immune responses to HPV 
infections, (ii) the cellular subtypes eliciting those responses and (iii) the cervical 
cytokine microenvironment at the time of specimen collection. 
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3.2 Materials and Methods 
3.2.1 Study Population 
lbis study involved the participation of 100 women between the ages of 18 
and 40 who had been referred to the Groote Schuur Colposcopy Clinic following 
diagnosis by cytology of CIN disease at the cervix. CIN status was subsequently 
confirmed by Colposcopy and Histology. In accordance with the Research Ethics 
Committee of the University of Cape Town all participants were fully informed 
regarding the study and their written consent was obtained. Women who were 
menstruating, post-menopausal, pregnant or had a thick discharge, any reports or 
visible vaginal and/or cervical infection (and therefore potential co-infections at the 
cervix which might skew the immune microenvironment) were excluded from the 
study. 
3.2.2 Procedures for Processing of Donor Samples 
From each patient, 3 tubes of Lithium Heparin anti-coagulated peripheral blood (for 
isolation of PBMC) and 1 tube of coagulated peripheral blood (for detection of serum 
antibodies) were obtained by venipuncture. In addition, two cervical cytobrush 
samples were obtained, one was used for isolation of cervical mononuclear cells and 
the second was used for detection of HPV types and viral load determination 
(described in more detail below). 
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3.2.2.1 Extraction of Serum from Clotted Peripheral Blood Sample 
Coagulated peripheral blood samples (collected in red capped vacutainer 
tubes, Beckton Dickinson) were clotted on arrival at the laboratory. In order to 
extract the serum from the cellular component of the sample, tubes were centrifuged 
at 280xg for 10 min, which allowed the blood cells to pellet and left a clear serum 
layer on top. Serum was extracted in lrnl aliquots, transferred to cryotubes and 
thereafter frozen at -20°C, 
3.2.2.2 Isolation of PBMC from Anti-Coagulated Peripheral Blood Sample 
Thirty milliletres of blood was collected from each patient into lithium-heparin 
coated vacutainers, to prevent coagulation of the blood cells. PBMC were isolated 
from the samples using the FICOLL-Hypaque (Sigma) density centrifugation method, 
which relies on the weights of the constituents of the blood sample in order to 
differentiate and separate the mononuclear cells (lymphocytes and monocytes) from 
the bigger blood cells (erythrocytes and granulotcytes). We used LeucoSep® tubes 
(Greiner Bio-One) to facilitate faster and more efficient separation of the whole blood 
through a fixed porous filter disk inside the tube. 
LeucoSep® tubes were prepared as per the manufacturer's instructions, by 
centrifuging 15rnl Ficoll (Sigma) through the filter disc at 1000 x g for 30 seconds in 
a Labofuge 400R centrifuge (Heraeus Instruments). Whole blood was then gently 
layered over the filter and centrifuged for 10 min at 1000 x g. The PBMC form a 
distinct 'buffy' layer between the plasma and ficoll as depicted in Figure 3.1. The 
buffy layer was transferred to a 15rnl conical bottom tube and cells were washed 
twice with 10rnl PBS for lOmin at 200 x g. The cells were counted using an 
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auloma!Cd Coutl.:!" Count.!r (Beckman Coulter. " 'lDt 18) m.ldullc Jnd ~djl"led 10 
2x l!teells/ml. 
I ,,, II posoUOll of ,hi: COfWIII ...... of ",h.>Ie blood foll ..... ,."1 dotiMy 
1ICp"""UU/l "" .. FlCOLl grad"'nL 
3.2.2.3 Collectioll >lod l'roces.~log 01' CI'T' -ka l C,lIs from C,n-I·8 rush Sample 
'''c ccrvical cytobrush sample was collected as described b) Mu!IC y ct al. 
( 1997) with the followiog modifICations. A Digcnc Cervical Sampler C}1oblUSh \\a~ 
Inserted into the ccrikal os and rotillcd 360". 1he blUSh was then rCIl\O\'cd and 
tmosfem:d mto a tra/1sport lUbe containing 3ml C\lituring media. C(IOSisting of 
I04FCS RPM! IUId SOU/101 IXmclllm. 50mglml streptomycin and 2.5 j.lglml 
amphotcricin B in order (0 pre,enl gro .. tb of Un\\~nled conlanunaling microbial 
oraanlsms, Samples were stored on itt and Ir,msponod to the laboratory .... ithm four 
hoors of cotlecuon. 
Upon IIlTival at the l abor~tory, eytobrush sample~ were incubated for 15 !lun at 
3TC. OlT. a murol),k agent, (500mM Ouhlothreitol; Sigm3·Aldrdch, G.:m1aI1Y) 
Willi then added 10 the samples and tbcse .. -ere iocub:lled for ~ funher 15 min 10 allow 
d'lHntcgralion of the mU(.~ colbti tucnl of the sample and allow the extmcuon of the 
T cells. 1hereaOer the ttrvical c)'tObrush wa.~ vigorously rota ted against the sides of 
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tile lllbc ill order to dislodge all of lhe cenical cells and funl .... rmore a plpo!lIe was 
ulilised 10 l1ush lhe media around ttr cytobrush to en,ure all cells were resuspended 
ill the medium. Cellu lar media was 1hc:1I removed to a COIIicai bonom 151111 tube lind 
cClitrifuged fOT 10 min aJ 200 x g in order to peUet IIIe cells. The supemat:ll1t was 
removed :lIId stored in) x 1m! cryowbes and kept at -20' C for usc in CBA bc:ld 
assays (section 3.4). Cells we1l' washed once in 10rni PBS wllh centrifugation al 200 
x g for IOnun and then resuspendc-d In 11111 PBS from "'hidl IWO ~ aHquots of 
sample were removed 10 2 BD Falcon FACS tubes. "The flISt n1iquot was used for the 
CD) "Screen" and 5111 anti·CD3 APe (BD Pharmingcn) antibody was added 10 sluin 
the cells. TIle second lUbe: was usc:d for IiCreening Rae cOfltaminatiOfl and IIlI 
CD235a·CyChrome (SO PlLmningen) antibody. These "serecn" tubes were 
incubated 31 4'C for 15 min to allow billding of the antibody to the respecti\e markers 
be:fore samples were washed with toml PBS and fixed in 4OO1l1 BO CeliFix (BD 
Pharmingen). These stained cells \\'ere ibcn acquired and unalysed on the S O FACS 
Caliber Flow Cylometer the follov. ing morning 10 dc-termlnc the qUaIltity oreD3 cells 
in the een'ical sample and secondly the red blood cell (RBC) conlllminatiun ur tile 
cervical sample (Sections 2.2.3 and 2.2.4. Chapler 2). 
The rest of the cervical cell sample was washed alICe again in 10m! PBS. 
resuspended in ImJ culture media und counted using the tr)'pan haenlCytometer 
method (section 2. 1.5). In ca.<oes where the ccn'ieal T cell population was greater 1h<1II 
the required 2xlo" eells/ml the cellu lar C(lncenlTlltioD was adjusted u,ing culture 
mellta. 
.t,t2,~ Stimulill j,on uf nnkal and pl.'riphl.'ral bluud T ct' lls " ilh 111'\'·16 1.1 ami 
E7 nnligl.' ns 
To in\'(:sligate T cdl responses 10 HPV·16. bOlh HPV l6 viru~ like panjdr~ 
(VLP: made up of LI ) and E1 prtMein weI'\! u.-ed as immulIOgen~, 1l\eSI.' two prol~in, 
II'rt'(' chosen \)(c1lUSC the majority of pubhcalions from dl~ascd as lI'ell as heallhy 
mdlviduals have sholl'n stroog T erll responses 10 eilher one or bolh of these IlPV 
I'mfcms (Mclean (I al .. 1993: Ch:unbcrs ct aJ .. 199·1; S~phcrd and Ullllon. 1999: 
I~ong et al.. 1991), 
" 
-' •. 2.2 ... 4. t Prrp.:lralion uoo quality (ontrol uf 111" '· 16 VLP 
HPV-16 VLP~ "ere kmdl ), Jl"CP'lrcd and purified by Eric "lUI de Walt (Dept. 
Mol~uJar and C~II Biolog)'. University of Cape: To,,·n). Bncny. HPV- 16 LI was 
c.~prcs;,.ed in BlICulo\il\ls «II~. i§Qlaled u,ing the sonic31iOO1TK'lhod (10 1}''oC cclh and 
release VLP) :md cOIICenlraled to allow extraction fll)m Ihe cdlular mIxture u..ing 
cent rifugation through cae~LUm chloride dcl'l.,it), gradients. 11Ie VLP were purified 
Ihroogh four round~ of dinJy,i~ u_ing PBS buffer. VlP-16 ~pan1Uons wert' scnt 
through rigorou~ qu:tl;ty checks: we,tern blOis (10 eonfiml reactivity 1I.;lh 
monoclonJIs nguin~1 L. I) and Cooma,~ic ~t3ining of PAGE gels (10 eonfirm si~c) 
(SuZllnllC Grove. Dept. Molecular :md Cell Biolog)'. Unlver~it)' of Cape TOII.·n). and 
eleclron microscop)' (Friu Tiede Depl. Medical Virology. Umversily of Cape Town). 
LI concentration "'3S dclermllled by Coomassle slainmg on PAGE (u_iog BSA 
M:mdanh lUll! gel dcn)itoJtlCuy 10 calculatc cOIICcntration) and confinued by ELISA 
u~ing V5 (3 monoclonal antlbod), directed again,l.l C()I1formational epito]lC'i. kindl)' 
provided by Or Neil ChrhU:nS()n. The Jake GIil1en Canl'Cr Re..earch In,cuu tc) aDd J4 
(a mooocional directed agtllllSl Iinc.Jf cpilOpc. .... nho pro\'idcd by Dr Nell Chri>lcnson). 
The ELISA t~hniqllC u<.ed VLP-16 of tr:no"'" cOl'lCcntr.Jlion (provided by 
McdImlllull('j :b lhe "and;ud again ... ",hieh IU calculate our In Hou.-.e. VLP ... J6 
conr:cnlr3tion. Figure 3.1 show~ IhI: quality control checks of the preparalion o f VLP-
16 used In this study. 
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1::i&lm_J.J An ~e of Ill< -....~ 01 VLP-16 prq>anIlion """" in thl' Rod,. VLP-16 
quoJil~ and concentrllion "'= cvIIIIIIW by 1M cIo;;tron mi<rooropy; (0) ~ 1>1 .. "linl 
_lonaI ..... ibod) iii deto:I L I (lITO'" indicate, """,ilion <II' L 1 band); and (e) VL!'·16 [USA usinl 
Vj _l<:nol l nliboJi .. l<> dcICCI LI (P;'-'" sq""'" indi<:ak Vj deIo:tioo of McdImmLdl< VL.I' and 
bilK dia_ i.ulical<: .....,g_icy 10 VLp·16 produoed. ucn. 
3.2.2.4.2 l'rtpMnllillll IIl1d f'ucitialioa of IIl'V. 16 £7 
HPV-16 107 protcm .... ere: kind ly prepared and purified by Dr Inga Becker 
(Dept. Mol«:ular and Cell Uiology. University of Cape Town). Uriefly. IIPY 16 101 
gene was amplified willi PCR using IIPV 16 L2E2E7 gene obfail>ed from John 
Schiller (l ..... boralOry of Cellular Oncology. Nat ional Cancer Institute, Ikthcsda) •• II 
lcmpla~. It was cloned inlo pI'ToEx'" IH i'rokaryotic Exp.ession Vector (life 
Technologies, GIOCOHRL). Competent DH50. ",ere tnmsfonned with lhe above 
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DNA and histidine tagged E7 protein was induced with O.6mM IPTG for 3h at 37°C 
and purified utilizing the batch wise purification protocol with Ni-NT A resin 
according to manufactures instructions. 
3.2.2.4.3 Stimulation of cervical and PBMC·derived T cells with Ll and E7 
Isolated cervical cells and PBMC, adjusted to 2 x 106 cells/ml, were 
transferred in 200111 aliquots into 4 wells (per sample) of a 96-well round-bottom 
plate. Each sample was stimulated with either (i) no antigen, (ii) the positive control 
PMAllonomycin (PMA 25nglml, Sigma; Ionomycin Illglml, Sigma) for 5 hr or 
HPV16 specific antigens (iii) VLP (lOllglml) and (iv) E7 antigen (9Ilglml) for 21 hr. 
The optimal length of stimulation for these HPV specific antigens was determined in a 
previous study (Milner, 2(03). Brefaldin A (lOllglml, Sigma) was added to the 
culture from the for the last 3 hours of the 4 hour PMNionomycin stimulation and for 
the last 5 hours of the unstimulated, E7 and Ll-stimulations. All stimulations 
occurred in the presence of co-stimulatory antibodies, anti-CD28 and anti-CD49d 
(lmglml; BD Pharmingen), since previous studies have shown that when antigen is 
presented by an MHC molecule to the corresponding T cell receptor (TCR), it is vital 
that the interaction between the two cells is stabilised and supported by various other 
costimulatory molecules. If the induction of the TCR lacks costimulation it has been 
shown to result in T cell anergy and subsequently tolerance of that T cell in response 
to the antigen (Nickoloff et al., 1994, 1995). Therefore it is essential to add antibodies 
to the co-stimulatory molecules found on the T cells. Cells were incubated at 37°C, 
5%C02• 
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3.2.2.5 Staining of stimulated cell populations 
Following completion of the staining protocol, cells were thoroughly 
resuspended and each well transferred to BD Falcon FACS tubes. The cells were 
washed once with 5% FCS PBS containing 0.01 % Azide (Stain Buffer) and then 
immediately incubated for 10 min at room temperature in 500J.lI BD 
CytofixlCytoperrn solution (BD Pharrningen) which simultaneously fixes the cells and 
their contents and perrneabilises the cellular surface membrane for access of 
antibodies to intracellular cytokines. It is important that the fixation occurs prior to or 
at the same time as the perrneabilisation in order to prevent the leakage of cellular 
contents out of the porous cellular membrane. 
Fixed cells were pelleted at 200 x g for 5 min and then washed with 2ml 0.1 % 
Saponin (0.01% Azide) (at 200 x g for 5 min). Saponin is a detergent 
perrneabilisation agent which will maintain the porous state of the cellular membrane. 
Washed cells were resuspended in saponin solution (± l00J.lI) and the following 
antibodies (obtained from BD Pharrningen) were added to all tubes: anti-CD3-APC, 
anti-CD8-FITC, anti-IFN-y-PE and anti-n...-13-biotin (which needed a secondary 
streptavidin antibody conjugated to CyChrome for detection). Staining was allowed 
to occur at 4 DC for 30 min protected from light (which could result in bleaching of the 
fluorochrome dye and reduction of the fluorochrome's intensity). Cells were then 
washed again in 2ml saponin and then stained with the secondary antibody for n...-13-
biotin detection, streptavidin conjugated CyChrome (BD Pharrningen). The 
streptavidin bound the biotinylated antibody and therefore resulted in amplification of 
each marker and improved detection of n...-13 production. Percentage CD4 T cell 
responses were extrapolated from the CD8-CD3+ population. 
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Stained cells were washed once again with Iml saponin and thereafter the 
pellets were fixed in 400JlI BD CellFix reagent. Fixed cells were acquired on the BD 
FACS Caliber Flow Cytometer within 24 hr of staining, and analysed using the BD 
Cell Quest software. 
3.2.2.6 Digene Cytobrush for evaluating HPV DNA infection, HPV typing and 
relative viral load 
The second cervical cytobrush specimen was taken using a Digene Cervical 
Sampler for use in determining the HPV types and the viral load at the cervix of 
patients participating in the study. The Digene Cervical Sampler includes a Digene 
Cervical Cytobrush and a tube of Specimen Transport Medium. The cytobrush was 
inserted into the cervical os and rotated one 360° rotation and then placed into the 
specimen transport medium and stored at -20°C until they could be processed as 
described in section 3.3 below. The Digene cytobrush used for detection of HPV 
infection and typing was always done after the cytobrush used for obtaining cervical T 
cells to minimize the chance of blood contamination of the first sample. 
3.2.3 Testing for active cervical HPV infection, HPV typing and Viral Load 
Determination 
It was obviously important to determine for each patient the HPV types 
causing infection at the cervix, and to obtain an indication of the quantity of HPV 
infection present at the cervix (viral load). The experiments to yield these results 
were the Digene Hybrid Capture® II HPV Test (to determine presence of high risk 
HPV DNA present at the cervix and an the relative viral load) and the Roche Reverse 
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Line blot assay (to identify the types of HPV infecting the cervix). The Digene 
Hybrid Capture II Test was kindly performed by Mr Bruce Allen (Dept. Medical 
Virology, University of Cape Town) and the Roche Reverse Line Blot assay was 
kindly performed by Ms Candice Sampson (Medical Virology Department, UCT). 
3.2.3.1 Digene Hybrid Capture® n HPV Test 
The Digene Hybrid Capture@ II Test allows the qualitative determination of 
how much viral DNA there is in each sample to give an idea of the viral load of each 
patient. In this study the Digene kit was used to detect DNA from the following high-
risk HPV types; 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. All reagents 
used were supplied by the manufacturer. Briefly, the samples which had been stored 
at -20·C, were thawed to RT and an equal volume of Denaturation Reagent was 
added to each sample (including a negative and a positive calibration control). The 
samples were mixed well by vortexing and this was followed with a 45min incubation 
at 65°C. The probe to the high-risk HPV DNA types were aliquoted into new 
eppendorfs (25~1) with 75~1 of the denatured sample and thoroughly mixed. The 
samples were then shaken on a rotary shaker (Thermolyne Maxi-Mix m, Type 65800) 
at 1100 r.p.m. for 3min to ensure samples were completely homogenous. Thereafter 
they were incubated at 65°C for 60min. Samples were then transferred to respective 
wells on the capture microplate and covered with a plate sealer to prevent spilling of 
the well contents through the next 60 min 1100 r.p.m. mixing period on the rotary 
shaker. Thereafter the samples were decanted and the plate was blotted welL 
Detection Reagent 1 was added to each well (75~1), the plate resealed and a further 
incubation commenced for 30min. After a second decanting of the well contents, the 
plate was washed 6 times in Wash Buffer and drained for 5min on paper towelling. 
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Finally each well was immersed in Detection Reagent 2 (75J.11) and the plate was 
allowed to incubate for 15min before the OD was determined through the use of a 
Luminometer. The OD reading was converted by the computer into a relative light 
units (RLU) value, which is indicative of the viral load of the patient. 
In order to standardise the test so that the samples from one experiment can be 
compared to those from another independent HC test, the test includes various internal 
controls. Firstly, the assay includes a positive and negative control, which are 
performed in triplicate and their results averaged. The positive control mean is used 
to determine the cut off value in each experiment. The relative light units (RLU) from 
each sample are then displayed as a ratio, in proportion to the cut off (RLU/CO). This 
allows standardisation of the experiment. The tests also include a positive and 
negative calibration control, the OD readings of which must fall within 10% of the 
means of the controls in order to validate the assay. The RLU/CO results are 
interpreted as positive if they are greater than or equal to 1 according to the FDA 
approved interpretation method. This 1 RLU/CO is approximately equivalent to Ipg 
of HPV DNA per Iml of sample media (Iftner and Villa, 2003). 
3.2.3.2 HPV Consensus PCR and Genotyping utilising Reverse Line Blots 
In order to extract and purify the DNA from inside the cervical cells which 
were collected with the Digene Cervical Sampler, the QIAamp® DNA Mini Kit 
(QIAGEN) was used. In order to perform HPV genotyping it was necessary to 
increase the quantity of viral DNA in the purified DNA sample by PCR. The PCR 
reagents for these experiments were supplied by Roche Molecular Systems, Inc., and 
the protocols followed were described by Mullis & Faloona (1987). 
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Reverse line blots (RLB) are a simple and efficient method of determining the 
actual HPV DNA types in a sample. The technique for using RLB was described by 
Gravitt et al. (1998). Each genotyping blot is a strip supplied by Roche Molecular 
Sytems, Inc, which has an array of immobilised oligonucleotide probes set at specific 
positions relative to an ink reference line. Two of the probes are control probes 
designated for 2 concentrations of the ~-globin PCR product. The rest of the probes 
are specific for various HPV types. The Roche RLB used in this study detected the 
following HPV types: high risk HPV 16, 18,26,31,33,35,39,45,51,52,55,56,58, 
59,68, MM4, MM7, MM9 and low risk HPV 6,11,40,42,53,54,57,66, MM8. The 
principle of the technique is that the amplified DNA will bind the oligonucleotides, 
which are complementary to that specific HPV type. The positions on the strip where 
hybridisation has occurred is visualised through labelling the primers (PGMY09111 
which were used to amplify the HPV DNA through PCR, section 3.3.2.2) with biotin 
and conjugating enzymes to the biotinylated fragment. Those enzymes are then able 
to break down the substrate which is added to the reaction well and this resulted in the 
formation of a dye at that position which stains the strip at the position of the 
hybridised DNA (Figure 3.3). 
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Figure 3.3 Illustrated method depicting the technique of reverse line blot detection of HPV types (taken 
from Gravitt et al., 1998). Initially HPV DNA is amplified using L1 consensus peR primers, thereafter 
the HPV DNA mixture is allowed to bind the corresponding oligonucleotide probes on the RLB strips, 
and the bound complexes are visualised through the addition of enzymes which cause substrate 
reactions to produce colour pigment at the position of the DNA complex on the strip. 
The methods followed were those described by Gravitt et al. (1998). Initially 
it was necessary to denature the PCR product (to allow hybridisation to occur between 
HPV DNA strands and their complementary oligonucleotides) by addition of an equal 
volume of Denaturation Solution (40J1I, Arnplicor). HPV genotyping strips (Roche 
Molecular Systems, Inc.) were prepared by placement into wells of typing tray and 
addition of 3rnl pre-warmed (53·C) hybridisation solution. Thoroughly mixed PCR 
product was added to each respective well (75J1l) and the strips were incubated in 
53·C waterbath with shaking for 30min. Vacuum aspiration was utilised to remove 
the hybridisation solution from each well to allow washing of the strips with 3rnl RT 
wash solution. This washing step involved a brief swirling of the wash solution over 
the strip to remove any extra hybridisation solution that may have been left behind 
after the previous aspiration step. Wash solution was removed and the stringency of 
the hybridisation was tested thr,?ugh another 15 min, 53·C incubation in 3rnl of pre-
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warmed wash solution (53°C). After careful aspiration of the second wash buffer 
solution, 3ml of SA-HRP solution was added to each well and the tray was shaken at 
70 r.p.m. for 30 min to allow complete conjugation of the horse radish peroxidase 
(HRP) enzyme to the biotinylated primers which were bound to the strip. The 
conjugate solution was then aspirated and the wells were rinsed with 3ml RT wash 
solution as before. Thereafter, two lOmin incubations on the platform shaker were 
performed with strips immersed in 3ml wash solution. After the second removal of 
wash buffer, the strips were incubated for 5min in 3ml citrate buffer and then 
immersed in 3ml colour development solution (comprising 4:1; Substrate A to B) for 
5min with shaking at 70 r.p.m. Finally strips were thoroughly rinsed with dH20 and 
stored in citrate buffer at 4°C to await manual interpretation using the specially made 
overlay. The overlay was a diagram of the strip which was printed on a transparent 
sheet and therefore could be placed over each strip, lining up the reference lines and 
used to determine what positions on the strip had been stained and therefore bound by 
a specific type of HPV DNA. Interpretation of RLB results is only qualitative and can 
not give an indication of the actual amount of viral DNA present in each sample since 
primers do not amplify the viral DNA equally and often have preference for certain 
viral types (e.g. HPV 16, in which case the HPV 16 position is stained much darker 
than other positions because it had a much greater amount of biotinylated hybridised 
DNA and therefore a higher number of conjuagated enzymes to break down the 
substrate and cause more staining to occur at that position). 
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3.2.4 Enzyme Linked Immunosorbent Assays (ELISA) to Assess HPV-16 
specific antibody (lgG) reactivity to HPV VLPs 
It has been shown that the presence of HPV -16 specific antibodies in the 
serum of individuaIs could indicate that they have had a previous infection and 
previous exposure to the HPV antigens (de GruU. 1996). Therefore in studies of 
immune responses to HPV it is of great interest as to whether the patients have an 
antibody response or not. However, looking at serum antibodies is not necessarily a 
good predictor of HPV infection, as there is a significant time lag between infection 
and sero-conversion. Serum antibodies specific for HPV-16 Ll have been shown to 
develop only -6 to 18 months after infection (Carter et aI., 2(00), with -40-60% of 
women failing to seroconvert at ail (Carter et aI., 2000; Kirnbauer et aI., 1994; Le 
Cann et aI., 1995). 
To test for antibodies in serum samples the simplest way is to utilise the 
method of enzyme linked immunosorbent assays (ELISA). This technique relies on 
the ability of the antibodies in the serum to bind to a specific antigen which the 
ELISA plate is pre-coated with. If serum antibodies bind and are 'captured' on the 
plate, then those antibodies are 'detected' by the addition of a secondary antibody 
(synthesised by the manufacturer to bind to for example human immunoglobulin) 
which has been conjugated to an enzyme that is capable of breaking down substrates 
resulting in either luminescence or colour changes in the well of the plate where the 
enzyme is located. Accordingly, the greater the amount of light or colour change 
detected, the higher the concentration of HPV specific antibodies in the patient's 
serum. 
There are many different uses for ELlS As so each one is tailored to the 
samples that it is testing for. In this experiment the protocols followed were 
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described by Studentsov et aL (2002). Since the unknown variable is the specificity 
of the IgG in the serum of the donors (i.e. whether there is an IgG specific to the HPV 
antigen), HPV VLP (lJlglml in PBS) was used to coat the of a 96-well flat-bottomed 
microwell plate overnight at 4°C wells (l00J.1l per well). The following morning the 
wells were washed twice with PBS and then blocked for 3hr at RT with 200JlI 
blocking solution (0.5% Polyvinyl Alcohol in PBS, ph 7.4). Thereafter the plate was 
washed 3 times with PBS and serum samples were added to each well (in dulicate) at 
a 1: 100 dilution with blocking solution. Both control and serum samples were loaded 
(lOOJlllwell) and the plate was then incubated for Ihr at 37QC in a waterbath. The 
three control samples are predetermined high, medium and low (negative) responders, 
obtained from a random batch of sera supplied by the National Healthy Laboratory 
Service (NHLS) in order to calibrate the experiment and control for interassay 
variability. Following incubation the plate was washed 6 times and then incubated 
with lOOJ.1l rabbit anti-human IgG secondary antibody (1:6000 dilution in blocking 
solution with 0.8% polyvinyl pyrrolidone) for 30 min at 37QC. The plate was then 
washed again and the substrate OPD solution (O-phenylenediamine dihydrochoride, 
2mg tablets; Dakocytomation, Denmark) was pi petted into each well (lOOJlI). The 
secondary antibody was conjugated to the horse radish peroxidase (HRP) enzyme 
therefore if any of the secondary antibodies had bound there would be a relative 
amount of HRP in the wells to break down the substrate and create the colour. The 
enzymatic reaction was stopped after 30min by the addition of lOOJlI 0.5M H2S04. 
The OD levels were detected at a wavelength of 492nm and 620nm (reference 
wavelength) by a VERSAmax ELISA Plate Reader. 
Before the results could be interpreted, it was necessary to check the assay's 
reliability in terms of the calibration controls. The means and ranges of the responses 
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from the three calibration controls, determined previously through multiple 
independent ELISA results, were as follows: high OD = 2.5 (3.0 - 2.0), Medium OD 
= 0.8 (0.94 - 0.62) and Low OD = 0.17 (0.21 - 0.13). Therefore to check that the 
assay has worked reliably those three controls should have values residing in their 
respective expected ranges. The seropositivity cutoff levels were calculated by 
Marais et al. (unpublished data) as 0.42 from the average OD value of children control 
serum tests against HPV VLP (minus outliers, plus 3 standard deviations). These 
experiments were kindly carried out by Ms Candice Sampson (Dept. Medical 
Virology, VCT). 
3.2.5 CBA Bead Kit to test for Inflammation at the Cervix 
Cervical cell supernatants from 23/33 patients from whom both cervical and 
PBMC samples had successfully been obtained and analysed, were tested for signs of 
inflammation at the cervix. This was made possible through the use of a BD 
Cytometric Bead Array (CBA) Kit (BD Pharmingen), which detects the presence of 
six cytokines all involved in the mediation of inflammatory responses: IL-6 
(costimulator of T cells), IL-8 (pro-inflammatory chemokine), IL-lO (inhibition of 
phagocytes), IL-1~ (activator of T cells and endothelial cells), IL-12 (most potent 
stimulator and activator of T and NK cells, inducing growth and differentiation into 
mature functional T cells) and TNF-a (activation of neutrophils, endothelials and T 
cells) (Abbas, 1994). 
The BD CBA kit comprises six bead populations that have distinct 
fluorescence intensities (in the FL3 detect~on spectrum). Each set of beads is coated 
in a single type of capture antibody to bind one specific cytokine. The six bead 
populations are mixed together and thereafter added to the test sample along with PE-
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conjugated capture antibodies (which are able to bind any of the six cytokines if they 
are bound to the beads) in order to fonn a sandwich complex attached to the beads. 
The beads are thereafter analysed using a flow cytometer, which separates the beads 
based on their FL3 fluorescence intensity and then detennines the respective PE (FL2) 
fluorescence intensity of each of the six populations. The BD CBA Analysis 
Software provided allows analysis of the final FL2 fluoresence intensities of the bead 
populations and through the standard curves set by the provided Human Inflammation 
Cytokine standards of known concentrations, it determines the relative concentrations 
of each of the six cytokines in the tested sample. 
The protocols to perfonn these experiments were supplied by the manufacturer 
(BD Biosciences). Briefly, the Human Inflammation Cytokine standards were 
prepared by doubling dilution from the Top Standard (1/10 dilution of stock) to the 
final 1:256 dilution. The assay diluent was used as a negative control. Next, the 
capture beads were prepared by removing a 10,....1 aliquot of beads for each test to be 
perfonned (including standards, samples and a negative control) and mixing together 
well the aliquots from the six individual bead populations. Aliquots of mixed capture 
beads (50,....1) were then transferred into each experimental BD Falcon FACS tube 
along with 50,....1 of PE-Detection Reagent. Thereafter 50,....1 of each test, standard or 
control sample was added to each tube and were incubated for 3hr at RT, protected 
from light. 
In parallel to the incubation, the Cytometer Setup beads were prepared. These 
were three tubes of 50,....1 of Cytometer Setup Beads which were mixed with (A) no 
additives, (B) 50!J.l of FITC Positive Control Detector and (C) 50!J.l of PE Positive 
Control Detector. The tubes were incubated at RT for 30min protected from light 
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exposure, and thereafter resuspended in 450j.l1 (tube A) or 400j.l1 of wash buffer 
respectively. 
Once the test sample staining was complete, the beads were washed with 1 ml 
Wash Buffer at 200x g centrifugation for 5 min. The wash buffer was carefully 
aspirated using a Gilson pipette and the bead pellet was resuspended in 300j.l1 of Wash 
Buffer and tubes were immediately analysed using the BD FACS Caliber Flow 
Cytometer and BD CBA Analysis Software using templates provided by Becton 
Dickenson. 
3.2.6 Statistical Analysis 
Where indicated, results were analysed for statistical significance using either 
the Mann-Whitney U test for unpaired non-parametric data or the Wilcoxon Rank 
Test for paired non-parametric data (Statistica®). 
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3.3 Results 
3.3.1 Description of women with varying grades of CIN attending the Groote 
Schuur Hospital Outpatients Colposcopy clinic 
3.3.1.1 CIN status of the study participants 
This study recruited 100 women who were presenting with abnormal cytology 
at the cervix and who had been referred to the Groote Schuur Outpatients Colposcopy 
Clinic run by Dr Lynnette Denny (Dept. Obstetrics and Gynaecology, Groote Schuur 
Hospital). Of the 100 patients, 9 could not be analysed due to blood contamination of 
the cervical specimen sample, another 8 could not be sampled when the doctor 
diagnosed them as they were suffering from micro-invasive carcinoma of the cervix, 
and the samples from 50 patients had to be discarded due to insufficient cervical T 
cell numbers (CD3 Screen cut off was set at >500 events, section 2.3.2.1). The 
remaining 33 patients were suitable for study and complete cervical and peripheral 
blood samples were obtained. The details of these 33 patients have been listed in 
Table 3.1. Seven of the thirty three (21.2%) women had histologically confirmed CIN 
I, 5/33 (15.2%) had CIN 2 and 9/33 (27.2%) had CIN 3. The remaining 12/33 
(36.4%) women were found to be negative for disease at the cervix upon presentation 
at the Colposcopy clinic. This group of women shall henceforth be referred to as the 
CIN negative popUlation, but it is very important to remember that these women are 
not true negative controls due to the fact that they were referred to the colposcopy 
clinic with a pap smear diagnosis of dysplasia at the cervix. Therefore, they are more 
likely to be patients in whom the CIN has regressed, than patients in whom no 
cervical lesion had occurred recently. 
In order to prevent peripheral T cell contamination of the cervical samples, 
any sample which was contaminated with RBC had to be discarded. The cut off for 
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RBC contamination was set at 30%, which correlated to a contamination of 0.03% 
white blood cells. The numbers of cervical samples which had to be discarded due to 
RBC contamination ranged from 1130 (3.3%) in the group of CIN negative women, 
4114 (28.6%) in the CIN 1 group, 3114 (21.4%) in the CIN 2 group and 1116 (6.3%) in 
the group of women with CIN 3. 
It was also necessary to discard samples that had too low T cell yields, 
therefore a CD3+ screen was implemented. The numbers of cervical specimens 
discarded due to low T cell quantities from each disease grade group were: 18/30 
(60%) in the CIN negative group, 6114 (42.9%) in the CIN 1 group, 7114 (50%) in the 
CIN 2 group and 7116 (43.8%) in the CIN 3 group. This study did not find that 
women with increasing disease severity were associated with lower cervical T cell 
recovery from their cytobrush specimens and were hence more likely to be excluded 
from the study. 
3.3.1.1 Antibody Seropositivity of the study participants 
Experiments to determine the serum antibody responses to HPV16 VLP were 
kindly performed by Ms Candice Sampson, Dept. Medical Virology, VCT. For the 
purposes of this study, it is appropriate to include this data in order to more 
comprehensively analyse the immune responses to HPV infection. since seropositivity 
could indicate previous infection. Seropositivity was detected in 13/33 (39.4%) of the 
women, with the highest number of antibody responses being detected in the disease 
free group (7112; 58.3%) and no responses (015) in the CIN 2 group. Interestingly. of 
the patients who were found to be antibody positive to HPV antigens, 2/13 were 
currently infected with HPV16 at the cervix, and 11113 were not infected with 
HPVI6. Of those 11 patients their current HPV status ranged from infection with no 
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HPV types to infection with 5 HPV types other than HPV 16. There were no 
significant associations between the seropositivity of patients and their subsequent 
ICC responses to HPV antigens. 
Table 3.1 Description of the women recruited into this study showing severity of cervical disease. type 
of HPV infecting the cervix. viral load and HPV -specific antibody resPOnses 
CIN Status Donor Age HPVTypes· 
Neg JP041 41 -
JP028 34 45 
JP034 28 51 
JP035 25 26,73 
JP047 45 16,69,83 
JP045 29 35 
JP058 30 16 
JP061 28 33,52,68 
JPOlO 25 51 
JP018 24 6,33 
JPOOI 50 33 
JP088 22 16 
Mean (±SD) N=12 31.8 ± 8.9 11112 infected with HPV 4112 infected with multiple types 
CIN 1 JP033 38 59 
JP084 40 56 
JP089 35 35,62 
JP091 26 51, 53, 59, 68,54 
JPOO7 37 -
JP013 23 53,51,39 
JP049 35 16,18,35,45,52,70,82,62,81 
Mean (±SD) N=7 33.4 ± 6.4 6n infected with HPV 4n infected with multiple types 
CIN2 JP060 31 35 
JP062 35 35 
JP008 42 68 
JPOll 28 16 
JP014 52 35 
Mean (±SD) N=5 37.6 ± 9.6 515 infected with HPV 0/5 infected with multiple types 
CIN3 JP029 31 18,35,39 
JP043 38 16,33 
JP048 38 16, 18,31. 53, 56 
JP055 62 16 
JP066 34 31,33 
JP068 34 -
JP017 36 16 
JPOO2 49 73 
JPOO5 42 52 
Mean (±SD) N=9 40.4 ± 9.7 8/9 infected with HPV 4/9 infected with multiple types 
aRLUlCO = Relattve Light Uruts/Control measured by Hybnd Capture II 
"values in brackets are negative for HPV DNA at the cervix in the HC test 
end = not done 
d? = equivocal 
* = data kindly provided by Ms C. Sampson, Dept Medical Virology, UCT 
t = data kindly provided by Mr B. Allan, Dept Medical Virology, UCT 
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Viral Loadt Antibody 
(RLU/COt Status· 
(0.25t + 
16.93 + 
56.03 
-
(0.25) 
-
4.44 + 
73.46 
-
39.72 ?d 
709.83 + 
(0.33) + 
6.39 + 
406.33 + 
n~ 
-
119.3 ± 229 7/12 
10.08 + 
nd ? 
nd 
-
nd + 
(0.34) 
-
2236.26 + 
64.49 -
577.6 ± 1106 3n 
490.63 -
(0.47) -
11.26 
-
745.02 ? 
3.58 ? 
250± 347 0/5 
121.64 
-
270.79 ? 
25.39 
-
272.34 -
695.43 + 
nd + 
80.46 + 
2.75 
-
231.37 
-
212.5 ± 222 3/9 
JJ. tJ HPV Genlllyping II r III I' "ully plrtidpMnlS 
Experiments til o:ktennine the HPV ~llOtypes Infe.:tmg each pahent's cerv,x 
were kindly perfonncd by Ms Candice SampSOfl. Depl. Mo:dirnl Virology. ucr. For 
the purposes of thIS study. II was nccCS5a1)' 10 melude this data m orocr to more 
comprehenm'c!Y analyse thc immune responses 10 HflV infeelion. 
Twenty two dlffcren. Iypes of high lind low risk Ill,\, were de1c<;lcd in the J3 
women lested through the U5C of Roelle I't'\'crse hne bioI genol~'Pmg (Figul't' 3.4). 
HflV 16 was lhe preoommilm type. fOlll1d in 9fJJ (27"'_) of lhe individuals 
panicip.lling in Ihe CIN Iiludy The nC~1 most prevalen1 HrV types were ilPV JS 
(23·~). HPV 33 (17%) and IlPV 51 (130/_). The number of women Wilh IIPV 
Infection rrable J.I) was nOl significantly grealer Wlln Increasmg disease severity. 
There was no com:lalion between multiple HI'V Inteclions and d'SCBse grade. 
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{i"\If!; 1 4 The 'n"'" 0( IlI''' ..... od in "'"",en ancndina the Colposaopr ~lInic. 'fhc, HPV 'Jre>"-"'" 
d<tto'minoed lhou.lJlh th. "'" Qr lI"""'}p,na""'",.e Ii"" bl",. IRlB) ... ppI~ by R,dIe IJi.,.,.,..,.,... 
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JXI"I;"ipllling in "'" ot...Jy 
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.\.3. 1."" Cornlal ion or ct"n ical diM-Mse lienril) wilh J JPV Vi r .. l I.ood 
~ Digcne Hybrid CaplU/"e (l1C) ® II IIPV Test allo .. '! lhe dctl."rminaLion of 
the relath·1." amount of high risk III'V D~A in the cells isolated from thl: IXrvix with a 
C}1obn1m. "Thcreforr II gl\~ !Ill Indtcation of thl: amounl or VJr.11 DNA and ' ·Irul 
replication occurring at thl: HPV InfeCied cenix. Fa thr PIllJ)O§d or th is study. the 
Ilybnd Capwre experi melll was l indly perfonncd by Mr Bruce Alkn. Dc",. Medical 
Virology. ucr. ~ data depicted preYious ly in Table 3. 1 re\'e~led high risk HPV 
DNA in the cen·kal cytobrush samples of 231'28 (82.",, %) of ~ticnts. Three of the 
fl.·e patients who were ncgali,·e fOl" high ri,1; liPV DNA nt the cervix using He were 
found to be positive fOl" HPV DNA Ill ihe cervix using the PCR pnd RLB method. 
This coold be due to the facl thai if there wa~ D very low copy nLlmNr o r ~IPV DNA 
in tOOse cervical cytobfush specimens. il might nOl h3.'e been enough to bind the lie 
probes. and even if il was delected by the HC probes.. the rt.'iultant wbMrule reac1ion 
would hm! been insufficient to change the 00 reading to :a ~th·e ,·alue since lie 
[oCt a cUI off for positivi ty at I pg/ml (:I: 5000 DNA copies). In tlv: RlB method. the 
IIPV DNA has been amplified through D prior PCR ' Iep. <,(l there ~ many ~ 
copies o f the IIPV DNA to blRd to IIv: RLB rrobes and theref~ many more 
oompkx~ cap;t.ble of IncreasIng (he magnirudc o f thc sub:.lnKe reaction. thereby 
increasing the detection oCthe HPV DNA. Also. (he HC test dotli not probe for aU (he 
I)·pe$ llul can be dclCCled using RLB. theref~. for patio!Q( JI'035 .. hleo had ~IPV26 
aod IIPV7.1 ;u the ccrvIJ.. the HC results would !law ~n oegative since the~ two 
HPV 1>"JlI."S are not detected in lie. 
The results from the Dt~ne Hybrid Capture«t Jl HPV test " ·o!re compared to 
the §tage of CIN disea.-e in the patient groop. Tbe datil is caplured in a box and 
,,·hisker plot (Figuo: 3.5). Each boll. n:prescnts the .ira] load data values for CIN 
" 
/lCgative. CIN I. CIN 2 and CIN 3 patients. The "hislcers are rcpn:scnt.:uive ofthc: 
uandard error orthe results and tilt: mean viral load value for each group is depicted 
by the center horizontal line drawn in each 0011. TIM: plot seems to indicate that I 
higher .. iralload was associated with CIN I patients. but due 10 tile magn;ll.de of tile 
Jilandard elTQr ~ and the facl thaI II>!: mean of all the gro<.tll'l are in close nn~ of 
one anoIher, il can be concluded Ihat then: is 00 significant correlll1ioo bnwccn the 
" iral loads and the CIN 5llItus. This was also conftnnal SlaliSlically by o"crlll) inll the 
plO! with a regression lilll:. the r value: of .. hiell WllS equal to 0.006 (data nO! sllo"n). 
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J.J.2 AI(( of womn r«rllllnl illiO IItt ~I.d)' .. d T n il ....rourr from Ib~ir 
CH"' ioCllI Sp«imcu 
The melll'1 a~e of Ill<: women .n each &fUUP showed a non.,ignificanl 
illCreI!sing lrend rrom 3 1.8 :I: 8.9 )'~an (mean ± SO) (orCIN l'IC'gali~~ wCtmtm 10 )).4 
.* 6.4. 37.6 h 9.6 and 40.4 * 9.7 )'ta/$ for CIN 1.2 and 3 respccti~ely [fable 1. 1). 
Ilocau:oc of the 10,," T eclb rid<b ... hieh .... cn:: obtained from the Ii", 2S pat;""", 
included in the ~tud)' (on .... hich no age restriction had been placed). i\ " lIS (\e(:idnllO 
4c1ude WOllltm who .... ere ei rher menopausal Of posI-menopRUsal (> 40 years of.,e). 
InCl't'Rsin8l18e and mcnop.rtusc is Ihought 10 impac, roegati\'cly on !lie cellular yield of 
women migrates into the cervical os. and the c;crvical T cells an: lherefon: Ic$!; 
accessible to,he cytobrush (Cromplon. 1976). Figure 3.6 oompares the I&e oflhe 
patien, y~ the T cell yield. from the CDJ.+. screens pcnOt!llnl on 22 .. omet\ 
attending the Groote Schuur Colpo5OOpy e lin;'" venus Ihelr respective 1&<:. 
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3.3.2 In l r" ..... lIul"r Cytokln" (IFN-y .. nd !L-JJ) Production Follo,,;ng 
Stimulation of C~n·k .. 1 and Peripheral T c-eHs using HPV1 6 Spedri c 
An t!gt'ns 
3.3.2,1 Indi\'K!uall'a tlenls ICC Respon.;es 
Cervical nnd PBMC T cells from 33 patients "'ere stimulated with IIPVI6 
specifie antigens (VLP L I and E7) and then stained for intracellular lFN-yand lL-J3 
eytokines responses. Figure 3.7 shows representative plolS from srimulllllon of donor 
JP088's cervical ce ll~ ilIld PBMC. It is clearly evi(icm that while cervical T cells and 
PIl.\IC both respond readily to PMNiollOmycin (0 non-specific stimulus). the 
frequency of their resPOllseS to HPV llllt igens is of a much lower magnitude. TIle r.lW 
data from the antigen specific stimulations of allthc patients' C<lrviea] and peripbcral 
T ce ll ,. which was acquired through the now cytometer. is listcd in Tablc A.I aoo A.2 
In f\p~ndix A. 'There were <I donors woose ICC responses III pantcular, stood out 
from the data: jp().l7 (eIN negative). JP041 (CIN negative). lP049 (CIN I), and 
JI'043 (CIN 3). Because each donO£ shov.·oo varied bockground c)10kine production. 
results !lavc been nomtalized per donor by clIpressi ng tbe pcrccmage response per 
donor as fold over unstimulated cells; thereFore each intraccllullll' cytokine (ICC) 
percentage lias been div ided by the percentage of positl\'c events in tile unstimulated 
popuJution from Ihat respective donor. This a!lowed stlllldardiZa! ion of the results so 
that me responses from different individuals coole! be compared. 
111e HI'SI donor of intM'CSt is If''O.*7. from the CIN negative group. This donor 
had un active HI'V 16 mfeclion allne cervix, and HPV l6 specific antibodies in their 
serum. Out of all the dollOl1l in the study. tile CD4 PBMC T cells From donor JP047 
el icited the largest (fold over tmckgroond) production of (FNy (9.5 fold and 78.5 Fold 
over background following stimulation with LI alld E7 respectively). 'The responses 
to both HPVI6 VLP LI and E7 3t the cervix of JP047, howcver, ""ere definitely 
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sLe ... .:.J to Th2 cytokine production.. 1lie CI).UIL-lJ production ... a, 6.03 and 3.118 
fold O,'tt background and the CD8/lL-IJ .... as 13 nud 7.5 fold over bockgroond. in 
respon~ to \l;muL:llion .... ith HPV I6 VLP LJ or E7 anti~n n:~pcct ively, The IFNy 
production in I'\"~ponse 10 LI or E7 .... as barely dctc:ctnble (al Ics~ Ihan 0,3 fold over 
bac~ground in both CD-' and CDS poptJ lalion~). 
Another C IN negative patient, JPC»I. .... ho was n04 infceted with HPVI6 III 
the ~'enl.'l, but .... ho did have ant ibody responses to HPVI6 VLP. >c..-med to hal'e 
n:mar~llbJy high Thl rC$poIl'>l:s 10 Ihe HPVI6 VLP Ll antige-n III the cervix Ilnd 
PBMC, The PBMC CD-' and CDS populations produced II and 7 limes the amount 
of IL- 13 compared to the background un<;timu):lIcd populalions, This was renect,,-d aI 
an even higher fold In Inc cervical T cell~ ..... here C~ cells produced 75.4 (fold Oler 
bac~groundland the CDS cells 8O.7S (fold over background) IL-1J in response 10 Ll 
antigen, The cervical T cell~ froln Ihis pllilent elicited ~ highest Th2 responses (fold 
nbO\'e bac~ground) to the HPVJ6 VLP LJ IlIltigens in comparison ",'ilh the Th2 
responses of aJlthe donor<o. 
JP049. ~ patient willi CIN I. h:td the higheSi number of HPV typc~ infecting 
the cer.'icaJ tissues. Nil'll: HPV typc~ ,,'en: dcte-ctcd through RLR including HPV 16, 
This patient had good IFNy teSJXNlSC!l to HPV 16 VLP L I and 1:7 III the PBMC. CD4 
T cell, pmdu=.i lfN-y respon)C5 o f .5 and 6 fold over backsround (followlI1g 
st:imulation with LI and E7 antigens n:Speclll'e]y). and the CDS T cells produced .5 
and 14 fold Ol'cr background (L1 and £7 antigens n:sptttivcl~), The.~e resu lt$ were 
reflected at the cervi:l:. '" here cerv~aj CD-1 cells produced IFNl re." ponses o f II and .5 
fold o"er background, al tbough the cervical CDS cells wen: less effective tMn the 
PB~C CD3+ T cells. producing only 2 folJ llbov~ background 1FN1 when scimulated 
with Lland no more IFNllhan the background populntions when stimulaled with E7. 
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1lJe only Thl r<!s[lOO<;Cs wllicll \lcre grealer Ihan 2 fold O\'cr IxIckgroond. were lOOse 
elicited by Ille PBMC und cervical C DS T celiS in response to E7 stimulmion. 
Finally. in donor Jf'O.t3 woo was sufrering witll CIN 3 and had an ac tive 
HPVI6 infection at the cervix. II was interesting 10 obsef\.'e that there was remarkably 
high Thl eylOkine production in the pa lient's PB MC. bul tile patient's (.'e",·ical ce!ls 
dId nol el icit any detectable rcspon).CS (e ithe r IFNl Of IL·13 produetlonj ubo\'e 
background. fo!lowing stimulation with lhe HPVI6 specific anligen~ 1lJe PS;\-1C 
CI)l. cells produced 48 and 46 t imes lbe amount of 1L·13 detected in the unstimulated 
populatioo (10 Ll and E7 antigens respectively) and the CDS ce ll s produced 10 and 9 
ti nJe.O; mon: IJ...J3 thllll Ille unsti mulated population. The CD4 Hnd C DS ce!ls did 
prodocc deleclable levels of TFNy. bUI these were low in comparison to the IL·13 
production (CD4: 3 and 5 fold above ~kground and CD8: L5 and :2 fold above 
background 10 L I and E1 respectively). The antibody ~1aIilS of tbis patien! was ncar 
the: cut-off for positive. which implies that. Ihe re~ult was not negative but it could not 
be re liably considered pos itive either. 
figure' 7. R"pn:,., ........ ·c fACS pl"" IIR ""',",'n on lhe roll ...... '''' 2 pales. dopicti", the popIllauon, 
nr CD3+C.'01! ... nd CD3+CD8. (CI)t .. ) T celli fro", (A) <:,,,,,eal 'I'edmcns and (B) PBMC 'pe(:ImoM 
or oonor JPO!!8 sl;mul .. e<J ,,-ilb PMAII (Shr; first """"I). IIPV\6 VLP L.I (second "" ... n. HPV 16 E7 
.nl;~n (I/urd "" .. I) or ltn unSl imul,1N (21 hr: 1>S1 I](I""!) In 1110 pn::sel>OO of C(lSllmulalory roolecuks 
and Bi'A (for II", 1.'1 Shr). c,,11 .... ere swned fo< CD3·AI'C. C[)I:l·ATC. IFN·y·PI! and IL·l)· 
C)Chro~ 10 allow JifrerenliailOll ofTh I .1Id lhl "'sron""s '0 ibe T ...:1\, lJOPU!auool- V31.cs sbo" n 
in .orh qW>dranl re~nl J>I'"",nI 3gcs of CD:J.+ T ce lls respMd'''~ m IIIc i"<:" SitmulllS. 
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CIIIIII, U 
.\.3.2.2 COnlll"riwn or ICC I(l'!o l)l}n"..." froUi 1111 ~tud.l PlHlidpants according 10 
diSt-use grud~ 
In II study orlllis l llld. II i~ of illl~n:SI whether there an: any signmCllllt trends 
between tIM: responscs from paticnb witll varying grodes of discuse. Unfonunatcly, 
the number of patiems included in the study from whom it wa.~ possible to lUIal~ 
both cen 'leal and PBMC T cells was small nod therefore ~trong sigmficant 
lI."-OCialions between tIM: vnrious ICC re~ponsc, and the patients ClN statu, "'lIS 
limned. Due to the amount of row dala from the 33 p.1licnts ( It ~ted in Table A.I and 
A.2 in Append;.' AJ. the re~uJts !lave been .ummarised in order to compare the 
possible trends tl\;l1 could bo: occurring nnd whIch might becOme 1110C'e ~ignificnl1l in a 
Iaf£~r "lilly popul~tlnn . 
The PMAll stimlilatioo wus included ao. B po~itive control to ensure that the 
cclb we re \ iable and cap.lble of producing immune responscs Wld also tn \'crify that 
the a,say was valid and working COntttly, llr dllla ~hown in Figure 3,& illuSlnl1c, 
that PMNI stimulation suece)5fully induced Thl e)1okioc production In boIh C04 
and C DS cells iMllated from either the ccrvilt Of the pcriplll"ral blood, PMAII IS 
pnmarilyan inducer of lbl cytokillC!o lherefore the: result, for the Th2 (IL·I3) 
eylOkines are faJ lower than fOf tbe Thl, In onier 10 ensure tbat the ItlCk of detection 
of IL-J3 Ic\'cls in the positive control was due to it DOl being produced and not due to 
a~say faihlrc to deTecl il. a Hick 2 cell hne wa.~ pureba-wd front BcckTOIl DictinMJn 
BIOIIienr:es, Thl< Hick 2 cell hoc IS primed TO produce: ",ell characterized levels of 
1lt2 eytotioes (slIC'h ao. TL-4 and IL- 131. thercfon: the cells wen: stained and analysed 
by our Slandard method and .... ~ found That the C'ytokiocs ..... en: cffectivel)' detected and 
Ie\'els of dcte.;(iQll compBl'ed wuh those repol1cd by the manufOClurer (data not 
,.oown), Therefore if IL· 13 wa. being produced il should with confidence be delecta!. 
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Figure 3.9 show~ n compnrison of lhe n,·cragc: ICC prodUChoo hy differen! T 
ccll subsets in responsc I., lhe HPV sp«ific ~llmulnllon condnions (VLP LI and E7) 
from the three grou~ of disc.lS('(( womcn and the group of CIN negauve women. No 
significant trend was llOticed In Icnns of c)tollllc response und dl:.case 'iI:\"cnty 
although i~ol:l!ed incIdence.<. of iigmlicanl respon'lt:S (oompanod to the neg;lt;IC group) 
were lIOI:ed. TIle relevance of Ihese siinifieant tindmg~ ;~ unclear. Theo;,e figure~ did 
IndieJte \hal the Thl responses clieiled by the cervical T ce ll s were gencrnUy 10"'cr 
tban tbose prodlJ(."Cd by the blood T ~'etts ItlId this b ~upponcd in the CD4+IFNy+ 
population "'here a comparison of the PBMC and c.:rvieal data from each patient in 
lh~ CIN3 group Wll.~ detcnniocd to be- significantly dlffe-rent (p=O.036: Wilcoxon 
Ranked test for dependant nonparuntelOc I·arinble.~). Thl' 'Ignlticance w~~ only 
nOliced in tile ItPVt6 VLJ> LI stimulated populations and WIi'> nOi found to be 
~ignitkant In the responses 10 E7 antigen. 
lltt· results in Figure 3.9 also suggest Ihat there might be: a trend of decreasing 
Th2 respon:.es in hoth PBMC and cervical T cells to both LI and E7 wuh disease 
!ielwity. The interesting dlfferella' WlSS lhat in cervical T cells the largest IL-13 
re~pon,("S were pnxh.ICed by celh collecled from CIN negalive worne-n. wherealO In Ihe 
PBMC reSponses. II~ largest respon$Cs were from T cells coIlccled from w'omen "uh 
lale I>lage CIN 3 d ISease. "These are Ixxh Interesting points 10 acknow ledge bul 
~ignificance "a~ only round 111 noc tJf the comparisons: III responses to VLP U. the 
ce .... ·ical CD.HIt.- 13+ response was significantly higher in the Ch" !legall''C group 
13.24' :. 1.376: me:)n ~ SD) than lhe CIN 3 group (0.7-' I ~ 0.273) {~.().\; Mann 
Whllncy U leSl comp;uing the resu llS of Independent IIOnparametnc doll'} points). 
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3.3.2.-' Th~ imp""1 Or.'~ l j H' III'\" 16 j n fec lj"n~ :II th l' c<'n IX un n 'n il' ,,1 and 
pt'ripheral hlood immune reslWlnses 10 L I and E7 
The abihty of cell~ to produce T edl IIPV antigen specific responses were 
compared in HPVI6 infected individu:lIs and tho>c without HPV I6 infeclion (but 
potentially sufferi ng from other HPV infections) in order to delermlne whcther the 
actual pre>ClICe of IlII IlCtive HPV infection at the cervix might Innucncc the responses 
of the patients T cells. 
Figure 3. 10 shows the mean ICC rcspon~ (IFNl and IL-IJ production in 
CD4+ and CD8+ T cells) to the VLP L l and E7 antigens, in both cervical cells and 
PBMC irn:spccti\"e o f the disease grade of the patient. 'The ~r.lphs seem to show th3t 
the PBMC of HPV16 infected patients elicited higher ICC responses than HPV·16 
DNA IlCgntive women on 8\"crnge. but this was not statistically significant. The 
~-ervical cells from HPVI6+ seemed to produce less IL- IJ (1b2) responses th3n the 
cells from the HPV 16 negative wmncn. 
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l1tc ICC re.poo~ to HPV 16 amlgen from cuber HPV 16 mfeeted wom(,Jl or 
IIPVI6 DNA negative WOJlK"Jl. an: <kpicled in Figures ).11 and ).12I1ccording to the 
pJtient"s diS<!ase status. and the ccllular subset elicihn, th(, l"C~ponses; PB!l1C or 
ccnkal cells. In PBMC cells. the CD4I1FNy respon.cs to E7 SlimuJalion seemed to 
increase (with disea.-.e grude) ill ~lPVJ6 negati'·e \l,00l('1l but decrc3.>e in HPV 16 
infected women. to.lo§t of the P8MC n:sjX\IIscs had such largc crror b3l"i (SEMJ that 
they \l,cre not able to in(hcaJe tnte trend, occurring in the daJa. There \1,&5 OOC' 
,igniricant posih''1.' com'latiOli in ;!II;rcasing CD8f1L·JJ respottses with disea..e Ilr.ide 
following E7 Mimulation elicited by PB~IC rrom the HPVl6 in[('("ted ,.Iomen 
(n:gl"C.);siOli va[t,IC. r-O.752). "The PB~ IC from women with funiw:r progressed CI~ 
produced mud! higher amOUR!..> of IL·I) cylOJ.a nc ttwn won~n with early 'tage or til) 
CIN disease at lhe cervix. 
In the graph, C()CTelatmg the e ll" Status of tOe p;1hcnts (ei ther II PVI6+ or 16 · 
won1<:n scp;1nltely) with the 3''1.'rage T cell l"C\JlOIlse elicited by their cervical T l-eJlS. 
the trends obscn·cd showed docn:a.~,"g levels of 11..,.1) c}'\okinc production conelated 
to an increase in disca~c progression in the CDS T cell ,u~t of HPVl6 infC('lcd 
samples (Figure ). 12). 'The correlation between CIN MalUS and magnttude of 
COS+IL·l)+ ~ponse~ (0 IlPVl6 1:7 amigcll tn the HPY I6 in fCClCtl p;1lien!..> was 
stamllcally strong (t..o.57), \I, itlt the CIN tlCgati\'e patients producing large Th2 
responses IlIld the C IN) patients producing the smallest Th2 responSC$. 1be.o;e In:n\h 
were only observed In thc HPV 16 infected p;llkllL groups. 
StaUSfkai rompariso .... of Ihc: ccrvical T cdl response~ between p;1lients \l,ho 
were suffenng from dIfferent stages of CIN but who were all infected w1th IIPV I6. 
rt,·e31ed thaI HPY16 infected p.lliems suffering from CIN ) responded to ~IPY I 6 
VLP l. 1 with significantly hlghcr Ie.·cls of CJ).I+IFl\'1'+ T cell~ than the ~IPVI6 
jnfcrlcd btu CIN nC£~li~t:" palicnl~ (0.050 ± 0.05 and 1.9~8 ± 0.891 n:speClivel)·; 1J1C,m 
± SEM) (p=O.034). TIte HPV I6 ncg~lj\"e "'omen wilh no C [N disea.,c lIud 
~ignifkanlly higher Icvels or CD.1+IL-1 J t T cells Ihan tile HPV 16 negative I'-omen 
suffering' from C1NJ al the cervix (4 .108 ± 1.753 and 00405 :I: 0.237 respectively; 
p=Q.OJ 4). 
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.l.3.-I Correlation between HPV Viral Load lind l') lol..ine ""'tlOn~e II I IIII' .~r. h 
and 5y~leminally 
The viraJ load results determined by Digcne Hybrid Caplure® II , were 
compared 10 lhe actual ICC T cell response~ elK-iled by PB!l1C and cervical cells from 
all or,he qudy pa,ienlS (Figure 3,13), This \\'as done to delermine ..... helher 'here "' .. as 
any COfI'I:'la1ion bet ..... cen the ndlllive quwlILty of vnul DNA at the cervix, and the 
abi lity o f the T cdls to respond 10 HPV oqx:ciflC anllgcn~. 
Imerestingly, il was ooted 'hat the eXtenllO .... ·hich a virus has been un~Olnll 
replicut ion seemed to hfll'e an implK:l On the magnitude or the C()4+IFNy+ respon'le! 
in both PBMC and cervical T cells. In the regres.~lon ~alter pt()(S comparing the 
impact of 1'[raJ load on the number "f T cell responses (Figure 3,13), there sccmed to 
be a trend in both cervical WId PBMC C04 T celt responses 10 VLP LI , of an iocreasc 
in IFNy production with increasing viral load (itres, 1llcse observations we supported 
by regru~ion values of ....0.57 for PBMe and ",,0.51 ror cervical T cells. II was also 
observed in stimulation using HPV1 6 E7 antigen, thaI increased viral load tilres 
>Ccmcd to be correlated to decreasing numbers of cervical C()4 T cells producing fCC 
(cuher J FNl' or IL·13). although this was not significant, 
It i~ Intereslinll 10 ooIC lhal when the OI.lI lier point which has exceptlon~lIy 
higher viraJload lh .. t the other samples is removed, the regression values for PMBC 
and ceo'ica] C()4 T cell responses 10 VLP LI are reduced to an e:\tenl that there is no 
longer il sigmficam rorrel:l1ion between high I iml load ilnd the ClIitenllo wluch T cells 
~spond 10 ~iraJ :lllllgcn. 
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.1.3.5 Th I \'ersus Th2 n'sponses In the blood wrsus at the eenh 10 liP\, 
anligell.'l LI and E7 
In order 10 interpret the data in another way, it was necessary \0 dctcnnine a 
posith'e eut off point. abovc which the observed responses could be assumed 10 be 
posi tivI' responsc:s to the antigen. thereby al lowing us 10 approltimatc the numhcr of 
dOrK}[5 who eiiL'iled responses 10 HPV 16 specifie antigens. Usually in immunological 
studies (of for eumple, Human lmmuoodeficicllC), Virus IHIVj or Tuberculosis 
ITB]) negative controls can be obtained [rom people wilo have nOl yet been infected 
b), the virus (frigona ct al.. 2003). The patient's uneltposed Status can usually be 
oonfinned by a lack of viml particles in tile patient and rK} antibody response to viml 
antigen in their serum. In tbe case of HPV . this is nOt possible, Fil1>tly thero: are many 
diffcro:nt types of HPV which can cause infection (and which might be able 10 induce 
immulH: responses "hich could be cross reactive against OIher HPV Iypes: Hllpn 1'1 
al.. 2000) and secondl)' not all patients are able to prodoce antibodies in response to 
the virus. therefore the lack of antibodies can not be taken as a sign that the palient 
has lIC"cr been infected wilh HPV (Carter ct ~l.. 2000; Kimbauer et a1 .. 1994; Le 
C3nn eI <II.. 1995). Therefore. in studies analysing respon$CS to HPV infection. 
oowin IIIg H ""e negmi \'1' control is a complicated task. For the purposes of this study. 
~lIIce it was not possible 10 obtain a true negative control, an empirical cut-off of two 
fold above backgroond (unstimulated) was considered:1 positi~e response. Therefore 
when Slating Ih~t a patient had a posith'c response to a specific antigen, this study 
ll\aJ.:es referctlce to the fact that the patient's ~ntigen specific stimulated T cells 
elicited an ICC response greater thall or equal 10 2 tilllCS the percentage of ICC 
producing T cells th~t were deteeted in their unstimulated sample populatIon. 
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In r~sp()IUC \() Ihe IWV 16 VLP LI. POMC appeared 10 irHllICC Il'IOrC' Th2 type 
respons.:s. AI thc IX!rvi~. 1m.: ,. o.:lIs induced Il'IOrC' oftcn Th2 (It·ll) cytolincs in 
response 10 E7 anligen bul in Ihe blood. T cells produced many tnOI"C TIll e)1oki~ 
f()l'Tl1ul in I' ig()re 3.14). 
In all analyses. lhe CIN I group ~1iciled the hi~ pm:cnUtga of responses 
againsl dther antigen. In lhe cervical 1 cell Mimulalions. IIv:; total pen:entagc:$ of 
re..~ponding T ccll~ (TIll plu~ Th2) ""ere lowest in the group of "'"Omen wlfrnnll "'i1h 
CIN 3 and "''en: highest in llw:: women ""illl I:fadc 1 CIN 1cslOnSallhc cervix. 
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].3.7 Th~ cen'ieal cytokllM' mlcrot'nvlronment or HPV infected .. omt'n 
Through the use of the BO Cytometric Bead Array Kit. it was possible to 
dctennillt:. the cytokinc microenvironrncnl at Ihe cervill of palients from .... hom 
cervical cytobrush samples were collected. In thiJi study. the CBA bead., were applied 
to a sample of the cytobrush collection and IrWlspon fllC'dia. into which the cytobrush 
had been insentd following l'OIalion in the cervical os. Therefore. any cytokines thai 
the: cytobrush might h:lVe collected from the cervical tissues would hne been 
resuspended in the cervical specimen supemuulllt. The kit used for delecuoo of 
inflamnl.1tory cytokines at the cervill can dctemljne the conceRtrutions of 1t.-12p70. 
TNF. It.-IO. IL-6. I L-I~ and IL-8 (the functions of which life liJited in Table 3.3). 
'IlK: l'tSuhanl CQI1centf'~lions of each cytokine revealed very low (pemaps 
negligible) levels of IL-12p70. lNFa. and it.-IO in all of lhe palienl samples. The 
ooncemration was less Ihan octectable in mOM cases. and never e:\ceedt::d 9pglmL In 
l'Omparison. for lL-6. lL-IP and IL-S there were considerably higher wnounl!i of 
e}1okine. the 10wCSl concentf1l.Lion deTCCted was >IOpglml. Therefore. analysis of the 
data hl\S been focused on the laner three c)'lOkincs. The data depicted in box and 
whisker plol!i in Figure 3.15 allows romparison of the results of cylokine 
concentrations for each of the CIN grade groups (Neg. CIN I. CIN 2. CL~ 3). [I is 
clear 10 sec that thefe are significantly higher levels of lL-S C)1okinc than any of the 
oCher c)10kil'lCS III lhe cervices of the all of patients. CIN I patients had higher 
a"emgc levels of IL-S c)1okinc than the other patienT groups (2711.5 pglml r 7:17.:1. 
mean r SE,'"I). but this result was only statis tically significant when romparcd to the 
levels of IL·S at lhe cervill of CIN 3 patients (636.9 pglml r 130.5) (p=O.0394). The 
erN negat ive patients also seemed 10 display higher Ievel$ of the: rL-S e}1ol.:me than 
CIN 2 and C IN 3 p'llicnl~. but this was oot significant. IL-6 was also present at a 
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significantly higher conccmrallon in Clt" I IMicms (7U7 pglml ± 105.5) than in 
women with CIN 3 disea<.c: (266 pglml ± 96.8). (p:O.05). Interestingly the mc:1l.D levels 
of IL·6 present ot the cervix of all " 'omen "'ere much lower than those for IL·8. In 
fae\. IL·8 was pn:sent al significantly higher levels than both IL·6 and IL. I~ 
throughout all women when grouped according to their grade of disease (p<Q.026J. 
Although IL·1 ~ cytokine was p!"Csent at the cervices of all patients at ,datively high 
detectable levd~. j, remained at a fairly coostant concentration through all of the 
pat".·nt ~an!plcs and did not seem to vary significantly with the grode of em lesion of 
the pallen!. 
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Sirn:c HPV infcclions do 001 disseminate, the major aim of tim ~Iud)' was to 
inl"estigate HPV-16 LI and E7 immullC mpons.cs Ut the eervi~ in women wilh 
cen-ical HPV tnfCCl ions and/or HPV-associ:.ted cer.'k:.1 disease and then to compare 
these responSC$ 10 tOOse detected in ~npheral blood. This was done by detemdning 
tile ~nOl)"JIC of T cells mporwling (CD.:t "c~us CD8) 0.11'.1 tlleir ability to pnxillt"e 
cylokines [Thl (IFN1): lhl (IL-IJ)] in respon o;c to IIPV 'pecific stimulus After 
recruiting 100 women into tile stl.llly from tile Groote Schuur Hospital Outpatients 
Colposcopy Clinic, only 33 women willi cervical discase r'.tnging from negJilil'e to 
CIN3 were suitable for study. This study has slJo>l..n tllnt tilt cylobrush ITICIIIOd of 
obt~ining ccrvical Iympbocyles combined with intlllCCllular c)1okine analysis and 
now cylonl('try in a oon-invasi~"C and pOIentially uscful approach 10 s.:udying immu!lC 
responses in tile genital tmet. 
Allhough ~"1llioos HPV-specific T cell rcspomc:s emerged II! being significaQt. 
til( mostll()lable re~pono;es ,,"'Cre women with CIN I eonsislently h:!llIIg the strongest 
CD4 IFN-y (but not lICCe5sanly CDS T cell) responses at lhe cervix 10 HPV. 16 
antigens compared to ""omen ,,"' lIh no cervical oeopla;;ia or those w;lh more severe 
d'iCa5e KIN 2(3), Thb was observed particularly if one focused on women with 
"",i \ e llrov 16 Inf«lIon bul also if One looked al I~ grotJp as :a ",hoi" (im:spoc:cli VI! of 
lilt type of IIPV causing inrcction). 
Theo: was a significant 10:00 IOwnn:is decreasing 1'112 responses (lL-13 
production) whh increa~inl! disease $C,'cnty, in een-'leal CD4 and CDS T cells to I>OIh 
HPV antigens (LI Dnd E7) if ooe looked ut Ihe group as a wOOle (and duin'( 51r'Jlify 
accon!ing 10 activc infeclion wi th HPV ·16). Conve!1;Cly. this [rend was revcrsed wi[h 
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increasing Th2 responses with increasing disease severity in the women with active 
HPV-16 infection (although the correlation coefficients for both increasing and 
decreasing Th2 responses were not particularly strong). 
When PBMC responses from women with HPV -16 DNA at the cervix were 
compared with those that were infected with other HPV types, the HPV-16 DNA+ 
women generally produced a Th1 dominant response (more IFN-yand less IL-13) 
which changed to a Th2 dominant response with increasing disease severity 
(particularly for E7 antigen). In contrast, the HPV-16 negative women (infected with 
other HPV types) showed a complete reversal of this profile with increasing IFN-y 
responses and decreasing IL-13 responses with increasing disease grade. The only 
cervical immune response that correlated with disease grade in this study was that 
both CD4 and CD8 T cell IL-13 production decreased with increasing disease severity 
but this was observed in both women infected with HPV -16 and those infected with 
other HPV types. Although evidence of HPV -16 specificity is lacking, the results do 
imply that Th2 dominant responses are associated with a "healthier" disease state and 
IL-13 responses (possibly driving a protective antibody-mediated response) diminish 
with increasing disease grade. Surprisingly, the magnitude of Th1 responses elicited 
by cervical T cells was generally lower than those produced by T cells from 
peripheral blood. 
3.4.1 Does age correlate with a decrease in T cells in the cervical epithelium? 
During menopause, the epithelial cells of the transformation zone have been shown to 
migrate upwards from the ecto-cervical area into the endo-cervical region through the 
cervical os (Crompton, 1976; Cartier, 1984). Therefore, one would expect lower 
numbers of cervical T cells to be recovered from the more mature cervices of older 
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women, since there is less of the transformation zone visible to the eye and within 
reach of the cervical cytobrush. Most studies therefore use age exclusion to ensure 
that the cervices of the patients being sampled are able to yield sufficient numbers of 
cervical T cells (Nakagawa et al., 2000; de Gruil et al., 1997). In this study a 
comparison of age versus cervical T cell did not give a significant correlation, but the 
reason for that might be because we had already excluded post-menopausal women 
above the age of 40. 
3.4.2 Lack of HPV16 Prevalence in Study Population 
HPV DNA was associated with 91 % of CIN in this study, which is slightly 
higher than the prevalence of HPV in CIN observed by other recent studies (Kay et al, 
2003; Chan et al., 2003; Molano et al., 2003). HPV16 was found to be the most 
common type of HPV infecting the cervix of patients in this study. Yet the results 
from previous studies have indicated that the prevalence of HPV16 in women 
suffering from CIN is in the region of 50% (Bosch et al., 1995; Kay et al., 2003). The 
27% HPV16 prevalence observed in this study was far lower than what we had 
expected. This could be due to the fact that the specimens used for determining the 
HPV type infecting the cervix was different in the previous studies. Cervical biopsy 
specimens of CIN diseased women were obtained and the HPV DNA extracted and 
typed whereas in this study we extracted and typed HPV DNA from cervical 
cytobrush specimens. A biopsy yields a much higher quantity of infected tissue 
(usually from deeper layers as well) than a cytobrush, therefore there may have been a 
much higher quantity ofHPV16 DNA available in the biopsy specimens for analysing 
and therefore higher levels of HPV16 positive patients. 
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In this study 39% of women were infected with 2 or more types of HPV. This 
is considerably high compared to other studies that have shown a multiple infection 
rate of 12% (Kayet al., 2(03). According to a follow up study of cytologically normal 
women infected with HPV at the cervix, it was shown that multiple HPV types were 
unlikely to put women at higher risk of lesion progression since clearance of multiple 
HPV types occurred at the same rate as clearance of single HPV types (Molano et al., 
2(03). Perhaps the numbers of HPV infections are increased in this study due to a 
decreased immune response in patients who might be immuno-compromised due to 
co-infection with human immunodeficiency virus (HIV). HIV is currently highly 
prevalent in the local South African population, but we did not have ethical approval 
to determine the HIV status of the patients. When interpreting the above data, 
however, it should be recognized that the small study size is not conducive to 
discussing HPV prevalence in the larger female popUlation. 
3.4.3 Type of cytokine microenvironment at the cervix 
The Cytometric Bead Array (CBA) kit allowed some insight into the cytokine 
microenvironment present at the cervix when the cytobrush specimens were taken. It 
was observed that the cytokine present at the highest concentrations at the cervix was 
IL-8 followed by IL-6 and then IL-l~. Interestingly, the women suffering from grade 
1 CIN had the highest amounts of IL-8 cytokine present in their cervical specimens 
compared with women with higher disease grades (CIN2 or 3) and those without 
disease. Since IL-8 is an inflammatory chemokine, this could imply that the immune 
cells at the cervix of women with CIN 1 lesions are eliciting large inflammatory 
responses to induce lesion regression. This is supported by data which has shown that 
85% of CIN 1 lesions actually regress back to CIN negative status (latrakis et al., 
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2004). Yet recent studies have shown a role for IL-8 in cancer progression, and have 
shown that cancer cells produced higher levels of IL-8, which correlated with tumour 
progression (Yuan et al., 2(05). In view of these developments this could suggest that 
it is the actively proliferating tumour cells that are inducing higher levels of IL-8 and 
perhaps IL-8 is not indicative of a strong immune response to the cervical lesion. 
The concentration of IL-8 was significantly higher at the cervix of all 
patients, in comparison to IL-6 and IL-l~, perhaps because all of the women in the 
study are either presently suffering or were previously suffering with CIN, therefore 
all of the women are likely to have inflamed cervical epitheliums due to the original 
disease. This hypothesis could not be tested, however, because no healthy HPV-
infected women were included in the study. 
The concentrations of IL-12p70, TNF and IL-1O were lower than results 
shown in previous studies, which show a peak of IL-12 cytokine at the cervices of the 
CIN 1 patients (Giannini at al., 1998). The supernatant in which the cytobrush was 
transported and washed vigorously is probably not ideal for measuring cervical 
cytokines concentrations (although it did contain the entire mucolytic component of 
the cytobrush sample and all cervical components other than cells). Future studies 
aiming at measuring cytokines from the cervix would have to investigate alternative 
collection methods and compare these with the approach used above. It would 
probably be more suitable for the samples of the cytokines present at the cervix to be 
collected by cervical lavage (where the top of the vagina and the cervix are flushed 
repeatedly with PBS). This might have improved the detection of the IL-I0, IL-12p70 
and TNF cytokines. 
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3.4.4 Individual ICC Responses of four interesting patients 
This study analysed a total of 33 women's cervical and PBMC responses to 
HPV specific antigens. Four donors who appeared to have the strongest and most 
interesting immune responses were isolated and their results described in detail. Two 
patients were from the CIN negative women; the patient with an active HPV 16 
infection at the cervix elicited a strong PBMC CD4IIFNy response to both HPV16 
VLP L 1 and E7 antigens. Yet the responses from the patient's cervical T cells were 
marked by a strong production of Th2 cytokine (IL-13), This suggests that perhaps 
following clearance of a lesion at the cervix this patient is attempting to regulate and 
balance the cervical environment, by inducing Th2 responses in the cervical T cells 
(reflected in the presence of serum antibodies to HPV16 VLP), yet in the PBMC 
population, there is still an immunological memory against the HPV antigens since 
there is still HPV16 infection at the cervix which needs to be cleared. 
The second CIN negative patients was not infected with HPV 16 but still had 
antibodies, which suggests that perhaps this patient had successfully cleared a 
previous HPV 16 infection. In this patient, both PBMC and cervical T cell responses 
were skewed towards a Th2 profile, which suggests that after successful clearance of 
HPV infection and regression of CIN, the patient is left with antibody immunity to 
prevent future HPV 16 infections. 
The third patient was from the CIN 1 group of women. This patient was 
actively infected with HPVI6, but was seronegative at the time of specimen 
collection. Interestingly, this patient had a high response in the cervical CD4/IFNy 
population to both the HPV16 specific antigens, which suggests that this CIN 1 
patient is currently attempting to induce lesion regression and viral clearance at the 
cervix through inflammatory methods. 
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Finally, the fourth patient was of interest because the cervical T cell responses 
of this patient were no higher than the background unstimulated population. In the 
PBMC T cells of this patient there was high production of Th2 IL-13 cytokines. This 
patient was infected with HPV 16 at the cervix, but their antibody status was 
equivocal, and could not be reliably determined. Therefore this patient might be an 
example of the type of immune response (or lack thereof), which facilitates 
progression of CIN lesions to CIN 3 and can not induce clearance of the HPV 
infection. 
3.4.5 Women with CIN 1 consistently showed the strongest responses to HPV 
antigens 
Women with CIN 1 consistently showed stronger CD4 IFN-y responses at the 
cervix but also in peripheral blood to HPV-16 antigens in all women with HPV 
infection as well as in women with active HPV -16 infection. This was not a function 
of increased HPV viral load, CD3 cervical count or any of the other criteria measured 
in this study. This significantly elevated recall response to HPV -16 antigens in 
women with CIN 1 was also mirrored in direct measurement of inflammatory 
cytokines (IL-8 and IL-6) in the cervical washing. It is clear from recent publications 
that progression from persistent HPV-infection to CINI occurs with much higher 
frequency than progression of CINI to CIN2/3 (Schlecht et al., 2003; Brenner and 
Syrjanen, 2(03). This indicates that the majority of CIN 1 lesions spontaneously 
regress following an effective immune response. Consistent with previous evidence 
from wart infiltrating lymphocytes that show CD4 T cell production of IFN-y 
correlates with lesion regression (Nicholls et al., 2001; Stanley, 2(01), this study also 
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found significantly higher levels of cervical CD4-mediated IFN-y production in CIN 1 
than in either CIN2/3 or women with no lesions. 
3.4.6 Trends in T helper responses between patients with varying grades of 
cervical disease 
The type of T helper response predominating in the environment where the 
host immune cells encounter a foreign organism, can influence the type of response 
that the host immune defence system chooses to fight the pathogen - i.e. anti-
inflammatory or inflammatory (Openshaw et al., 1995; Counsins et al., 2(02). 
Therefore it is of interest to determine whether the cervical or blood T cells are 
predisposed to induce a Thl or Th2 environment (or type of response) when 
stimulated with HPV antigens following HPV infection. 
The trends in the data indicate that the numbers of Thl responses at the cervix 
were far fewer than that in the blood and this was found to be significant for CD4+ T 
cells producing IFNy in particular. It seemed that cervical T cells from patients 
suffering with late stage cervical dysplasia (CIN 3) were significantly less responsive 
to HPV16 specific VLP Ll antigens than their PBMCs. Since there was no 
significant difference between the magnitudes of the T cell responses elicited by 
PBMC and cervical cells isolated from women with no lesion, CIN 1 or CIN 2, this 
could imply that these patients had equally effective cervical and PBMC responses. 
This suggests that patients with weak cervical CD4 T cell IFNy responses are unable 
to control their HPV infection and therefore are likely to progress to CIN 3. This 
supports the data found in previous studies of a correlation between Th 1 cytokines at 
the cervix and subsequent lesion regression (Al-Saleh et al., 1998; Luxton et al., 
1997). Although an alternative (and equally likely) explanation would be that 
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women with CIN 3 have higher frequencies of HPV -responsive cells in their PBMC 
than women with lower grade disease and this increased frequency results in 
significantly elevated PBMC responses compared with those at the cervix. The 
reasons for comparatively depressed responses in CIN3 women at the cervix 
compared to PBMC are unknown but very interesting. HPV causes localized 
infections that do not induce an inflammatory response and hence, it is generally 
believed that the systemic immune system remains ignorant of the infection. The 
fmding here then that peripheral blood responses are greater in magnitude than 
cervical HPV responses is difficult to reconcile with this hypothesis of peripheral 
immunological ignorance. The female genital tract is however recognized as a 
necessary "immuno-privileged" or tolerogenic environment to ensure reproductive 
success and this could largely account for the observed weak cervical responses 
measured in this study. 
The differing cervical and PBMC T cells responses found in this study are 
important to bear in mind when interpreting the data from other studies only analyzing 
PBMC responses to HPV specific antigens. Since it is clear from this study that 
PBMC responses to HPV antigens do not necessarily imply that there are T cell 
responses to HPV at the cervix of the patient, were active infection is occurring. 
The data from this study highlight a potential correlation of decreased Th2 
responses of both cervical and peripheral blood T cells with increased severity of 
cervical disease. Yet the difference between the PBMC and cervical populations was 
that the cervical cells isolated from women with no CIN had the highest Th2 
responses, whereas in the PBMC, it was the women with the most severe CIN 3 
disease who had on average the largest Th2 responses to HPV16 VLP. These results 
imply that a CD4IIL-13 response to HPV16 VLP L1 at the cervix might be optimal 
109 
for prevention of lesion formation, whereas a CD4IIL-13 response detected in the 
peripheral blood T cells of patients could be a risk factor for disease progression to 
late stage cervical dysplasia. Another important factor is that perhaps responses in 
CIN negative women are due to an effective immunological memory, which in 
previous studies has been shown to last for 20 months (Nakagawa et al., 2002). 
3.4.7 Impact of HPVa 16 infection on local and systemic T cell responses 
As would be expected, patients actively infected with HPV16 at the cervix 
were found generally to exhibit higher PBMC responses to the HPV16 specific 
antigens. This was not reflected in the cervical T cell populations, which is 
interesting to note since the cervical T cells are located at the site of active HPV 
replication. Therefore one would expect the cervical T cells to be more responsive to 
HPV-16-specific antigens since they are the immune cells closest to the cervical 
infection to receive priming of the HPV16 antigens through presentation by the 
infected keratinocytes. Because it is well recognized that epithelial cells do not have 
the necessary co-stimulatory molecules to enhance the antigen presenting synapse (by 
virtue of the fact that they are not antigen-presenting cells) and that T cell responses 
inadequately primed by poor costimulation are often termed tolerant or anergic, the 
results from this study must be interpreted with this in mind (Maljezyk et al.,1997). 
Interestingly, women infected with HPV types other than HPV-16 were also 
able to elicit responses to the HPV16 specific antigens which imply that the T cell 
primed to other HPV types may be able to cross react with HPV 16 VLP and E7. This 
phenomenon has been observed in previous studies (Kadish et al., 2002). This 
information is valuable for future vaccine considerations, since it suggests that 
vaccination against HPV16 could cross protect the cervix from other types of HPV 
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infection. More likely, however, is that the T cell responses detected in women with 
HPV infections other than HPV -16 may reflect that they had been infected with HPV-
16 at some time point prior to this study (supported by detection of HPV-16 specific 
antibodies in 39.4% of women) but had subsequently cleared this infection and had 
readily detectable HPV-16-specific memory T cell responses in the absence of active 
infection. There was, however, no significant difference observed between the T cell 
responses of patients who were HPV -16 seropositive versus those that were 
seronegative. 
In the comparisons of responses from HPV 16 infected women and those 
infected with other HPV types according to the severity of their cervical disease, there 
was a strong positive correlation between IL-13 production from CD8 T cells in 
PBMC and severity of the cervical lesion. These responses were induced by the E7 
protein stimulations only, which suggests that perhaps due to the nature of a non-
productive HPV infection (where E6 and E7 are produced abundantly in comparison 
to Ll and L2), the further the patient's CIN has progressed, the more E7 would be 
found in the region of the CIN (Middleton et al., 2(03). This also supports evidence 
ofTh2 responses allowing lesion progression (Scott et al., 1999; de Gruil et al., 1999). 
The results also showed that the CD4 T cells from the cervical specimens of 
the HPV16 infected CIN 3 patients produced significantly higher levels of IFNy than 
the CD4 cells of the CIN negative group. Either this suggests that a CD4 IFNy 
response at the cervix is not a correlate of protection for patients exposed to HPV or it 
implies that CIN3 women induce a Thl type immune response at their cervices in 
order to defend the host against both the pathogenic invasion and neoplastic changes. 
This latter idea is supported by the results from women with non-HPV16 type 
infections that showed significantly lower levels of IL-13 cytokine production in the 
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CIN 3 group than the CIN negative group. This could be due to a skewing of the 
immune profile at the highly dysplastic cervix to a Th1 inflammatory response, in an 
attempt to clear the HPV infection (too little too late). Since many studies have 
shown the importance of the Th1 inflammatory profile in clearance of HPV and 
regression of lesions, it seems that the latter explanation is more likely. This is also 
supported by the finding that CIN negative women have a more balanced Th1:Th2 
ratio at the cervix than CIN 1 patients (who all had high levels ofTh1 cytokines at the 
cervix; Scott et al .• 1999). 
3.4.8 EtTect of HPV viral load on T cell responses at the cervix 
Detection of the quantity of HPV DNA in cervical specimens by Digene 
Hybrid Capture can be used as a useful correlate of HPV viral load (Pretet. 2004). 
The limitations to this assay are that the viral load is not absolute but more a relative 
guide. The main disadvantage of this approach is that there is no control for the 
number of cells collected by the cytobrush. Therefore if there were a higher number 
of cells collected for one patient, the resultant viral load could be confounded if this 
result were compared directly to the same result from a patient with low cervical cell 
count 
No correlation between grade of cervical disease and HPV viral load was 
found in this study. This was important to note, because if viral load was associated 
with CIN status this might skew the T cell responses being investigated. A 
significant correlation between high viral loads and high levels of IFNy cytokine 
production by CD4 T cells was observed following stimulation of the T cells with 
HPV16 VLP Ll. This result is important since the significance held true for CD4 
IFNy production in both the cervical and the PBMC specimens. These results suggest 
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that high levels of viral DNA at the cervix results in CD4+ T cells undergoing 
constant priming by the capsid proteins of the viral particles as the virus replicates and 
produces much viral progeny. This shows that in response to an active HPV16 
infection, the immune system elicits primarily Thl CD4 responses both locally and 
systemically and that this is directly associated with the amount of antigen present 
(viral load). 
3.4.9 Summary of the cellular immune environment in response to HPV 
infection at the cervix of women with varying grades of CIN 
Even though there were many interesting trends in both cervical and systemic 
T cell responses to HPV antigens that associated with grade of cervical dysplasia, this 
study did not have the statistical power to significantly confirm these trends and this 
was primarily due to the fact that so few of the 100 women enrolled had sufficient T 
cell numbers in their cervical specimens for in depth analysis. 
Therefore for future studies, the following three points should be taken into 
consideration. Firstly, it is recommended that the study recruits the largest number of 
women possible. If only approximately one third of the women recruited are eligible 
for study, then at least 300 women would have to be evaluated to give 100 eligible 
study participants. 
Secondly, this study found that PBMC and cervical T cell responses to a given 
HPV antigen are often significantly different in matched samples from the same 
woman. This shows that future studies can not only study PBMC responses to HPV 
antigens as being representive of the cervical immune response to HPV infection. It is 
necessary to study both the cervical and the PBMC responses in order to obtain a 
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more accurate picture of the complete immune response elicited by a patient to HPV 
infection. 
Thirdly, it was also noted that the eIN 3 patients elicited significantly higher 
Th1 cervical responses to HPV antigens, whereas the eIN negative patients produced 
significantly higher Th2 responses to HPV antigens. In terms of correlates of 
protection, this implies that Th1 type responses are not protective but are associated 
with increasing disease severity. In contrast, responses from the eIN negative patient 
populations appear to be associated most strongly with Th2 cytokine production, 
which could be the result of the immune system switching from Th1 responses (which 
might have induced previous lesion regression) to Th2 responses to HPV antigens, 
since there is no longer a lesion and therefore no longer a need for inflammatory 
action in response to HPV antigens. 
Finally, the most significant points of interest which emerged from analysis of 
the data collected in this study were that patients with early cervical dysplasia (eIN 1) 
elicited the highest and largest overall responses to HPV antigens, whereas patients 
with late stage cervical lesions (eIN 3) elicited the fewest and lowest responses to 
HPV 16 specific antigens. 
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CHAPTER FOUR: 
HPV-16 SPECIFIC CDS T CELL MEDIATED CYTOTOXICITY IN WOMEN 
WIm CIN: PERFORIN AND CDI07 A AS MARKERS OF CYTOLYTIC 
POTENTIAL AND FUNCTION 
4.1 Introduction 
Host immune responses to viral pathogens rely on a combination of different 
mechanisms to elicit protection. One of the most important mechanisms is antigen 
specific cytotoxicity elicited by the CD8 cytotoxic T lymphocytes (CTLs) (Barry and 
Bleackley, 2(02). These T cells are vital in response to viral infection since they are 
able to specifically kill the cells which are infected with virus, and therefore interrupt 
the viral lifecycle and abort viral reproduction. Cytolytic activity in CD8 T cells is 
induced when the T cell is activated by antigen that it recognizes as foreign to the 
host. CD8+ T cell receptors interact with the MHC I antigen presenting molecules 
which are displayed ubiquitously on all cells (Abbas et al., 1994). If a CTL 
recognizes that the peptides displayed by MHC I on antigen presenting cells are 
foreign it will induce cytokine production and cytotolytic activity in order to induce 
apoptosis of the infected cell. Direct cytotoxicity involves recruitment of cytotoxic 
granules to the membrane location of the activated T cell receptor (Peters et al., 1991). 
These lytic granules contain lytic proteins perforin and granzymes. The membrane of 
cytotoxic granules (enclosing these cytotoxic proteins) contain lysosomal associated 
membrane glycoproteins (LAMPs; also known as CD107), which are not usually 
found on the outer surface membrane of the T cells (Peters et al., 1991). CDI07 or 
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LAMP is further divided into CD107a (LAMP-I) and CD107b (LAMP-2). On 
stimulation of the CTL, these granules fuse to the cell surface membrane and secrete 
their contents via exocytosis into the synapse between the T cell and the target celL 
Perf orin molecules polymerize and form ion channels through the surface membrane 
of the target cell (Abbas et al., 1994). This permeabilisation of the infected cell's 
outer membrane, allow various granzyme proteins into the cell and these trigger a 
cascade of nuclear destruction and subsequent cellular apoptosis by cleaving a family 
of caspase proteins (Barry and Bleackley, 2(02). 
Since the functional capability of CD8 T cells is an important factor in the 
strength of an immune response again viral pathogen, many studies of HPV infection 
have used assays to directly measure the amount of target cell lysis by primed CTL 
(measured by Chromium release). Previous studies of cytotoxic response to HPV 
infection in women suffering from CIN have revealed conflicting results, although it 
appears that there are significantly more cytotoxic responses to HPV antigens in 
disease free women, than in patients suffering with CIN (Nimako et al., 1997; 
Nakagawa et al., 1996, 1997). CTL responses from HPV16+ patients seem to be 
associated with clearance of the infection and have been shown to last for up to 20 
months post clearance (Nakagawa, 2000, 2(02). These results indicate the 
importance of a CD8 T cell cytolytic response in the defense against HPV infection 
and associated CIN. Therefore in order to more comprehensively understand the 
abilities of the immune system in defense of HPV infections, it was decided that this 
study would include the development of an assay to assess the cytolytic ability of T 
cells. The assay was developed on PBMC with the intention for future use on cervical 
T cell specimens. 
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Traditionally the method used for testing the cytolytic functional ability of T 
cells was the chromium release assay (Nakagawa et al., 2(00). This is a complicated 
assay and the process involves many steps. Firstly, it requires 1-3 week stimulation 
and culturing of the patient's T cells. Secondly, it in necessary to prepare target cells 
which are infected with modified viral genomes to induce production of HPV specific 
antigens (e.g. VLP Ll, E6 or E7) and which are labeled with radioactive chromium. 
Thirdly, these target cells are added to the cultured effector CD8 T cells and the 
amount of chromium which is released during the assay is measured as a reflection of 
the ability of the CD8 T cells to elicit cytotoxic functions against HPV infection 
(Nimako et al., 1997). Apart from being time consuming and involving potent 
radioactivity, a further disadvantage is the need for in vitro bulking up of responsive 
CD8 T cells in order to obtain an activity level which is detectable. This step is 
necessary since the assay is not sensitive enough to detect responses directly ex vivo. 
Another method of studying CTL activity involves the use of flow cytometry 
in order to measure the various cytotoxic markers inside T cells (such as perforin, 
granzyme A and B, or LAMP) (Appay et al., 2000; Sandberg et al., 2001; Betts et al., 
2(03). Perforin is stored inside CTLs in granules and following activation of the T 
cell by antigen presented by an antigen presenting cell, these granules are released 
into the synapse between the two cells in order to cause damage to the infected cell's 
surface membrane, and thereby cause the cell to undergo apoptosis. Because perforin 
is expressed by CTL and is one of the main cytolytic molecules involved in lysing 
infected target cells, it could potentially be a useful surrogate marker for either 
cytolytic potential or function. There are two main complications when using perforin 
as a marker of cytotoxic activity: firstly, constitutive levels of perforin vary widely 
between different donors and are often very low (Lichtenheld et al., 1988; Appay et 
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al., 2000; Sandberg et al., 2001) and secondly, perforin is released when CTLs 
degranulate to facilitate direct cytotoxicity. One must therefore measure perforin both 
before and after stimulation in order to determine how much perforin was released 
and from this infer how cytolytically active the cell was. Perf orin is instead a very 
useful marker of cytolytic potential (how much cytotoxicity can be generated by a 
particular CD8 cell) rather than cytol ytic function. 
A recently published paper has established a new technique for the ex vivo 
study of cytotoxic function in T cells using extracellular surface expression of LAMP 
or CD107 as a marker (Betts et al., 2003). CD107 are found in the membranes of 
cytotoxic granules, therefore when cytolytic granules move to the cell surface during 
CTL degranulation in order to release their cytotoxic contents, the CD107 molecules 
are transiently exposed on the outer surface of the cell (Peters et al., 1991). The 
transient exposure of the CDI07 molecule is sufficient to allow antibody conjugation 
and staining of the CD107a molecule. In this way it is possible to determine precisely 
how much cytotoxic activity was mediated by each T cell following stimulation. 
In this chapter, the use of CD 107 a staining as a marker of cytotoxic activity of 
T cells has been investigated on PBMC with the aim that the assay could at a later 
stage be applied to cervical cells. Both CD107a and CD107b can be used as markers 
of cytolytic function by T cells but Betts et al. (2003) demonstrated that CDI07a 
staining consistently gave the most reliable results. Development of the CD107a 
Cytotoxicity Assay involved (i) comparing markers of degranulation (perf orin versus 
CD107a) and determining which marker provides the most efficient and accurate 
representation of the degree to which degranulation has occurred, (ii) establishing the 
optimal positive control for CD107a expression, and (iii) determining the optimal 
period of stimulation with whole protein antigens for CD107a expression. The 
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CDI07a Cytotoxicity Assay was used to determine the cytotoxic ability of HPV16 Ll 
and E7 responsive T cells isolated from the peripheral blood of women with HPV-
associated CIN. 
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4.2 Materials and Methods 
4.2.1 Isolation ofPBMC 
Donor PBMC used for the development of the cytotoxicity assay were 
obtained from the Western Province Blood Transfusion Service (WPBTS), but once 
the assay was optimised, it was performed on PBMC isolated from heparinized whole 
blood samples from 23 consenting women who were attending the Groote Schuur 
Colposcopy Clinic. Essentially all PBMC were isolated using the Hypaque-Ficoll 
(Sigma) density centrifugation method described in Chapter 3 (Section 3.2.2.2). This 
method relies on the weights of the constituents of the blood sample in order to 
differentiate and separate the mononuclear cells (lymphocytes and monocytes) from 
the more dense red blood cells and granulotcytes. 
LeucoSep® tubes were used as described in detail in Chapter 3. Isolated 
PBMC were stored at a concentration of 20 x 106/rnl per cryovial in 10% 
Dimethylsulphoxide (DMSO) Fetal Calf Serum (FCS) freezing medium at -80·C. In 
order to ensure the temperature of the freezing medium was decreased at a constant 
rate, thereby preventing excessive rupturing of the cellular membrane by the 
formation of ice crystals, a Mr Frosty container (Sigma) was used, which uses 
isopropanol to regulate the freezing temperature to decrease at an average of l·C per 
minute. 
When it was necessary to thaw PBMC, the cryovial containing the frozen cells 
was thawed in a 37·C waterbath. Then lrnl of 1O%FCS RPMI was carefully added 
dropwise whilst agitating the sample. This step was performed cautiously since the 
difference in osmotic potential between the two types of media (freezing and 
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culturing) could result in cell death if it was adjusted too rapidly. Cells were then 
washed twice with lO%FCS RPMI for lOmin at 200 x g. Cells were usually adjusted 
to a concentration of 2 x 106/ml. 
4.2.2 Analysis of Perforin as a marker of cytotoxic activity 
4.2.2.1 Stimulation of PBMC to determine constitutive and post-stimulation 
levels of perforin 
PBMC from eight anonymous donors from Western Province Blood 
Transfusion Services (WPBTS) were thawed (as described in section 4.2.1), adjusted 
to 2x106cells/ml and transferred in 200JlI aliquots in duplicate into a 96-well round-
bottom plate for incubation either unstimulated or with PMAllonomycin (PMA 
25nglml; Ionomycin 1 Jlglml). Cells were incubated at 37°C, 5%C02 for 1 hr (in the 
presence of BFA, lOJlglml) or 4hr (with last 3hr in presence of BFA). 
4.2.2.2 Intracellular Staining for Perforin 
Following stimulation, it is necessary to stain the cells with antibodies to the 
various phenotypic and functional markers. Cell surface markers (e.g. CD3 and CD8) 
can easily be stained since these are displayed on the surface of the cell. For 
intracellular markers, such as perforin, the staining process involves an additional step 
- permeabilisation of the cellular membrane. This is necessary since it creates 
openings through which the antibodies to intracellular molecules are able to enter the 
cell and bind to their respective targets. It is also important when performing 
intracellular staining to first 'fix' the cells, to prevent the target intracellular molecules 
from being released through the same permeabilised membrane openings. 
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Stimulated cells were transferred to individual BD Falcon FACS tubes and 
fixed and permeabilised simultaneously in the dark for 1000n in 500~1 BD 
CytofixlCytoPerm solution (BD Pharmingen). The cells were pelleted through 
centrifugation at 200 x g in a Labofuge 400R centrifuge (Heraeus Instruments) and 
washed with Iml 0.1% Saponin PBS (containing 0.01% Sodium Azide). Pellets were 
resuspended in the dead volume of saponin (approx. 50-100~1) and antibodies were 
added to the tubes as follows; anti-CD3-APC, anti-CD8-FITC and anti-Perforin-PE. 
Staining was performed at 4°C, protected from light for 30min. Thereafter the cells 
were washed with 1 ml 0.1 % Saponin, fixed in 400~1 BD CellFix reagent (BD 
Pharmingen) and stored at 4°C to be analysed on the Becton Dickenson FACS Caliber 
flow cytometer using the BD Cellquest Aquistion software. 
4.2.3 Staining of PBMC for CDI07a expression 
4.2.3.1 Intracellular staining for CDI07a 
Freshly thawed PBMC from three independent donors were adjusted to 
lx106cells/ml and viability was confirmed to be above 90% using trypan staining and 
counting on a haemocytometer. Cells were stimulated in 96-well round-bottom plates 
(in 200~) as described above with either no antigen (unstimulated) or with SEB 
(lO~glml) in the presence of Monensin (lO~glml). Monenesin is a Na+/H+ ionophore 
which prevents the secretion of intracellular molecules but does not block CTL 
degranulation. It also neutralizes the pH of the intracellular endosomes and 
lysosomes which is important since acidic conditions within granule compartments 
may quench the fluorescence from the tagged intracellular antibody to CD107 
(Mollenhauer et aL, 1990). Anti-CDI07a-CyChrome was added at the beginning of 
the incubation period as Betts et al. (2003) had previously demonstrated that CD107a 
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surface expression is transient and its incorporation right from the beginning of 
stimulation substantially increased the level of sensitivity of the assay. Once 
stimulation was initiated the cells were incubated at 37°C, 5%C02• After 4 hours, 
unstimulated and stimulated cells were transferred to BD Falcon FACS tubes and 
stained for cell surface antigens using anti-CD3-APC, anti-CD8-FITC. CD107a 
would have been stained during the incubation period. Cells were analysed on a BD 
FACS Caliber Flow Cytometer within 24hr of staining and data analysed using BD 
Cell Quest software. 
4.2.3.2 Kinetics of cell surface CDI07a versus intracellular Perforin expression 
following stimulation 
In order to compare the kinetics of perforin release versus CTL degranulation 
(indicated by cell surface CDI07a expression), PBMC were stimulated with SEB and 
levels of intracellular perf orin and exposed labeled CD107a molecules were 
compared. Again freshly thawed PBMC from three independent donors were 
adjusted to IxlcfceUS/ml and viability was confirmed to be above 90%. Cells were 
stimulated in 96-well round-bottom plates (in 2ooJ.1I) as described above with either 
no antigen (unstimulated) or with SEB (lOJ.1g1ml) in the presence of Monensin 
(lOJ.1g1ml). Anti-CD107a-CyChrome was added at the beginning of the incubation 
period as described by Betts et al. (2003). Once stimulation was initiated the cells 
were incubated at 3TC, 5%C02• At 30 minutes, 2hr, and 4hr, stimulated cells were 
transferred to BD Falcon FACS tubes and immediately incubated in the dark for 
lOmin in the presence of 5ooJ.11 BD CytofixCytoperm reagent. Thereafter they were 
stained following the protocols described in section 4.2.2.2, using anti-CD3-APC, 
anti-CD8-FITC and anti-Perforin-PE. Cells were analysed on a BD FACS Caliber 
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Flow Cytometer within 24hr of fixing and data analysed using BD Cell Quest 
software. 
4.2.3.3 Comparison of PHA, PMAlIonomycin and SED-stimulation for induction 
of CDI07a expression 
To further optimize the CD107a cytotoxicity assay, various stimulants were 
investigated for use as a positive control. The stimulants compared were (i) a 
mitogenic agent, phytohaemagglutinin (PHA) which non-specifically interacts with 
the T cell receptor (TCR) through cross linking thereby mediating T cell activation 
and subsequent degranulation (Baran et al., 2001), (ii) a pharmacological agent; 
phorbyl myristate ester (PMA) which activates a Ca+ dependant protein kinase C to 
phosphorylate the CD4 co-receptor and induce signaling cascades through the TCR 
with the assistance of a calcium ionophore (Ionomycin) [Imboden and Stobo. 1985]; 
and (iii) a superantigen, Staphylococcus enterotoxin B (SEB), which is a potent T cell 
stimulator (Herman et al., 1991). It was necessary to compare the stimulants, since 
each mediates T cell activation through a different method and this study aimed to 
find the stimulation agent which generated the highest levels of degranulation of the T 
cell. PMAII has been shown to be the most potent stimulator of T cells (Baran et al., 
200 1). yet it also results in down regulation of the CD4 receptor molecule (Petersen et 
al., 1992). This down regulation does not happen following stimulation of T cells 
with PHA (Baran et al., 2001). Superantigens. such as SEB, are antigens from 
bacteria or viruses. but unlike the HPV16 specific antigens being used in this study, 
superantigens are capable of inducing massive T cell responses in most T cells since 
they stimulate the T cell through a different and more generic interaction with the T 
cell receptor than the specific antigens which can only induce responses in T cells 
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which have been primed to recognise a specific element of the antigen (Herman et al., 
1991). 
Freshly thawed PBMC (2x106/ml) were transferred in 200J.Ll aliquots into 96-
well round-bottom plates and incubated at 37°C, 5% CO2 for 5hr in the presence of (i) 
no antigen (unstimulated), (ii) PHA (5J,lglml), (iii) PMA (25nglml)IIonomycin 
(lJ,lglml), or (iv) SEB (lJ,lglml). Antibody to the CD107a molecule (anti-CD107a-
CChr) was added to each well for the full incubation period. Additionally, the 
microtubule inhibitor Brefeldin A (BFA; IOllglml) was added to each well to block 
the endoplasmic reticulum and golgi transport apparatus, thereby preventing the 
secretion of intracellular cytokines. In this instance, BFA was used instead of the 
secretion inhibitor monensin since it had subsequently come t9 my attention that 
studies have shown that monensin can induce IL-l expression in monocytes (Yewdell 
and Bennink, 1989). Since IL-l acts as a mediator of immune responses and 
costimulator of T cells, the resultant T cell responses might be skewed by the 
unnatural production of the IL-l cytokine (Abbas et al., 1994). 
After 5 hours, cells were transferred to BD Falcon FACS tubes and stained 
following the protocols described in section 4.2.2.2. Briefly, the cells were fixed, 
permeabilised and washed with 0.1 % Saponin. Pellets were resuspended in the dead 
volume (approximately 50-100J.Ll) of saponin and antibodies to the cell surface 
markers CD3 and CD8 (anti-CD3-APC and anti-CD8-FITC) were added to each tube 
and incubated at 4°C in the dark for 30 min. Cells were then washed and finally fixed 
in 400J,l1 BD CellFix solution. Stained cells were acquired using a BD F ACS Caliber 
Flow cytometer and analyzed using BD Cell Quest software. 
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4.2.4 HPV·16 Ll and E7 specific cytotoxicity (CDI07a) Assay on PBMC from 
women with HPV ·associated CIN 
4.2.4.1 Colposcopy Clinic Study Population 
Twenty three women from the larger cohort of 100 women who had been 
referred to the Groote Schuur Colposcopy Clinic following diagnosis by cytology of 
CIN disease at the cervix were recruited into this study. The details of the 23 women 
recruited into this part of the study are described in Table 4.1. In accordance with the 
Research Ethics Committee of the University of Cape Town all participants were 
informed regarding the study and their written consent was obtained. From each 
patient, a 10 ml anti-coagulated (Lithium Heparin) peripheral blood sample was taken 
for PBMC isolation (as described previously) and a Digene cervical cytobrush was 
taken for HPV typing. 
4.2.4.2 HPV Typing using Roche Reverse Line Blots 
It was of interest to determine for each patient the types of HPV infecting their 
cervical tissues and this was done using Roche Reverse Line Blot strips. The 
experiments were performed by Candice Sampson from the Medical Virology 
Department, UCT. The methods used for HPV typing cervical specimens using 
Roche Reverse Line Blot technology were exactly the same as described in detail in 
Chapter 3, Section 3.2.3. 
4.2.4.3 CDI07a Cytotoxicity Assay following stimulation with HPV·16 Ll and E7 
The final cytotoxicity assay that was used on the PBMC from patients of the 
Colposcopy clinic combined the methods used for the 5hr positive control stimulation 
and the 21hr antigen specific stimulation (sections 4.2.3.3 and 4.2.3.4). PBMC 
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(2x106celllml) from the 23 patients were aliquoted into 96-well round-bottom plates 
and subjected to the following stimulation conditions: (i) no antigen (unstimulated), 
PMAlIonomycin (25nglml, IJ.1g1ml; 5 hours; positive control), HPV16 VLP (lOJ.1g1ml; 
21 hours; kindly provided by Mr E. van der Walt) and HPV16 E7 antigen (9J.1g1ml; 21 
hours; kindly provided by Dr I. Becker). Antibodies against costimulatory molecules 
(anti-CD2S/49d, Imglml) were added to each well along with anti-CD107a-CChr. 
BFA (lOJ.1g1ml, Sigma) was added to each well for the last 5hr of stimulation in order 
to inhibit release of the intracellular cytokines. Once incubation at 37°C, 5%C02 was 
complete, the cells were transferred to 5 ml BD Falcon FACS tubes and stained using 
the protocols described in section 4.2.2.2, with antibodies to CD3, CDS and IFNy. 
Following fixation of the cells, they were immediately acquired and analysed on the 
BD FACS Caliber flow cytometer using BD CellQuest software. 
4.2.5 Statistical analysis 
Where indicated, results were analysed for statistical significance using either the 
Mann-Whitney U Test for unpaired non-parametric data or the Wilcoxon Rank Test 
for paired non-parametric data (Statistica ®). 
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4.2 Results 
4.2.1 Heterogeneity in the level of intracellular Perf orin expression in CTLs 
from ditTerent donors 
In order to investigate donor variability in the intracellular levels of perforin in 
CD8+ CTL, perf orin expression in 8 different PBMC donors (from WP Blood 
Transfusion Services) was assessed. In these donors, perforin expression in CD8 T 
cells ranged from 0.1-26.2% (Figure 4.1 panel A and B). When the same donor was 
assessed in independent experiments, the level of perforin positive T cells varied 
widely (ranging from 0.1% - 2.77%; Fig 4.1C). This indicates that not only is there 
substantial inter-donor variability in perforin expression, but there is also significant 
inter-assay variability. This is an important indicator that perf orin might not be an 
accurate and reliable marker of CTL activity or functional capability. The high levels 
of inter-assay variability is particularly concerning as it implies that either (i) the 
assay itself is error prone, (ii) the assay is technically poorly standardized; or (iii) that 
depending on thawing and general culturing conditions, constitutive levels of perforin 
may really vary. 
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Lhm: indcpcfl(\enl npcrimCfllS .... hich utiliscd aJiqUOlS of the same donor"s PDMC 
(Fig 4 .4). lltc ~sullS .I~ ",,,,,aJed some degre.c of intCr-ll$$3~ variabilil) .... ,;th a 
ma.-<imum difl"etrnCC of 5% bct .... ..,en the highest arwI 10"'«1 percentages fOf each 
slim ulation condition (10.81 - 15.5:2% "IIA .uimulatcd; J.g~ - 1.7.rA. SEn 
stim ulated). 
Interesting to not<:, lhe~ is a considerablc diffcn:ncc In !he COI07. 
cl<pn:S5ion dep<:nding on .... hich positive control ag~nt was used to stimulllC the 
POMC. SED stimulation yielded the loweS( pcm:nlllgc CD107. c.-.:prcssiotl13.84%) 
.. hilS: PI IA 51imulal;oo e xceeded th is value b) OVcr 5 fold (lO.III%. COI07. positive 
T ce lls). 
lD. In~' •• .,. v .. -,. III 'AC0107. D jH ... ton 
_.II>eSIBGr_ .... ~""' ..... 
, 
"'--"~-.. "~.,.,.-. 
, 
.~ 
.-
EiiDR (.(. 1""-,, .'orioI!iU'~ ,. ...... ..t ... CIlIM .... "'""" ... ,)( f),,*,'", KIl. ~r .. CI>I' T 
coils. The """'" .row. are rn,." ...... _ .ucd In ,""'" I~ .. pen......... 1:adI ..... 
• <jli ........ p<n><nIa&t: or C 1>1 07. pooiIi • ., ........ In ,"" ella_cm. pOpUleI_ 101"",1", 51"0-
.. ;n.u •• t1on wlth am.. Mill (blue bono) 01 1'1110 {pi"'- bono~ .. _ UlIM •• ,body ..... ~ r ... 
f ... l InaAloIi<oI period. Cdh .. ~ fiXftl. ,"'" 'ill!ed ~ 1Iai ..... (0I1ow" .IIIuloIion nI ... en: 
<ad (III "'" 80 fACS CoIiba-11oor c)"""'-"'<r .. ,(/Un 24bt 0I_"'1IS-
" .2.-1 Comp"ri~on of PH.-\.. SEn lind l''' i,VIonom~cin all 1I!,:"n !.!, 10 indm'\' 
nlasim.u i CO I 0711 expre_ ...~;"n on adi, au'tl T ~ells 
Onte COlO711 wa, confimMld tn be a uscfulmilrker for c)1MoXH: functioning 
in c;ell ~. il was IleCCS5ary 10 optimise by comparing "arious agents for usc ali a posiu\c 
control. Some tommon posllive conl rn l ~ (rcagc nt ~ v.'1l1ch arc: capable of sl1mulaung 
al l PBMCs) v.hich rul\'e been utiliud in many of tile: experiments in this project. are 
PHA. PMN lonomycln nnd SED. The ubilily of PHA. PMNIonomycm and SEa 10 
octi\'atc Ihe C}'lotoXtt fuoct juns of thc CDS T cells was compared 111 '2 II1dependent 
aperimcnls shOIO.· n in FiJ! 4.6. It W <l) found initially that PHA was II mllch bencr 
COlO7a expression mducer than SEB (9.41 % \'S . .5 . .57 % Il:sp.:cti\'dy; Figure: 4 . .5 A). 
In the second ellpcrimenl. PHA and PMNI aClj\'3linn \I'ere compared and 
PMAIlonomycin W~ found 1'1 be. beller Mi mlllllllllhllll PH". yielding pertentages of 
COI07. posiu"e e,'enlS of 7.22 % V~. 3.67% respc.'Cthc1y (FIgure -1 . .5 B). l'ht-n:fore II 
10.'3.<1 decided that lbe posilh'c control for use in the cytotOx itil)' e xperiments would he 
PMAllonom)'Cin. 
.,. 
A. PHA Stimulated S[BS'imwl~lcd 
9.41% 
B. I'MAII Stimul.ted 
7.22% 
tlll.m.j.~, Comrwi ..... of I'MNlon<>mydn. 1'11,0. ond SE;O 10 ind~ "1'OIo>i< .... hf~ .. (CI)101. 
,,",~I ",f e lL We oompan.-d. tOl.ll or 3 d<>norJ .... ng PHAIS£fI <lim"llll;"" ond ''''0 00n0r. 
",j.h PMNPIIA ,,;m"IoI""'. l'IiMe ""m: .. lm~I.<d f .. 5 fir in 111< """"'"'" of ",,",,;m" '.OI')' 
antibodies, IIIlIi-CnlO?.cCIIr ..... 1M """""";H """iii>" "",,1r<JI 1,0. I SEB ur PIIA ""d Ill) I'MI\II .". 
PH". FoIlowioK .,lmul.l"" ~II .... ..., stained ... ·jlh """,l:>o<Ii .. to ,hot CDl ... d CD3 I'IIarUn. r"ed ond 
!hen "'l"ircd ond anaI)'..,.j on "'" IIIl FA(,"S CoIib<t fl.,... C)Ulmc\el u.sI~ 8D Ccl'Ou<>t 11011,,'101'<.. 
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.1.2.5 C D 107" c.~pn:.""jo l1 folio" in;.t ~t imul:otion "illl II PY . 16 L I and E7 Ami;:cn 
by PB~IC frolll p3tienlS \' ilh l"n i~1I1 di"",'lw 
4.2.5. 1 Dest ripl lon of wom~n \I 1111 II I'V.as.wciall.'d ct'n iclll di...ease ~nrolled ill 
lids study 
This study cecruited 23 women ",bn were presenling wilh abnomlal e~1ology 
al Ihe cen ix and "'ho had been referred to thc Groote Sehuuc Outpatients Colpo>.eopy 
Cdime run by Dr Lynncne Denny (Dept. Ob~tetrics and Gynae<:ology. Groole Schuur 
Hospital). o r tbe 23 patient~. 12123 (52.2%) were actively infected wi lh HI'V·16 
(indicated by tbe presence of HPV-16 DNA at IIIe cervill.) wbile 11123 (47.S%) wen-
infecled wilb Iypes other Ihan HPV· 16. Table 4. 1 gh"es a full description of Ihc 23 
womt:n investigated in thi~ chapter togelher with their CIN Sl3tUS and HI'V typing 
,13IUS. Thinel!n of tweol.y thR'C (56.5%) of the women had hbtologically confirmed 
C IN or cancer wilh 6123 (26.1':t» prescol.ing with CL\J 1. 4123 (17.4%) presenllng wilh 
ClN 2. 2/23 (8.7%) presenting with C IN 3. and 1123 (4.3%) presenting with adeno 
carcinoma. The remailling 1M3 (43.5%) of the womCII were foo nd to be JJ('gative for 
d io;easc 31 tbe cervix upon presentation at Ihe Colposcopy d inic. Twel~e of twenty 
three (52.2%) of the women were actively infected wi lh HI'V- 16. 9123 (39. 1 %) wece 
illfcclNl ... i,h :)Iher lIPV·types ami 212] (8.7%) had no detectable HPV DNA al lhe 
cervix. IIPV -16 was the most frequendy detected IIPV type. 
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".2.5.2111'\'· 16 1.1 <Iud E7.sJlKlfic cytolo_~idly u.~ing COI07 .. as II I11Hrker uf 
PBMC collecled from 23 women auending !he Colposcopy Chnic (Table 4.1) 
werc ~timul:lted ""lIh either HPV-16 LI or E7 antigens for 21 hours :1m.! Ihe 
percentage cells express ing CDI07a (cytolytic marker) and IFN-y wa~ measured. The 
level of bolh !FN·y and CD IU7" expres~ ion in re~pon:.e 10 PMA Slimulallon WlI, 
highly variahle. A mean of 1.48% (± 1.76 SO) CDS T cells cxpn..'s"cd COlO7 
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t<)lIowing PMA stimulation. Of the rOMe ",h~h degnululato:d (i.e. wen: C0107a+) 
following rMAIl !;Iimulation. the majority al50 induced production of lFN-y (87.4 :0: 
19.6 "ro: """an::i. SI») as illuruatcd In rig~ ~ .6 and 47 ~Iow In C«II~5Of1, only. 
minority of IFN...., producing CDS T cells also c~ COJ07a follo .. ing stimulation 
[ 14.6~0 (ic SD 9,~.) of the tOlaIIFN...., pruducing cel ls were also CDI07a positivcl , 
111i5 daUI Indicates !hat cells "'h rch we strongly stimulated 10 degnmulatc, will 'cry 
til cly also produce IFN-1' in response 10 the stimulus, But cells that producc IFN-y in 
rcspo.- IQ the stimulus do not necessarily 01$0 clthibit cytol)11c Ikgranulalion, 
1.9Il"/o 1.19" . 5.48-;0 
t . 1I1'\ ,.t \ '1.1' U 
1,05"". 0.01 0/0 O.OJ"~ 
0.9t~ 
• 
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In comparison IOoJlh the strong II;\. -,\, IIS.-IoOCiJtion to cells e"pressing COI07a 
)hown abo\'e after PMAII stullul:llion, the dala from respon~s 10 ~imulahon wllh the 
HPV specific Dntlgen. "'(\.0, moch 10lOoer (Figure 4.8). This i. IIndenlarn.\able MI1Ce 0fK' 
expeclS fur fe ller R~ponding ("('II. in the lane r stimulatioll J,cchU.)C antigen spec-Ifl(: T 
~"eUs are rare c,"enlS and lherdorc far 1000er Il'"'rcenlagc, of J;el1~ .... iII be capable of 
rcsponding to the stimulating agent. 
In resp!XL<ie 10 IIPVI6 VLP 1I stimulation. an average ofO.l~ (:toO.I ..j 'l: SO) 
of CD8 T ceUs produced IfN-1 and 0.02% (:to 0.07% SO) de"rnnulllled (I.c. expressed 
COI07a dunng srimullllion) (Figun: 4 .8; these results arc expressed as percentage 
COI071l expression 10 VLP abovc background unstimululed ). Of !he PBMC that did 
degnonulate. 75<;t. (~ 42.49% SO) ..... ere alw prodUCIng IFN-,\, IIlId o f ,he IFN-1 
producing PBMC only 20.9'l· (:to 39A I % SO) lI'ere positil'e for COI07a (FiJUIl.' 4.9). 
Stimulation of PBMC .... ith IIPV 16 f.7 anttgen induced cylOloxic activity (i.e 
C0107a ClpRS$lon dunng stimulation) ill 311 a>erage of 0.16% (:0.1% SO) and IFN-
1 prod.uctioo III 0.13% (:!: 0.1 4% SO) of CDS T cells (Figure ·U: again resullS are 
expressed as percenlage COI07a expression to E7 abo\c background unstimulated). 
As can be s«n in 11M: graphs bdoll (Figure 4.S) the E7 IIlltigen appears to dIcit man)' 
more e)1OloAK: re_ponses from T cells tlian the VLP U W1tigen. llIe a'eruge 
pC'rt"enlllge of cells po!Iime for botll 1I13rkers ..... as rrouced in the E7 stimulated 
populations in comparison wilh tile VLP LI stimulated J"e.)Ulb. Only 1 3.67~ (0:: 
32.13% SO) o( the PBMC ..... hich dcgrnnulaled ..... ere olso produemglFN-l and the 
pem:nlaSe o( IFN-y produt;lng I:ClIs Illal .... er-e al..a tllpre»ing C0107a on their 
5urfoce during stlmulallOrt was 8.S'll (:t 23.710;1, SO) (Figure 4.9). The:.e 'alues all 
have large standard de\·iations. IIhlCh itldlCOlt Ihal I~ was a liigl! level of 
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\nnablhty In the nugnitude of n:~pon>c) bc:tl'een the \;U;Olb PBMC donon, It is 
al>.Q intcmun& to noIe when oompanng the anligen ~poci l1c mponscs to tile mitogen 
(P~ I AII) n:spon~s, th:Il the a,'erage pe~t'ntage) of CDI01a+ ~Ils .... hich were tll ~o 
podoclng IFN-y C)10~1lC' were slighlly reduced in the CDg T Ct'lls ~Iimu lmcd wlI h 
VLP (7.5% ,'crsus g1'l> In PJI,WIJ butl'crc greatly reduced in COl! T cells stimulated 
with IIPV 16 E7 antigen (13.7%) (Figure 4.9). 1be average percentuges of IrN-y 
pmducing Ct'lls I' hich had abo dcgranu laled in response 10 the Slimulus. were less 
"nriable; 14,7% in PMN I stimulated, 20.9% in VLP Ll s[imu",[ed and 8.8<;t In E7 
~timul8ted PBMe. The.\.(' results appear to irxlicall.' Ihat stimulation I'jlh VLP LI 
;lIduct'S a comprc:hcJJSi\'e rc:sponst (uf degnum[alion and C)'tOklllC' prOOUCllon) III a 
higher nu mber of the CDS T IXlls thm the positive control PMN I stimulal,on. 
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FjlWl'C f L Individuol """"""" elicited by COO T ulls of 2J _ fbll""'IIJI .. 1"",111;'" willi IIP V 
"I""'if", antill~ 1"'1 ~ P> VI.p·I6.11I1 ~ to 1:."7. Red bors Indical. -.:Ii .... '"feed .... 
,,·ith IIPV·16 ... 11M: ",""I~ "bUe bhlC !>oro rq>rcsa>I "" IIPV_,6 ON'" .. the =-i ... PO'-'C "'.,., 
.um"l .. ed rr.- 21'" ";111 ';\hcr IIPVI6 VU' LI <>r IIPV16 1;1. ill !he ~ of OO5li"",1IIwrr 
rookcu!es, or.tH:l)107..ca.- .. clbo<Jy and Brefaldi" '" r..- the .... Shr or sti ..... lotioft. ~I. were then 
f'-'Cd. pennat>lIlscd .. Ii.<l&intd (ar COl. CD .... J IFN·l. A"'I"i,;,;,," anti onaI},>is or OIainc<l .... Ii 
fi~od P6MC wa> ptrl'0I'fTI<d Oft. OD fACS Caliba- !\oW c,........... u.l"l HD CcIlQ\>esl,;oft .......... 
I'.-dI ...... It>< pap. ~ It>CaI pm:enI&go. "r p.ooilin ...,... ror <lD< dnDor «'JI'ee1I bon. 
%(;0107. ox.,....,.; .... ; Rod boD. %!fN'T producIion). ",II ~ ""<n> ptoJ r ... CDl+COI - en. 
only. 1"" val..." Jiven hove hom a.JjOSb>tl for boockVOO"d (i.e. tbc: pcrccttogc ",,"i~v. r""" !he 
moIim .. l0u0;J ...",~ """ bce<o .... buac1ed From \he: l<:S1 ...",pic). 
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~, 
• I ~ '[0) • i 2 8D 
T~ III • 
8_ J. T . ~ .J.. • M .- .L. 8 , . ,. . 
-
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fiJilft 4.? Gnpbs '" dId"'- .. a,on&" ~ (_..-......,. of .... _I of tti .... laoo.l 
P8 \ tc ~I"""in. bo&h!lor IH'-Y ODd CO L07 . ..... \;on, ~6MC ... ,"' .. .....a-d for 21 '" h . .... 
s",r.ldln A rOt .... 1M.t S!w) in III< ~of"""imul~"""""" .,.;...co107...co.r -...I " ...... 
PMAII (1" bat). I (l>V 16 VU' 1.1 It'" bat) or II/' VI6 U .. I.., (3" bat~ followiq ... mulaion cdl • 
......... fi «d. , ... '" t"li.....:ltrldulfttd f,e COl. COl onJ 1\-";.,.. ~ ... rn. ....... &i'u c:u",.ilo:o! 
ot citho:r ( .... , "olUI07 •• ocIh &I .. produol\l In •• , or (8 ) ~'"N-r cdb abo ck..-. ... ttl\! 
"""""' ... CO I01o . 1'1a- oti ............ -ith _ "'~_~. r ....... _ II ..... ",""", been 
ooJjW<d r", bU:poo.cI li."- "'" ~ posIb, ,, r..,.., "'" ...... ........., .ample 11M t-~
i-om "'" '''' ....,pk~ 
The !IITIlIli sample s.ize Qf this scudy limits the SUIIi!t~1 signif..:anec of • 
"-Ol'llen ""1m no I IPV· 16 DNA at tho: cnvix. Bul there In: some: in~TC$Iing ImId.~ in 
Ihe data .... hich mM)' be flO1cd. Gnlphic.J rep'e50.'11l11lion of ,he <!ala IihDwing avOCfa~ 
IIPVl6 infa:ltd groop (0.1 ,, 0.04 %: mcan ot S/: M) are similar 10 rcspoosc~ In 11M:: 
grollp wilh 1>0 I-II'V· 16 DNA Rilhe cCl'Vix (0 .09 ci O.OS %; Figure 4. 10). Yet CO I07a 
expression in rcsponsc 10 VI.. P 1..1 appeII~ [0 only UCl:Uf in Ihe IU'V 16+ group (0.04 '"' 
003 %) since lhe average r(}f'the III'VI&- group was 0"10. These pc~nll!geS are 
exceptiONIlly kl" and signirlCllACe of pGSil;,'c values as low as 0.04'11. is doubtful. 
The SlIme si luauOIl sct.'11 5 W OCCUr in lhe r OMC Slimulated " 'ith IIPV 16 E7 antigen; 
O.IS% (± 0.04; SEM) of IlI'VI6+ women on average produced IFN")' in response to 
E7. "hich 15 COlllpMIble 10 0. 1% (:I> 0.05) in the 16- group. The avrrage pcrcentage 
of CD107. e~ion "'as high<:T folkNo ing F.7 stimulation than after VLP LI in both 
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tile IWY· 16 Infected .... omen (0.23 3: 0.07'1) lind the non·HPY·I6+ group (0. 1 1: 
O.().I%), There appears to be a 004iceable difference bet .... een the perttntall<'s of 
resJ1'OIIding cells from ""Iomen who have ~n C~~ to the HPY 16 virus and women 
who have other non·HPY· 16 type infections (0.23% versus 0.1 %, respeai>-ely, 2.3· 
fold difference) , 
In tbe event of no troe negative oontfOl. to facilitate analy~is or the dma. 
rc)pon)oC) were deemed to be positive If they were 3 fo ld above tile b~ckgmund In 
the YLP Ll stimulated popul:11ions. on ly 1/12 HPV·16 DNA+ patlem responded" Ilh 
CDI07a C}10iOxicit)· (S.3'lo) while 0111 ""OffiCn with non·HPY· 16 t)llC inrcction~ 
responded. In the E7 stimuhued s:unples. 4112 (33.3%) HPY· 16 DNA+ p;uiems had 
c)'oco~ic respollSCs to HPVI6 E1 antigen while only 1111 (9.1%) women ",ilh non· 
HPY·16 mfections had responses >3·fold abo"e background. 
Also inkrcsting 10 lIO(e is lhat only one p;thent had eytOlo:dc responses to both 
of the HPY 16 anllgens. YLP LI and E7. This pauent .... as Infecled .... ·nh HPV 16 at 
the cervi" and sufferi ng from sc,,'ere grode CrN 3, 1be four otherC) tOlOlI.ic: responses 
were elicited to £7 ant igen only, in ",-omen who "'ere not sl.Irrenng from CL'I altllt' 
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fllIU 4.11}, C'OIIIpw;1oCWI bot ......... !he ryd.;ne IlrN..,) .nd C)1OIOlIk: (CD 1070) rapC1115eS d id'''' b) 
\hi: COl T , .. U. or III'V 16 Info<:l<:d IHPVI6+) _on ... IIPV 16 1IotpI;"" oJo.wn. f<lllowi", ocrmullotlorl 
"illl UPVI6 sp«ifi .... u ..... PBMC _ a.hnolalocl f ... 2 1 hr In 11>0....-_ 01 ...... VlJ' 1. 1 .,.. 
£ 7 ."d .... cootomul>lOry ""*""'100 .. d wltb B",roldLn " ooldcd tOr !he I~ ,hr. A .. lbo.:Ie:o 10 
COI07' ... "'" oddod (tr emre Rim"1abon period ond alkr .. imula.1on <ells "' ..... n><td. .,..,....,.bll....., 
-' ..... oN "'illl .,"bool..,,., cn. COI ... d IFN_y. Slained....:l fixed cells _ ... 01)"l<1li on .... IlC 
fACS Coiibcr now q_""';", SO Cd~ soli .......... Loch bar 0111>0 p:1Optl <Ioplw!he..-
_ .... oc..donI ...... 0It'-' _ <>I"pooiti_e ........ ~ for ci""" COI07 ... ~ 
~~).,.. I .~~ .... (red.-pm). 11' .. ...r .... Ii ...... hI~ 110m JodjIlOltd f..-
!I .. , ""'~ pooid .. ..... !he lINIionulalod sample hubcu..tMroc\nl from 1Ior",", oamp,lo) 
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4.3 Discussion 
The ability of T cells to elicit cytotoxic acitivity in response to viral pathogens is 
a highly important part of the host's immune system. Viral pathogens use the cells 
they have infected both for producing viral offspring and also to hide from the 
immune system. In order to engage in effective defense of the host it is necessary for 
the immune cells to be able to specifically identify and kill cells which are infected 
with viral pathogens. Therefore cytotoxic functional abilities of T cells are always of 
interest to immunologists studying immune responses to viral pathogens. 
Many studies analyzing the T cell immune response to HPV have utilised 
Chromium release CTL assays (Nakagawa, 2000). These allow determination of the 
cytotoxic ability of CTL through the use of target HPV infected cells that release 
radioactive chromium (C~l) when lysed. Therefore when the HPV specific CTL 
recognize the HPV antigen presented by the infected target cells, they will attempt to 
lyse the target cell and if they are successful it will result in release of radioactive 
chromium into the culture medium which can then be analysed using a 'Y-radiation 
counter. This technique is laborious requiring an 1 - 3 week in vitro stimulation 
period and preparation of HPV antigen expressing, antigen presenting cells (APC) 
which must then be labeled with radioactive chromiun before the actual CTL assay 
commences (Nakagawa et al., 1999; Nimako, 1997). 
In this chapter, the development of a CTL assay which will allow direct ex vivo 
determination of the cytotoxic ability of HPV specific T cells, using the technique of 
flow cytometry and fluorochrome conjugated antibodies to cytotoxic markers has 
been described. The aim of this chapter was to develop this assay and use it in 
conjunction with the ICC assay on cervical T cell samples. Previous studies have 
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utilised fluorochrome-conjugated antibodies to label cytotoxic markers of interest 
(such as perforin and granzyme B) for analysis through fluorescent microscopy 
(Bontkes et al., 1997). This allowed determination of whether cells in cervical 
biopsies had the potential to elicit a 'kill' response, by analysis of whether cytotoxic 
molecules were present in the cells. But this does not indicate whether those cells 
actually induce a cytotoxic response to antigens. Recently papers have been 
published which describe the use of flow cytometry to analyse the functional 
cytotoxic ability of PBMC in response to antigen (Appay et al., 2000; Sandberg et al., 
2001; Betts et al., 2003). This technique uses fluorochrome conjugated antibodies to 
various cytotoxic markers to stain PBMC, following stimulation with antigen. The 
labeled cells were analysed using flow cytometry to determine whether a cytotoxic 
response had been initiated. 
The markers of interest when studying cytotoxic responses in T cells are located 
within cytotoxic granules (Peters et al., 1991). Following stimulation of a T cell 
receptor and induction of cytotoxic signals, these granules are recruited to the location 
of the activated T cell receptor, where they fuse with the cell surface membrane and 
exocytose their cytolytic contents (including granzyme B and perforin) into the 
immunological synapse between the T cell and the infected cell. During this process, 
lysosomal associated membrane glycoproteins (LAMPs, also known as CD107a1b) 
which are found only in the lipid bilayer of the cytotoxic granules, become transiently 
exposed on the outer surface of the T cell. Thereafter the LAMPs are endocytosed 
and return to their original location in the lipid bilayer of the cytotoxic granules. 
Perf orin, Granzyme B and CD107a are the markers of interest when analyzing 
cytotoxic activity in T cells. 
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For the purposes of this study, the efficiency of CDI07a and perforin as markers 
of cytotoxicity were compared. The results show that immediate disadvantages of 
using perforin as a marker of cytotoxicity are (i) the high variability in the levels of 
intracellular perf orin between different donors (as much as 0.1 - 26.2%) and (ii) the 
inter-assay variability in the intracellular levels of perforin in one individual donor 
(assayed in 3 independent experiments) (0.1 - 2.6%). These results indicate that the 
reproducibility of the cytotoxicity results when using perforin as a marker could be 
compromised. Finally, since cytolytic activity involves perforin release, the final 
percentage perf orin levels in the cells have to be compared to the original levels in 
order to determine the relative amount of activity which occurred during stimulation. 
This is an important factor when using perforin release as a marker of cytotoxic 
function, since the amount of perforin released by CIL in response to antigen specific 
stimulus might differ significantly between donors but might not be indicative of a 
significant difference between each donor's cytotoxic ability. 
The advantages of labeling CD 1 07 a While it is transiently expressed during the 
process of degranulation are 0) it is a direct marker of cytotoxic potential in the cell 
and (ii) the labeled CD107a molecules accumulate inside the T cell allowing 
subsequent analysis of cytotoxic activity in individual cells with the flow cytometer. 
Comparison of the data from three independent experiments, where PBMC from the 
same donor were stimulated identically, shows that CD107a is a relatively reliable 
marker capable of producing reproducible results. CDI07a was also shown to be an 
accurate marker of the degranulation process. since the percentage of CD 107 a 
positive cells increased as the percentage of perforin positive cells decreased. 
Therefore it was concluded that CD107a could be reliably used as an effective and 
accurate marker of the cytolytic activity occurring in CDS T cells. 
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The first stage of developing any assay is to determine the optimal positive 
control - in other words the protocol control test that can be included in every 
experiment to verify that the assay itself had worked and the results should be 
reliable. This assay involves the stimulation of PBMC with an HPV specific antigen 
and then the staining of the cells to determine whether any of the T cells were able to 
mount a cytotoxic immune response. Therefore the positive control in this situation 
needed to be an antigen that would non-specifically cause CD8 T cell stimulation and 
therefore reveal whether the donors T cells were capable of reacting to any stimulus at 
all. Previous experiments have utilised various positive controls including: mitogenic 
agents (PHA), pharmacologic agents (PMAII) and superantigens (SEB). Comparison 
of these agents revealed PMAII to be the optimal positive control for determining 
inherent cytotoxic ability in CD8 T cells. Interestingly the cells stimulated with SEB, 
which should induce massive CTL responses (Herman et al., 1991), actually only 
expressed 5 fold less CD107a than the PHA stimulated cells. A possible explanation 
for this vast difference in degranulation capabilities is that SEB induces less 
intracellular calcium during the T cell stimulation process than other antigens, which 
results in an inability of the CTL to perform cytoloysis (Fuller and Braciale, 1998). 
When developing assays for use with specific antigens, to which only 'rare 
event' responses are expected, it is necessary to consider other factors; for example 
the optimal length of stimulation period in order to generate a detectable response. In 
this case, the optimal stimulation for the HPV16 antigens (VLP L1 and E7) was 21hr, 
therefore it was necessary to establish at which point in the stimulation period the 
antibodies to CD 107 a should be added to the culture medium and whether the 
CyChrome fluorochrome would be sufficiently stable to withstand 21hr of incubation 
at 37°C, 5%C02 without becoming bleached and losing fluorescence intensity. The 
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results revealed that the anti-CD107a-CChr antibody was stable enough to be used for 
the duration of the 21hr stimulation period, and it was preferable to add the antibody 
for the entire 21hr stimulation period (as opposed to just for the last 5hr as was done 
for the positive control), which suggests that cytotoxicity is not a cumulative event 
(such as cytokine production) but that the cell responds immediately to the T cell 
receptor stimulus with release of most of its cytotoxic granules. 
The optimised cytotoxicity assay was successful in assessing the cytotoxic 
function of CD8 T cells when stimulated with either the positive control or the 
HPV16 specific antigens. The benefit of this flow cytometry based assay for 
cytotoxic activity is that unlike previous assays which can only quantify the amount 
of cytolytic activity which has occurred by determining target cell lysis, this assay 
facilitates the analysis of the functional characteristics of the cells which are 
performing the cytolytic activity. Therefore with this cytotoxicity assay it is possible 
to determine which cells are capable of 'killing' the infected cells and what other 
functional characteristics these cells possess (e.g. cytokine production). 
Due to the small size of the study population in this pilot study of cytotoxic 
responses, it is not possible to draw any statistically significant conclusions. Yet, this 
assay has still revealed some interesting points. It was noticed that HPV16 E7 was a 
much more effective antigen than VLP L1, inducing higher levels of CD107a 
expression (i.e. degranulation) across a larger number of patient samples. The 
production of IFN-y cytokine and degranulation process seemed to be mutually 
exclusive events in the PBMC responding to E7, and observing double positive 
responses (IFN-y+CD107a+) to E7 antigen was rare. This was unexpected since in all 
the positive control stimulated PBMC samples, most of the CD107a+ cells were also 
producing IFN-y, which would seem to be the natural process of immune response 
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events in T cells. Perhaps the unusual nature of the T cell response to E7 is due to the 
fact that HPV infected patients the infection might cause a disturbance in the function 
of the T cells and results in impaired immune responses to the HPV antigens 
(Nickoloff et al., 1994, 1995). This observation may however be an artifact of the 
low numbers of positive events following stimulation with HPV antigen. So perhaps 
if responses to HPV specific antigens occurred more often or if a greater number of 
PBMC could be analyzed to improve the significance of each positive event, this 
would result in a greater number of double positive cells (IFN-y+CD107a+) in the 
HPV antigen stimulated populations. 
The majority of cytotoxic responses were elicited by women infected with 
HPV16 at the cervix which supports previous studies that have shown that patients 
with CTL responses were likely to be suffering from persistant HPV infections (de 
Gruil et al., 1996). Also, the majority of the cytotoxic responses were elicited by CIN 
negative women (in whom cervical lesions are likely to have regressed since these 
women were referred to the clinic with CIN but on arrival at the clinic were found to 
be disease free). This concurs with previous studies, which have shown that T cells 
from healthy women elicited more effective CTL responses to HPV antigens than T 
cells from CIN diseased women (Nakagawa et al., 1997). 
Despite extensive setup and validation of the assay on PBMC samples, the low 
frequency of CDI07a expression to HPV antigens and the low yields of cervical T 
cells from patient cytobrush samples made it impossible to perform this assay on 
cervical samples as originally intended. 
In conclusion, this chapter has described the development and optimization of 
a cytotoxicity assay which may prove invaluable in the analysis of CTL responses to 
antigen specific stimuli. It has been shown how CD107a is a reliable and direct 
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marker of the degree of degranulation in CD8 T cells, with reproducible results across 
independently performed experiments. Since CTL defense in the face of viral 
pathogens is a crucial part of the immune response, this is a highly important area in 
immune response research. This assay has described a simple, direct ex vivo method 
for accurately quantifying the magnitude of potential CTL activity and assessing 
various other phenotypic or functional characteristics on each individual cell of the 
experimental population. 
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CHAPTER 5: 
DISCUSSION 
5.1 Overall Objectives of this Project 
First and foremost, the main aim of this project was to investigate the type of 
cellular immune response elicited by cervical T cells in women with HPV -associated 
cervical disease (CIN 1-3) in response to HPV infection and to compare these cervical 
T cell responses with those from peripheral blood. Many published reports of CMI 
responses during HPV infection have focused on responses in the peripheral blood of 
infected or diseased women. It is well recognized that HPV types that infect the 
genital mucosa (such as HPV-16) do not cause systemic infection but rather, viral 
replication is localized, highly tissue specific (only infecting basal keritinocytes) and 
tightly controlled. The value of studies of systemic T cell responses to such a 
localized infection is questionable without a representative comparison from T cells 
isolated from the site of pathology, the genital mucosa. 
Secondly, the fact that almost half (47-58%) of CIN2I3 lesions and 85% of 
CINI lesions are likely to regress completely (Chan et al., 2003; Schlecht et al., 2003; 
Brenner and Syrjanen, 2003; Iatrakis et al., 2(04) highlights the value in determining 
(through this cross-sectional study) the type of immune responses which were elicited 
by T cells from women with CIN. Therefore it was of interest in this project to 
compare the ICC responses from CIN negative women to those suffering with 
cervical dysplasia, to determine whether there were any significant differences 
between their responses and whether those significant responses were potential 
correlates of protection to HPV infection and associated cervical disease. 
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This project also aimed to develop techniques in order to (i) improve the 
efficiency of the current protocols for processing cervical cytobrush samples and (ii) 
to analyse the functional cytotoxic ability of T cells using a newly described marker 
of degranulation in combination with the technique of flow cytometry. 
5.2 Development of Methods to Process Cervical Samples 
Since this study was interested in the actual immune response at the site of 
mucosal HPV infection, it was necessary to isolate cervical T cells for further analysis 
and process them in such a way that these cells would be both competent for use in 
direct ex vivo functional studies and sufficient in number for the results to be 
statistically meaningful. The published protocols on the processing of cervical 
cytobrush samples needed to be refined in several areas (Musey et al., 1997). 
Of primary importance, it was necessary to determine whether a cervical 
cytobrush sample had yielded enough CD3+ T cells in order to continue with the 
stimulation and analysis of the sample. This is because, when T cells undergo ex vivo 
stimulation with various virus specific antigens, the frequency of positive events that 
occur to those specific antigens is low (Waldrop et al., 1997), therefore the number of 
events evaluated by flow cytometry need to be as large as possible so that the strength 
of numbers might lend significance to the few positive events above the background 
unstimulated population. From these experiments it was determined that a CD3+ 
Screen could be utilised to determine the validity of the cellular sample and whether it 
should be analysed or discarded. It was established that a CD3+ event number >500 
in the CD3+ screen would serve as an optimal cut off, ensuring sufficient T cell yield 
in the sample such that in the final analysis the number of T cells would be sufficient 
to support differences between the antigen specific stimulation and a background of 
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0.85% to 1.7%. The differences between antigen stimulated responses and 
unstimulated responses which were observed in this study were, however, rarely large 
enough, with the frustrating result that many of the individual low positive responses 
could not be considered significant. 
5.3 Analysis of HPV -specific cervical and peripheral blood T cell Responses 
by intracellular cytokine staining and Dow cytometry 
This project aimed to use flow cytometry to analyse the type of cytokine (Th 1 
versus Th2) responses elicited by the CD4 and the CD8 T cells. There are many 
benefits of the use of flow cytometry to determine the T cell responses to HPV 
specific antigens in comparison with techniques previously used such as proliferation 
(Luxton et al., 2003) or Chromium release assays (Nakagawa et al., 2001). Firstly, 
other assays require a 1-3 week in vitro culturing period in order to induce expansion 
of the T cells and facilitate subsequent detection of the positive responses. Flow 
cytometry has higher sensitivity to detect positive responses, therefore it allows the 
direct ex vivo analysis of T cells and eliminates the need for a potentially problematic 
and misrepresentative culturing period. 
Secondly, flow cytometry has the added advantage of allowing detection of 
multiple parameters individually on each single cell of a cellular population. 
Therefore, through this method it is possible to determine the exact numbers of 
responding T cells, whether they belong to the CD4 or CD8 subset, and whether the 
responding cells are capable of producing one or more cytokines of interest. 
Therefore flow cytometry facilitates a comprehensive and accurate analysis of the 
responding populations of T cells following stimulation with specific antigens. 
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Due to the sample size of this study, where only one third of the 100 recruited 
women had sufficient cervical T cell numbers to be fully analysed, it was found that 
statistical power of the results were limited. This being so, analysis of the data was 
continued and subsequently many interesting trends were observed. 
Interestingly, it was found that often the types of responses eilicted by 
matched PBMC and cervical T cells samples from a single patient, to stimulation with 
the same HPV specific antigen, were highly different. The differences between 
cervical T cell responses, and those elicited by the PBMC were most significant in the 
CIN 3 women, whose responses were significantly reduced at the cervix. This could 
imply that patients with weak cervical CD4 T cells IFNy responses are unable to 
control their HPV infection and therefore are likely to progress to CIN 3. It is 
recommended that an important consideration for future studies, especially when 
interpreting results from PBMC responses, would be that the detection of responses to 
a specific antigen in a patient's PBMC specimen does not necessarily imply that there 
are T cell responses at the cervix of that same patient. 
The most consistently high and significant responses were elicited by the 
PBMC and cervical cells of women with CIN 1. These women had the strongest CD4 
IFN-"( responses at the cervix to HPV-16 antigens compared to women with no 
cervical neoplasia or those with more severe disease (CIN 2/3). This is consistent with 
previous evidence from wart infiltrating lymphocytes studies (Nicholls et al., 2001; 
Stanley, 2001), which show that CD4 T cell production of IFN-"( correlates with 
lesion regression. These results also support those reported in other studies where a 
correlation was found between Th 1 cytokines at the cervix, and subsequent lesion 
regression (AI-Saleh et al., 1998; Luxton et al., 1997). The strong inflammatory Th1 
responses detected were also reflected by the detection of inflammatory cytokines in 
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cervical washing, which revealed significantly higher inflammation at the cervix of 
the women with CIN 1 (IL-8) than any of the other patient groups. This implies that 
the immune cells at the cervix of women with CIN 1 lesions might be eliciting large 
inflammatory responses to induce lesion regression and HPV clearance. This 
supports the results of previous studies, which have shown that the vast majority 
(85%) of CIN 1 lesions spontaneously regress (Iatrakis et al., 2004) as opposed to 
only half (47-58%) of CIN2 and CIN3 lesions (Schlecht et al., 2(03). Finally, a 
significant correlation was observed between high viral loads and high levels of IFNy 
cytokine production by CD4 T cells following stimulation of the T cells with HPV16 
VLP L1 demonstrating increased immune responsiveness driven by increased antigen 
load. This shows that in response to an active HPV16 infection, the immune system 
elicits primarily Th1 CD4 responses both locally and systemically. 
As expected, patients actively infected with HPV16 at the cervix were found 
generally to exhibit higher PBMC responses to the HPV16 specific antigens, although 
women infected with HPV types other than HPV -16 were also able to elicit responses 
to the HPV16 specific antigens. In the absence of no true negative control group (a 
group of women without previous history of HPV infection; both HPV DNA and 
antibody negative), the magnitude of responses in women with active HPV-16 
infection compared with women infected with non-HPV-16 responses is difficult to 
interpret as is the potential cross-recognition of HPV -16 antigens by T cells elicited 
during non-HPV -16 infections. 
In the comparisons of responses from HPV 16 infected women and those 
infected with other HPV types according to the severity of their cervical disease, there 
was a strong positive correlation between IL-13 production from PBMC CD8 T cells 
and severity of the cervical lesion in women infected with HPV 16, when cells were 
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exposed to HPV16 E7 antigen. This data indicates that in women with active HPV 16 
infections at the cervix, the immune response to the HPV antigens is predominantly 
anti-inflammatory (Th2) and this supports the hypothesis that an inadequate 
inflammatory immune response could result in progression of the cervical lesion. 
Yet it has also emerged from this study that CIN 3 patients appear to elicit Thl 
IFNy responses (possibly as a last attempt to rid the host of the infection), which 
could be interpreted as a contradiction to the hypothesis that lesion progression is 
associated to a Th2 type of cytokine profile. However, overall the CIN 3 Thl type 
responses were noted to be smaller in magnitude and number than the responses 
elicited by other patient groups. In comparison, the CIN 1 patients elicited the highest 
number and largest responses to HPV specific antigens and it is the data from these 
patients that suggest that a Thl inflammatory (CD4IIFNy) response at the cervix of 
HPV infected women is the strongest correlate of protection against HPV infection 
and subsequent cervical disease. 
5.4 Markers of HPV-16 specific Cytolytic Activity by peripheral blood T 
cells: CDI07a versus perf orin 
One of the most important immune response mechanisms is the antigen 
specific kill mechanism elicited by the CD8 cytotoxic T lymphocytes (CTLs). In 
HPV infected women, these responses were found to be highly associated with the 
regression of CIN (Nakagawa et al., 1996; 1997). CTL responses from HPVI6+ 
patients have been shown to last for up to 20 months post clearance (Nakagawa, 2000, 
2002). These results indicate the importance of a CD8 T cell cytolytic response in the 
defense against HPV infection and associated CIN. 
160 
There are various methods of detecting the cytotoxic function in T cells. Most 
HPV immune response studies have utilised the chromium release CTL assay. But 
due to a lack of sensitivity, this method requires a 1-3 week culturing of the T cells 
prior to the assay. in order to amplify responding cells in order to facilitate detection 
of the positive responses. It also involves generating a line of HPV antigen 
expressing antigen presenting cells to serve as targets for the HPV specific T cells. It 
is through the lysis of the target cells by the CD8 T cell population that the relative 
amount of cytotoxic activity is determined. This highlights another disadvantage of 
this method. it does not measure the actual cytolytic activity of CD8 T cells. rather it 
measures the death of target cells, and therefore indirectly the relative amount of 
cytotoxic activity. A recently published method used the flow cytometer to determine 
directly on antigen stimulated CD8 T cells how much degranulation had occurred in 
response to the stimulus (Betts et al., 2(03). It reported that a fluorochrome 
conjugated antibody to the CD107a molecule could be used as a marker of 
degranulation, since CDI07a is located only on cytolytic granules, and is transiently 
exposed on the surface of a degranulating cell during exocytosis of the cytotoxic 
granules contents (e.g. perforin and granzyme) (Betts et al., 2(03). 
Therefore, this study sought to develop an assay that could analyse the 
cytotoxic ability of T cells in response to HPV16 specific antigens. through the use of 
the flow cytometer. Initially cytotoxic T cell responses to HPV-16 Ll and E7 
antigens were investigated in PBMC from twenty three women with HPV -associated 
cervical disease (CIN) , with the intention to develop the assay for use on cervical 
cytobrush samples. Although the study population was small and statistical power 
limited, I observed that higher levels of CD107a expression (Le. degranulation) were 
elicited much more frequently to HPV16 E7 than VLP Ll. Yet in comparison to the 
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PMAII stimulated PBMC where all CD107a+ CTL were also producing IFNy in 
response to the mitogenic stimulation, PBMC which were stimulated with HPV16 
specific E7 antigen showed a completely different profile with the production of IFN-
y cytokine and degranulation process seeming to be mutually exclusive events (Le. to 
observe double positive responses (IFN-y+CD107a+) to E7 antigen was rare). 
Whether this is an artifact of the very low frequencies of these events or indicative 
that cytokine production and the cytotoxic ability of the T cells are induced by 
different and independent T cells, remains to be determined. 
In this study, the majority of cytotoxic responses were elicited by CIN 
negative women. This supports previous studies, which have shown that T cells from 
healthy women elicited more effective CTL responses to HPV antigens than T cells 
from CIN diseased women (Nakagawa et al., 1997), and also confinns that this assay 
could be a reliable method for detecting HPV specific CTL activity in HPV infected 
women. 
Despite extensive set up and validation on PBMC, due to the low frequencies 
of CDI07a expression in response to HPV antigens and the low yields of cervical T 
cells from cytobrush samples, it was impossible to perfonn the developed CD107a 
assay on cervical cytobrush specimens. 
5.5 Future Considerations for the analysis of HPV -specific cervical T cell 
responses 
Through the experiments perfonned in this thesis, some fundamental 
considerations have been established, which will significantly assist future studies. 
Firstly, it is crucial for a sample to have sufficient numbers of T cells for further 
analysis. It is beneficial in the early stages of the study to determine a CD3 screen 
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and appropriate cut off value in order to prevent the loss of time, money, valuable 
resources and intensive labour on the stimulation, staining and subsequent attempt at 
analysis of samples with insufficient T cell yields. 
Secondly, due to the heterogenous nature of cervical cytobrush specimens, 
which yield such variable quantities of T cells, and of which so many samples had to 
be discarded due to insufficient T cell populations, the following options are highly 
recommended. When commencing applications to undertake a project which analyses 
cells through collection using cervical cytobrush, the applicant should request ethical 
pennission for as large a study population as is physically possible to process. Yet 
even if this is taken into consideration, an inclusion rate of 33% (33/100) as described 
in this study is very low. Since screening and processing of the 66% of samples, 
which were ultimately not suitable for inclusion into the study, also required 
significant personnel and financial resources, enrolling more women to increase 
suitable cervical specimen inclusion might not be the most viable option. 
Perhaps a more suitable and efficient option would be to increase the numbers 
of responding T cells using in vitro culturing and repeated stimulation with either 
mitogenic stimuli, or HPV specific antigens (Luxton et al., 2(03). This would greatly 
improve the numbers of responsive T cells in the total population and thereby prevent 
the need for a CD3 screen, allowing the inclusion of many more cervical T cell 
samples into the study population. The later option will be investigated in future 
studies of HPV -specific T cell responses from cervical cytobrush specimens. 
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Appendix A 
T hI AIR D f a e aw ata rom ICCR f ·alT 11 esoonses 0 cervlc ce s stlmu ate d . h PMAII HPV16 VLP L1 d E7a WIt an 
Stimulation % Above Aba Fold % Above % Above % Above 
Donor CIN Condition %CD4+IFN+ Unstlm (StlmlUnstlm) %CD8+IFN+ Unstlm Aba Fold %CD4+1L-13+ Unstlm Aba Fold % CD8+IL-13+ Unstlm Aba Fold 
JP001 neg UNSTIM 0 15.63 0 26.32 
PMAII 4.76 4.76 #DIVlO! 40.55 24.92 2.59 0 0 #DIVIOI 5.27 -21.05 0.20 
VLPL1 0 0.14 #DIVIOI 16.28 0.14 1.04 5.27 0.14 #DIVIOI 13.88 0.14 0.53 
JP010 neg UNSTIM 0.17 0.24 0.44 0.06 
PMAII 35.55 35.38 209.12 72.73 72.49 303.04 20.83 20.39 47.34 9.1 9.04 151.67 
VLPL1 0.13 0 0.76 0.29 0.05 1.21 0.88 0.44 2 0.17 0.11 2.83 
JP018 neg UNSTIM 0 1.01 0 0.87 
PMAII 5.55 5.55 #DIVIOI 32.65 31.64 32.33 0 0 #DIVIOI 5.93 5.06 6.82 
VLP L1 0 0 #DIVIOI 0 0 0 1.8 1.8 #DIV/OI 2.12 1.25 2.44 
JP028 neg UNSTIM 0.28 0.57 1.97 1.15 
PMAII 7.58 7.3 27.07 77.73 77.16 136.37 0.38 -1.59 0.19 1.3 0.15 1.13 
VLP L1 0.5 0 1.79 1.47 0.9 2.58 0.33 -1.64 0.17 1.13 -0.02 0.98 
JP034 neg UNSTIM 0.51 0.5 0.51 0.52 
PMAII 17.29 16.78 33.90 87.34 86.84 174.68 0 -0.51 0.00 1.98 1.46 3.81 
VLP L1 4.66 4.15 9.14 1.31 0.81 2.62 0 -0.51 0.00 0.37 -0.15 0.71 
JP035 neg UNSTIM 1.03 1.06 0.93 1.05 
PMAII 26.39 25.36 25.62 67.42 66.36 63.60 0 -0.93 0 1.5 0.45 1.43 
VLP L1 0 -1.03 0 3.7 2.64 3.49 0 0 0 1.07 0.02 1.02 
E7 1 -0.03 0.97 0 -1.06 0 1.16 0 0 0 -1.05 0 
JP041 neg UNSTIM 0.23 0.27 0.05 0.09 
PMAII 1.89 1.66 8.22 4.69 4.42 17.37 0.05 0 1 0 -0.09 0 
VLP L1 0.7 0.47 3.04 4.76 4.49 17.63 3.n 3.72 75.4 7.27 7.18 80.78 
E7 0.58 0.35 2.52 0.32 0.05 1.19 0.34 0.29 6.8 0.74 0.65 8.22 
JP045 neg UNSTIM 0.45 0.3 0.08 0.6 
PMAII 7.73 7.28 17.18 23.99 23.69 79.97 0.42 0.34 5.25 0.69 0.09 1.15 
VLP L1 0.42 0 0.93 0.36 0.06 1.2 0 -0.08 0.00 0.09 0 0.15 
E7 0.1 0 0.22 0 0 0 0.36 0.28 4.50 0.29 0 0.48 
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StImulation % Above Aba Fold % Above % Above % Above 
Donor CIN Condition %CD4+IFN+ Unstlm (StimlUnatim) %CD8+IFN+ Unatlm Aba Fold %CD4+1L-13+ Unatlm Aba Fold % CD8+IL-13+ Unatlm Aba Fold 
JP047 neg UNSTIM 0.67 1.09 0.4 0.35 
PMNI 3.68 3.01 5.49 21.61 20.52 19.83 3.4 3 8.5 4.77 4.42 13.63 
VLP L1 0.1 0 0.15 0.29 0 0.27 2.41 2.01 6.03 4.55 4.2 13.00 
E7 0 0 0 0 0 0 1.55 1.15 3.88 2.61 2.26 7.46 
JP058 neg UNSTIM 1.63 2.08 0.81 2.08 
PMNI 17.2 15.57 10.55 86.67 84.59 41.67 1.08 0.27 1.33 20 17.92 9.62 
VLP L1 0 -1.63 0.00 0 -2.08 0.00 0 -0.81 0.00 0 -2.08 0.00 
E7 0 -1.63 0.00 0 -2.08 0.00 0 -0.81 0.00 5.88 3.8 2.83 
JP061 neg UNSTIM 0.25 0.24 0.87 0.16 
PMAII 29.59 29.34 118.36 63.63 63.39 265.13 2.24 1.37 2.57 0.49 0.33 3.06 
VLP L1 0.06 0 0.24 0.09 0 0.38 0.06 0 0.07 0 0 0 
E7 0.14 0 0.56 0.19 0 0.79 0.34 0 0.39 0.19 0.03 1.19 
JP088 neg UNSTIM 0.46 0.54 0.91 0.54 
PMNI 19.21 18.75 41.76 56.8 56.26 105.19 0 -0.91 0.00 0 -0.54 0.00 
VLP L1 0 -0.46 0.00 4.06 3.52 7.52 1.52 0.61 1.67 0 -0.54 0.00 
E7 1.69 1.23 3.67 0.88 0.34 1.63 0 -0.91 0.00 0 -0.54 0.00 
JPOO7 1 UNSTIM 0.06 0.18 0.05 0.24 
PMAII 39.18 39.12 653 88.86 88.68 493.67 0.43 0.38 8.6 2.21 1.97 9.21 
VLP L1 0.1 0.04 1.67 0 -0.18 0.00 0.05 0 1.00 2.11 1.87 8.79 
JP013 1 UNSTIM 0.21 0.24 3.1 0.15 
PMNI 20.39 20.18 97.10 5.64 5.40 23.50 15.91 12.81 5.13 5.60 5.45 37.33 
VLPL1 2.77 2.56 13.19 0.17 0.00 0.71 2.02 0.00 0.65 0.10 0.00 0.67 
JP033 1 UNSTIM 0.19 0.9 0.56 0.9 
PMNI 5.48 5.29 28.84 72.41 71.51 80.46 0 -0.56 0.00 0 -0.9 0.00 
VLPL1 0.16 -0.03 0.84 2.85 1.95 3.17 0.39 -0.17 0.70 1.42 0.52 1.58 
JP049 1 UNSTIM 0.39 0.06 1 0.18 
PMAII 44.25 43.86 113.46 74.93 74.87 1248.83 0.4 -0.6 0.40 0.43 0.25 2.39 
VLPL1 3.55 3.16 9.1 0.12 0.06 2 0.78 -0.22 0.78 0.31 0.13 1.72 
E7 1.81 1.42 4.64 0.06 0 1 1.7 0.7 1.70 0.42 0.24 2.33 
JP084 1 UNSTIM 0.65 0.68 0.65 0.68 
PMNI 11.71 11.06 18.02 41.18 40.5 60.56 0.71 0.06 1.09 1.79 1.11 2.63 
VLP L1 1.12 0.47 1.72 2.18 1.5 3.21 1.01 0.36 1.55 0 -0.68 0.00 
E7 1.3 0.65 2.00 1.76 1.08 2.59 0.29 -0.36 0.45 0.44 -0.24 0.65 
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Stimulation % Above Aba Fold % Above % Above % Above 
Donor CIN Condition %CD4+IFN+ Unstlm (StimlUnstlm) %CD8+IFN+ Unstim Abs Fold % CD4+1 L-13+ Unstlm Abs Fold % CD8+IL-13+ Unstlm AbsFold 
JP089 1 UNSTIM 0.14 0.24 0.14 0.24 
PMAII 15.03 14.89 107.36 61.02 60.78 254.25 1 0.86 7.14 2.26 2.02 9.42 
VLP L1 0.13 -0.01 0.93 0 -0.24 0.00 0.07 -0.07 0.50 0.4 0.16 1.67 
E7 0.82 0.68 5.86 0.23 -0.01 0.96 0.44 0.3 3.14 0.9 0.66 3.75 
JP091 1 UNSTIM 0.38 0.34 0.38 0.68 
PMAII 20.92 20.54 55.05 69.34 69 203.94 3.35 2.97 8.82 1.09 0.41 1.60 
VLP L1 2.08 1.7 5.47 0.95 0.61 2.79 1.04 0.66 2.74 1.42 0.74 2.09 
E7 0 -0.38 0.00 0 -0.34 0.00 0 -0.38 0.00 0 -0.68 0.00 
JPOOB 2 UNSTIM 0.27 0.46 0.08 0.53 
PMAII 69.04 68.77 255.70 78.56 78.10 170.78 60.97 60.89 762.13 76.40 75.87 144.15 
VLP L1 0.51 0.24 1.89 0.43 0.00 0.93 0.04 0.00 0.50 1.89 1.36 3.57 
JP011 2 UNSTIM 2.94 0 0.85 0 
PMAII 32.89 29.95 11.19 78.95 78.95 #DIVIOI 2.15 1.3 2.53 0 0 #DIVlO! 
VLP L1 10.17 7.23 3.46 0 0 #DIVIOI 0.91 0.06 1.07 0 0 #DIVlO! 
JP014 2 UNSTIM 2.02 3.64 
PMAII 41.86 39.84 20.7 69.14 13.96 10.32 3.84 6.34 
VLP L1 4.33 2.31 2.14 0.61 4.23 0.59 1.16 1.33 
JP060 2 UNSTIM 0.53 0.17 0.14 0.17 
PMAII 20.41 19.88 38.51 54.93 54.76 323.12 0.15 0.01 1.07 0.53 0.36 3.12 
VLP L1 0.22 0 0.42 0.32 0.15 1.88 0.4 0.26 2.86 0.48 0.31 2.82 
E7 0.4 0 0.75 0 0 0 0.19 0.05 1.36 0.17 0 1 
JP062 2 UNSTIM 0.1 1.3 0.1 0.33 
PMAII 1.6 1.5 16 12.8 11.5 9.85 0.07 0 0.7 0 0 0 
VLPL1 0 0 0 0 0 0 0 0 0 0 0 0 
E7 0.13 0.03 1.3 0 0 0 0 0 0 0 0 0 
JPOO2 3 UNSTIM 
PMAII 
VLP L1 0 0.14 #DIVIOI 0 0.14 #DIVIOI 0 0.14 #DIVlO! 1.09 0.14 #DIVIOI 
JPOOS 3 UNSTIM 0 11.1 7.51 14.31 
PMAII 0 0 #DIVlO! 24.99 13.89 2.25 16.67 9.16 2.22 33.37 19.06 2.33 
VLPL1 0 0.14 #DIVIOI 33.35 0.14 3.00 0 0.14 0.00 20.01 0.14 1.40 
JP017 3 UNSTIM 3.14 0 6.97 9.94 
PMAII 27.8 24.66 8.85 13.16 13.16 #DIV/O! 0 -6.97 0.00 0.00 -9.94 0.00 
VLPL1 2.55 -0.59 0.81 2.94 2.94 #DIVIOI 4.26 -2.71 0.61 3.02 -6.92 0.30 
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Stimulation % Above Aba Fold % Above % Above % Above 
Donor CIN Condition %CD4+IFN+ Unatlm (StlmlUnatlm) %CD8+IFN+ Unstim Aba Fold % CD4+1L-13+ Unatlm Aba Fold % CD8+IL-13+ Unatlm Aba Fold 
JP029 3 UNSTIM 0.06 0.57 0.41 0.26 
PMAII 2.15 2.09 35.83 76.26 75.69 133.79 0.37 -0.04 0.90 0 -0.26 0.00 
VLPL1 0.77 0.71 12.83 2.06 1.49 3.61 0.35 -0.06 0.85 0 -0.26 0.00 
JP043 3 UNSTIM 0.59 0.25 0.59 0.5 
PMAII 23.09 22.5 39.14 57.11 66.86 228.44 2.54 1.95 4.31 1.83 1.33 3.66 
VLP L1 0.62 0.03 1.05 0.28 0.03 1.12 1.04 0.45 1.76 0.28 -0.22 0.56 
E7 1.07 0.48 1.81 0 -0.25 0 0 -0.59 0 0 -0.5 0 
JP048 3 UNSTIM 0.81 Too Low 0.81 Too Low 
PMAII 10.87 10.06 13.42 CD8+ Cell 7.97 7.16 9.84 CD8+ Cell 
VLPL1 1.78 0.97 2.20 Count 0.44 -0.37 0.54 Count 
E7 1.21 0.4 1.49 5.65 4.84 6.98 
JP055 3 UNSTIM 0.25 0.11 0.17 0.22 
PMAII 24.74 24.49 98.96 82.49 82.38 749.91 0.85 0.68 5.00 4.75 4.53 21.59 
VLPL1 0.73 0.48 2.92 0.53 0.42 4.82 0.7 0.53 4.12 0.43 0.21 1.95 
E7 0.36 0.11 1.44 0.22 0.11 2.00 0 -0.17 0.00 0.03 -0.19 0.14 
66 3 UNSTIM 0.17 3.85 0.5 1.92 
PMAlI 3.23 3.06 19.00 32.11 28.26 8.34 0.42 -0.08 0.84 1.83 -0.09 0.95 
VLPL1 0 -0.17 0.00 3.85 0 1.00 0 -0.5 0.00 0 -1.92 0.00 
E7 0 -0.17 0.00 6.45 2.6 1.68 0.19 -0.31 0.38 0 -1.92 0.00 
68 3 UNSTIM 0.11 0.34 0.11 0.34 
PMAII 4.48 4.37 40.73 30.18 29.84 88.76 0.24 0.13 2.18 1.61 1.27 4.74 
VLPL1 0 -0.11 0.00 0.35 0.01 1.03 0.1 0 0.91 2.08 1.74 6.12 
E7 0.1 -0.01 0.91 0 0 0 0 0 0 0.9 0.66 2.65 
a In some cases donor samples were unable to be stImulated With E7 antigen Since It was not available at the time of the expenment. 
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Table A.2 Raw Data from ICC Resoonses of Perioheral Blood T cells (PBMC) stimulated with HPV16 VLP Ll and E7a 
elN Stimulation % Above % Above % Above % Above 
Donor Status Condition " CD4+1FN+ Unstlm AbsFold "CD8+IFN+ Unstlm AbsFold " CD4+1L-13+ Unstlm AbsFold " CDB+IL-13+ Unstlm AbsFold 
JPOO1 neg UNSTIM 0.05 0.21 0.45 0.18 
PMAII 0.21 0.16 4.2 4.02 3.81 19.14 1.82 1.37 4.04 0.03 -0.15 0.17 
VLPL1 0.08 0.03 1.6 0.09 -0.12 0.43 0.03 -0.42 0.07 0.06 -0.12 0.33 
JP010 neg UNSTIM 0.17 0.24 0.44 0.06 
PMAII 6.48 6.31 38.12 11.23 10.99 46.79 1.64 1.20 3.73 0.25 0.19 4.17 
VLP L1 0.13 -0.04 0.76 0.29 0.05 1.21 0.88 0.44 2.00 0.17 0.11 2.83 
JP018 neg UNSTIM 0.57 2.6 0.49 0.67 
PMAII 5.94 5.37 10.42 23.57 20.97 9.07 0.65 0.16 1.33 3.05 2.38 4.55 
VLPL1 0.64 0.07 1.12 1.93 0 0.74 0.5 0.01 1.02 1.35 0.68 2.01 
JP028 neg UNSTIM 0.06 0.31 0.06 0.07 
PMAII 0.87 0.81 14.50 12.22 11.91 39.42 1.40 1.34 23.33 0.61 0.54 8.71 
VLP L1 0.06 0 1.00 0.15 -0.16 0.48 0.24 0.18 4.00 0.14 0.07 2.00 
JP034 neg UNSTIM 0.04 0.16 0.03 0.07 
PMAII 3.62 3.58 90.5 29.56 29.4 184.75 0.06 0.03 2 0.05 -0.02 0.71 
VLPL1 0.02 -0.02 0.5 0.07 -0.09 0.4375 0 -0.03 0 0.01 -0.06 0.14 
JP035 neg UNSTIM 0.44 0.61 0.87 0.31 
PMAII 0.75 0.31 1.70 9.92 9.31 16.26 21.64 20.77 24.87 0.42 0.11 1.35 
VLPL1 0 -0.44 0.00 0.18 -0.43 0.30 0.00 -0.87 0.00 0.00 -0.31 0.00 
E7 0.56 0.12 1.27 0.35 -0.26 0.57 2.26 1.39 2.60 0.18 -0.13 0.58 
JP041 neg UNSTIM 0.03 0.07 0.03 0.02 
PMAII 4.93 4.9 164.33 12.07 12.00 172.43 0.41 0.38 13.67 0.24 0.22 12.00 
VLPL1 0.04 0.01 1.33 0.27 0.20 3.86 0.33 0.30 11.00 0.14 0.12 7.00 
E7 0.06 0.03 2.00 0.36 0.29 5.14 0.02 -0.01 0.67 0.01 -0.01 0.50 
JP045 neg UNSTIM 0.06 0.10 3.13 0.04 
PMAII 1.83 1.77 30.50 2.11 2.01 21.10 2.17 -0.96 0.69 0.02 -0.02 0.50 
VLPL1 0.02 -0.04 0.33 0.04 -0.06 0.40 3.37 0.24 1.08 0.07 0.03 1.75 
E7 0.03 -0.03 0.50 0.06 -0.04 0.60 1.46 -1.67 0.47 0.02 -0.02 0.50 
JP047 neg UNSTIM 0.02 0.16 0.02 0.07 
PMAII 2.66 2.64 133.00 6.44 6.28 40.25 0.21 0.19 10.50 0.47 0.40 6.71 
VLPL1 0.19 0.17 9.50 0.14 -0.02 0.88 0.02 0.00 1.00 0.03 -0.04 0.43 
E7 1.57 1.55 78.50 0.97 0.81 6.06 0.08 0.06 4.00 0.15 0.08 2.14 
JP058 neg UNSTIM 0.07 0.06 0.17 0.04 
PMAII 2 1.93 28.57 5.27 5.21 87.83 1.08 0.91 6.35 0.37 0.33 9.25 
VLPL1 0.02 -0.05 0.29 0.03 -0.03 0.50 0.09 -0.08 0.53 0.04 0.00 1.00 
E7 0.1 0.03 1.43 0.09 0.03 1.50 0.Q7 -0.10 0.41 0.03 -0.01 0.75 
JP061 neg UNSTIM 0.04 0.34 0.08 0.07 
PMAII 3.86 3.82 96.50 15.88 15.54 46.71 1.29 1.21 16.13 0.14 0.07 2.00 
VLPL1 0.02 -0.02 0.50 0.12 -0.22 0.35 0.16 0.08 2.00 0.09 0.02 1.29 
E7 0.03 -0.01 0.75 0.41 0.07 1.21 0.08 0.00 1.00 0.11 0.04 1.57 
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CIN Stimulation % Above % Above % Above % Above 
Donor Status Condition "CD4+IFN+ Unstlm AbsFold "C08+IFN+ Unstlm Aba Fold " CD4+1L-13+ Unstlm AbsFold " C08+IL-13+ Unstlm AbsFold 
JP088 neg UNSTIM 0.02 0.03 0.01 0.01 
PMAII 6.4 6.38 320.00 16.19 16.16 539.67 0.06 0.05 6.00 0.02 0.01 2.00 
VLP L1 0.04 0.02 2.00 0.07 0.04 2.33 0.05 0.04 5.00 0.02 0.01 2.00 
E7 0.08 0.06 4.00 0.19 0.16 6.33 0.01 0 1.00 0.01 0 1.00 
JP007 1 UNSTIM 0.15 0.15 1.06 0.35 
PMAII 22.48 22.33 149.87 15.53 15.38 103.53 0.61 -0.45 0.58 0.10 -0.25 0.29 
VLPL1 0.29 0.14 1.93 0.36 0.21 2.40 0.21 -0.85 0.20 1.10 0.75 3.14 
JP013 1 UNSTIM 0.21 0.24 3.10 0.15 
PMAII 22.33 22.12 106.33 17.42 17.18 72.58 1.01 -2.09 0.33 0.12 -0.03 0.80 
VLPL1 2.77 2.56 13.19 0.17 -0.07 0.71 2.02 -1.08 0.65 0.10 -0.05 0.67 
,11M 0.03 0.09 0.02 0.02 
PMAII 4.37 4.34 145.67 11.94 11.85 132.67 0.48 0.46 24.00 0.17 0.15 8.50 
VLPL1 0.08 0.05 2.67 0.16 0.07 1.78 0.02 0.00 1.00 0.06 0.04 3.00 
JP049 1 UNSTIM 0.06 0.05 0.35 0.01 
PMAII 4.65 4.59 77.50 12.69 12.64 253.80 0.86 0.51 2.46 0.10 0.09 10.00 
VLPL1 0.28 0.22 4.67 0.25 0.20 5.00 0.47 0.12 1.34 0.01 0.00 1.00 
E7 0.35 0.29 5.83 0.71 0.66 14.20 0.59 0.24 1.69 0.04 0.03 4.00 
JP084 1 UNSTIM 0.2 0.41 0.13 0.13 
PMAII 8.75 8.55 43.75 33.4 32.99 81.46 2.41 2.28 18.54 1.45 1.32 11.15 
VLPL1 0.2 0 1.00 0.4 -0.01 0.98 0.55 0.42 4.23 0.46 0.33 3.54 
E7 0.47 0.27 2.35 0.89 0.48 2.17 0.58 0.45 4.46 0.56 0.43 4.31 
JP089 1 UNSTIM 0.01 0.01 0.01 0.02 
PMAII 1.45 1.44 145.00 5.55 5.54 555.00 0.05 0.04 5.00 0.06 0.04 3.00 
VLPL1 0 -0.01 0.00 0 -0.01 0.00 0.02 0.01 2.00 0.02 0 1.00 
E7 0.04 0.03 4.00 0.04 0.03 4.00 0.01 0 1.00 0.01 -0.01 0.50 
JP091 1 UNSTIM 0.05 0.01 0.03 0.02 
PMAII 12.59 12.54 251.80 34.22 34.21 3422.00 0.38 0.35 12.67 0.05 0.03 2.50 
VLP L1 0.02 -0.03 0.40 0.01 0 1.00 0.08 0.05 2.67 0.04 0.02 2.00 
E7 0.06 0.01 1.20 0.03 0.02 3.00 0.02 -0.01 0.67 0.01 -0.01 0.50 
JPOO8 2 UNSTIM 0.27 0.46 0.08 0.53 
PMAII 5.83 5.56 21.59 19.73 19.27 42.89 0.22 0.14 2.75 0.08 -0.45 0.15 
VLPL1 0.51 0.24 1.89 0.43 -0.03 0.93 0.04 -0.04 0.50 1.89 1.36 3.57 
JP011 2 UNSTIM 0.07 0.12 0.09 0.18 
PMAII 8.98 8.91 128.29 20.18 20.06 168.17 0.56 0.47 6.22 0.17 -0.01 0.94 
VLPL1 0.05 -0.02 0.71 0.19 0.07 1.58 0.12 0.03 1.33 0.19 0.01 1.06 
JP014 2 UNSTIM 2.13 0.29 3.16 
PMAII 11.73 9.6 5.51 27.2 26.91 93.8 3.21 0.05 1.02 0.77 
VLPL1 1.59 0 0.75 0.34 0.05 1.17 3.79 0.63 1.2 0.22 
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CIN StImulation % Above % Above % Above % Above 
Donor Status Condition "CD4+IFN+ Unstlm Abs Fold "C08+IFN+ Unstlm Aba Fold " CD4+1L~13+ Unstlm Abs Fold " C08+IL-13+ Unstlm Aba Fold 
JP060 2 UNSTIM 0.01 0.01 0.08 0.03 
PMAII 3.38 3.37 338 5.89 5.88 589 1.18 1.1 14.75 5.35 5.32 178.33 
VLP L1 0 -0.01 0 0.01 0 1 0.07 -0.01 0.875 0.06 0.03 2.00 
E7 0.04 0.03 4 0.06 0.05 6 0.02 -0.06 0.25 0.01 -0.02 0.33 
JP062 2 UNSTIM 0.04 0.2 0.04 0.14 
PMAII 3 2.96 75 10.25 10.05 51.25 0.92 0.88 23 0.85 0.71 6.07 
VLPL1 0.05 0.Q1 1.25 0.15 -0.05 0.75 0.06 0.02 1.5 0.11 -0.03 0.79 
E7 0.1 0.06 2.5 0.21 0.01 1.05 0.05 0.01 1.25 0.13 -0.01 0.93 
JPOO2 3 UNSTIM 0.06 0.06 0.09 0 
PMAII 2.46 2.4 41 11.62 11.56 193.67 0.56 0.47 6.22 0.02 0.02 #DIVIOI 
VLPL1 0.03 -0.03 0.5 0.13 0.07 2.17 0.06 -0.03 0.67 0.03 0.03 #DIVIOI 
JPOO5 3 UNSTIM 0.04 0.19 0.07 0.85 
PMAII 24.72 24.68 618 50.42 50.23 265.37 8.66 8.59 123.71 22.28 21.43 26.21 
VLP L1 0.04 0 1 0.33 0.14 1.74 0.05 -0.02 0.71 1.17 0.32 1.38 
JP017 3 UNSTIM 0.28 1.23 2.14 1.18 
PMAII 7.19 6.91 25.68 10.94 9.71 8.89 8.56 6.42 4 0.5 0 0.42 
VLPl1 0.76 0.48 2.71 0.96 0 0.78 3.34 1.2 1.56 0.48 0 0.41 
JP029 3 UNSTIM 0.04 0.32 0.04 0.27 
PMAII 1.07 1.03 26.75 20.03 19.71 62.59 0.12 0.08 3.00 0.43 0.16 1.59 
VLP L1 0.04 0 1 0.24 -0.08 0.75 0.02 -0.02 0.50 0.11 -0.16 0.41 
JP043 3 UNSTIM 0.02 0.12 0.01 0.03 
PMAII 5.64 5.62 282 11.62 11.5 96.83 2.00 1.99 200.00 0.06 0.03 2.00 
VLPL1 0.07 0.05 3.5 0.17 0.05 1.42 0.48 0.47 48.00 0.30 0.27 10.00 
E7 0.1 0.08 5 0.27 0.15 2.25 0.46 0.45 46.00 0.28 0.25 9.33 
JP048 3 UNSTIM 0.08 0.06 0.09 0.01 
PMAII 2.79 2.71 34.88 7.78 7.72 129.67 1.08 0.99 12.00 0.32 0.31 32 
VLP L1 0.12 0.04 1.50 0.11 0.05 1.83 0.08 -0.01 0.89 0.06 0.05 6 
E7 0.12 0.04 1.50 0.35 0.29 5.83 0.16 0.07 1.78 0.15 0.14 15 
JP055 3 UNSTIM 0.03 0.05 0.03 0.01 
PMAII 8.55 8.52 285 55.86 55.81 1117.2 2.3 2.27 76.67 1.5 1.49 150 
VLPL1 0.26 0.23 8.67 0.3 0.25 6 0.03 0 1.00 0.01 0 1 
E7 0.08 0.05 2.67 0.16 0.11 3.2 0.07 0.04 2.33 0.03 0.02 3 
JP066 3 UNSTIM 0.01 0.16 0 0 
PMAII 0.47 0.46 47 2.89 2.73 18.06 0.17 0.17 #DIVIOI 0.23 0.23 #DIVIOI 
VLPL1 0.04 0.03 4 0.09 -0.07 0.56 0 0 #DIVlO! 0.02 0.02 #DIVIOI 
E7 0.22 0.21 22 0.92 0.76 5.75 0.02 0.02 #DIVIOI 0.07 0.07 #DIVIOI 
JP068 3 UNSTIM 0.08 0.03 0.01 0.04 
PMAII 0.55 0.47 6.875 0.31 0.28 10.33 0.09 0.08 9 0.07 0.03 1.75 
VLP L1 0.01 -0.07 0.125 0 -0.03 0.00 0.03 0.02 3 0.01 -0.03 0.25 
E7 0 -0.08 0 0.01 -0.02 0.33 0.01 0 1 0.Q1 -0.03 0.25 
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ApPENDIX B : SUBSTRATES AND SOLUTIONS 
Cell Stimulation Solutions 
PBS - phosphate buffered saline pH 7.2 
RPMI 
Ingredient Final Concentration 
KCI 2.7mM 
KH2P04 l.2mM 
NaCI 138mM final 
Na2HP04.7H20 8.1mM 
r 
Adjust pH to 7.2 
Make up Water to 11 
Autoclave and store at 4°C. 
Amount Added 
0.20g 
0.20g 
8.0g 
2.16g 
900ml 
1640 Medium with Glutamax-l and 25mM HEPES 
(Invitrogen Corporation, UK) 
To all RPMI, the following were added: 
Penicillin (1 x 106iulml) Iml to lOOml RPMI 
Streptomycin (0.5 ~glml) Iml to lOOml RPMI 
Amphotericin B Iml to lOOml RPMI 
(supplied by Invitrogen Corporation UK) 
10% FCSRPMI 
Fetal Calf Serum (Fetal Bovine Serum) was heat inactivated at 56°C and then 
added to RPMI (l0ml to lOOml RPMI). 
10% ABRPMI 
Heat inactivated serum collected from AB positive blood donors, was heat 
inactivated and filtered before addition to RPMI (10ml per l00ml RPMI) 
Staining Solutions 
Staining Solution 
5%FCS 
0.01% Azide 
made up to volume with PBS. 
0.1 % Saponin PermeabUization Solution 
0.2g saponin 
0.01% azide 
200mlPBS 
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1 % Azide Stock Solution 
O.5g Sodium Azide (NaN3) 
50mlPBS 
Agarose Gel Solutions 
1.8% Agarose Gel (w/v) 
I.8g Agarose 
I x TAB (make up to lOOml) 
Tris Acetate ButTer (TAE) (SOX) 
242gTris 
57.1 ml Glacial acetic acid 
lOOml 0.5MEDTA 
Loadin ButT Ig er 
Ingredient Final Concentration 
Xylene cyanol 0.25% (w/v) 
Sucrose 40% (w/v) 
EDTA (O.5M,pH 8.0) 20mM 
Water 
Roche Reverse Line Blot Solutions 
SSPE (2Ox) 
For ll: 74gNaCl 
27.6g NC16H2POJIzO 
7AgEDTA 
Hybridisation Solution 
Ix (4x SSPE. 0.5% Sodium Dodecyl Sulphate) 
for 11 : 20x SSPE 200ml 
20% SDS 25ml 
dH20 775ml 
Wash Solution 
Ix ( Ix SSPE; 0.1 % SDS) 
for 11 : 20x SSPE 50ml 
20% SDS 5ml 
dH20 945ml 
110mi 
25mg 
4.0g 
OAml 
To lOml 
SA-HRP(streptavidin conjugated Horse radish peroxidase) 
Conjugate Solution 
For lOOml : Ix wash solution 100ml 
Amplicor SA-HRP 0.3ml 
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Citrate Buffer 
For 11: 
ELISA Solutions 
Blocking Solution 
O.5%PVA 
20x Citrate Solution 50ml 
dH20 950ml 
make up to required volume in PBS pH 7.4 
OPD Substrate Solution 
3 OPD tablets (2mgltablet) 
9mlROH20 
3.751J.1 H202 
Stop Solution 
O.5M H2S04 
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